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2ABSTRACT
Obstructive sleep apnoea (OSA) is common worldwide. Cardiovascular diseases such as 
hypertension, heart failure and coronary artery diseases are highly prevalent in OSA population. 
Although the precise mechanisms for disease development in OSA are ambiguous, endothelial 
dysfunction (ED) is regarded as a crucial step. Indeed endothelial dysfunction has been 
demonstrated in peripheral vasculature in OSA population, however the effects of ventilatory 
dysfunction on coronary microcirculation and myocardial perfusion is unknown.  
I performed comprehensive assessment of endothelial function in moderate to severe OSA 
subjects compared with healthy and hypertensive controls, using flow mediated dilatation (FMD), 
laser Doppler flowmetry (LDF), flow cytometry in addition to studying vascular elastic 
properties. In order to investigate coronary endothelial dysfunction, I studied myocardial 
perfusion in sub-endocardial region using myocardial contrast echocardiography (MCE). 
Additionally, as OSA is related with left ventricular diastolic dysfunction and high risk of atrial 
fibrillation, I also investigated cardiac remodeling using real time three-dimensional 
echocardiography (RT3DE). It is noteworthy that RT3DE and MCE have not been used in 
moderate to severe OSA subjects previously. Finally, the effects of continuous positive airway 
pressure (CPAP) therapy on these central and peripheral markers of macro- and micro-vascular
dysfunction were also studied after 6 months.  
I demonstrated endothelial dysfunction in the peripheral circulation, when compared with healthy 
subjects. Using ‘state of the art’ techniques, I showed endothelial dysfunction in the sub-
endocardial region and cardiac remodeling in OSA compared with healthy subjects. However, 
contrary to available data, I did not note a significant change in the indices of arterial stiffness and 
in the flow cytometric analysis of endothelial progenitor cells and circulating endothelial cells
3amongst the three groups. Most importantly, the peripheral and coronary endothelial dysfunction 
improved dramatically in OSA subjects, after they were treated with CPAP therapy for 6 months. 
In summary, micro- and macro-vascular dysfunction exists in otherwise healthy moderate to 
severe OSA subjects compared with healthy subjects and can be improved with effective CPAP 
therapy. These findings may have strong clinical and prognostic implications, which ought to be 
tested in future studies. 
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1.1 Obstructive Sleep Apnoea and Cardiovascular Diseases 
1.1.1 Introduction
Obstructive sleep apnea (OSA) is characterized by episodic partial/complete collapse of the 
upper airways alternating with normal breathing, leading to chronic intermittent hypoxia, 
oxygen desaturation, sleep fragmentation and cortical arousal.  OSA is common worldwide 
and a higher than normal risk/prevalence of cardiovascular diseases has been observed in 
OSA population [Bradley et al 2009][Phillipson et al 1993]. Several landmark OSA studies 
observed epidemiological patterns of coronary artery disease, heart failure, cardiac 
arrhythmias and stroke in this population [Table 1-1]. OSA also strongly coexists with 
cardiac risk factors such as hypertension and impaired glucose tolerance. In fact, screening 
for hypertension has been recommended amongst newly diagnosed OSA patients [Chobanian 
et al 2003]. Hence unsurprisingly, OSA has been implicated in the initiation and progression 
of a myriad of cardiovascular disorders such as coronary artery disease (CAD), heart failure, 
systemic hypertension (HTN), pulmonary hypertension, cardiac arrhythmias and stroke 
[Table 1-1].  On this note, evidence from several cohort studies indicated that even mild form 
of OSA is independently associated with increased likelihood of cardiovascular morbidity.
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Table 1-1: Epidemiological studies on the relationship between obstructive sleep apnea and cardiovascular disease
Reference n Dominant 
gender 
Associated disease Study design and findings
Shahar et al 2001 6424 Male Stroke, Heart failure, Coronary 
artery disease
Large study, questionnaire based  assessment, 
overnight polysomnography used to detect apnea 
hypopnea index, supported 
Nieto et al 2000 6132 Female Hypertension Multi centre study, interview based assessment, 
manual blood pressure, demonstrated dose dependent 
rise in systolic and diastolic blood pressure with 
worsening sleep related breathing measures across all 
ages and ethnic groups
Peppard et al 
2000
709 Male Hypertension Four year follow up study, Manual blood pressure 
monitoring, independent dose dependent response in 
hypertension was seen in association with sleep 
disordered breathing
Lavie et al 2000 2677 Male Hypertension OSA is independently and profoundly associated with 
hypertension
20
Hoffstein et al 
1994
458 Male Cardiac arrhythmias Arrhythmia assessment by isolated ECG lead analysis, 
prospective study, prevalence of arrhythmia was 
comparable to nocturnal hypoxemia but not snoring. 
Rules out snoring as a cause of cardiac arrhythmias 
Laaban et al 2002 169 Male Heart failure Left ventricular assessment by MUGA scan, 
prospective study of patients with 
polysomnographically diagnosed OSA, suggested 
impact of OSA on day time left ventricular systolic 
function
Peker et al 2000 62 Male Coronary artery disease Questionnaire based  assessment, OSA and non-OSA 
patients were identified by full overnight sleep study, 
small study but statistically significant higher risk of 
CAD development in OSA group
Arzt et al 2005 1475 Male Stroke 4 year follow up, apnea/hypopnea index of 20 or more 
was associated with increased risk of stroke (P=0.02)
OSA= obstructive sleep apnea; CAD= coronary artery disease; MUGA scan= multi gated acquisition scan; ECG= electrocardiogram
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As screening tools, Epworth’s score, Berlin’s score and overnight oximetry are commonly used 
but neither of these is sensitive or specific to accurately diagnose OSA [ Abrishami et al 2010]
[Chervin et al 1999]. Multi-channel sleep study (MCSS) is regarded as a gold standard tool to 
diagnose and classify OSA subjects according to the disease severity. During a standard MCSS, 
heart rate, blood pressure, respiratory rate, oxygen saturations, airflow through the nasal 
apertures and chest wall movements are monitored. Based on the number of hypopnoeas and 
apnoeas per hour, Apnoea-Hypopnoea Index (AHI) is estimated. The OSA with the AHI of 5-
15 is classed as mild, whilst 15-30 and more than 30 is regarded as moderate and severe 
respectively [Shamsuzzaman et al 2003]. Notably, the latter two groups are the primary target 
for treatment with continuous positive airway pressure (CPAP). 
Convincing data from randomized controlled trials in OSA patients with hypertension or heart 
failure have demonstrated that the CPAP treatment improves clinical outlook and may improve 
OSA associated cardiac morbidity [Table 1-2,1-3]. Hence, significant links between 
cardiovascular morbidity and OSA and CPAP led benefits, warrant a better understanding of 
the syndrome and its related disease developing mechanisms.  
In this chapter, I shall provide a comprehensive overview of OSA, including its 
epidemiological patterns, previously proposed mechanisms/hypotheses of OSA related disease 
developing mechanisms and its historical relatrion with various cardiovascular disorders. 
1.1.2 Epidemiology 
OSA affects up to 14% of the middle age Western population, with even higher prevalence in 
the men, elderly and obese population [Ferini-strambi et al 2004][Redline et al 1994] [Young et 
al 2002] [Duran et al 2001a][Duran et al 2001b]. It is therefore not surprising that the majority 
of epidemiological studies have male preponderance although some large studies have 
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predominantly recruited females [Table 1-1]. Given that the risk of cardiovascular morbidity 
increases with age, it is sometimes difficult to appreciate if OSA causes cardiovascular disease 
or whether they are merely epiphenomenon. 
Although a number of studies demonstrated the effect of age on the development of OSA 
independent of other confounding factors, data addressing the age related absolute change in 
disease severity are deficient.  Some authors claim limited whilst others suggest marked 
deterioration in disease severity - as much as doubling after 10 years (calculated using AHI) in 
a given OSA population [Young et al 1993][Bixler et al 1998].  Like the increasing age, weight 
gain has also been shown to be a strong predictor of worsening OSA [Peppard et al 2000].  Of 
note, increased prevalence of OSA is seen in patients with congestive cardiac failure (CCF) 
[40%], stroke [60%] and end stage renal failure [50%] [Sin et al 1999][Yaggi et al 2005][Hanly 
et al 2001]. 
1.1.3 Pathophysiology
Although the association between OSA and CVD has been well known for decades, the 
underlying pathophysiological mechanisms have begun to unfold only recently. Endothelial 
dysfunction, autonomic overdrive, subclinical systemic inflammation, metabolic dysregulation 
and coagulopathy are some of the potential mechanisms which have been proposed to explain 
this complex link. Whilst vascular, metabolic, humoral and autonomic factors have their own 
relative impact; it is yet unclear which one plays the central role [Figure 1-1].  
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Figure 1-1: Pathophysiological mechanisms linking Obstructive Sleep Apnoea to Cardiovascular Disorders
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Inflammation 
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1.1.3.1 Endothelial dysfunction (ED)
A large body of evidence suggests that impaired endothelial function accompanies OSA [Grebe 
et al 2006][Kato et al 2000][Budhiraja et al 2007]. The relationship between endothelial 
dysfunction and CVD is also well established and endothelial damage/dysfunction has a key 
role in the development of CVD [Napoli et al 2001]. The existence of endothelial dysfunction 
in OSA and vascular disorders is probably not a mere coincidence and in fact may indicate 
close underlying pathological links; therefore it is imperative to understand the cellular biology 
and physiology of the endothelium in OSA. 
The endothelium is a live tissue which is more than merely a separation between the blood and 
the vessel wall. The role of endothelium in the maintenance of vascular tone, cellular 
proliferation, coagulation cascade and the modulation of the activity various blood constituents 
such as platelets and monocytes by secreting various vasoactive substances, is well recognized 
[Harrison et al 2003][Budhiraja et al 2004][Chin et al 1998][Sanner et al 2000][El-solh et al 
2002]. 
How and what starts the process of endothelial dysfunction in OSA?  Although the precise 
mechanisms of endothelial perturbation remain ambiguous, it has been postulated that OSA 
related hypoxia, inflammation or oxidative stress initiates the process [Venugopal et al 
2002][Valgimigli et al 2003]. Also the inter-relationships amongst these factors are probably 
multifactorial.  For example, NO is a vasodilator secreted by endothelium, and a reduction in 
NO is associated with endothelial dysfunction [Kato et al 2000], with an impairment of 
quantifiable endothelial mediated vasodilatory response [Celermajer et al 1996][Panza et al 
1990][ Linder et al 1990]. OSA patients also have reduced NO levels as well as impaired 
endothelial mediated vasodilatation [Ohike et al 2005]. Nonetheless, it is uncertain what 
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precisely leads to the reduced NO bioavailability in OSA. Inflammation and other cytokines 
may potentially play a role. Since the endothelium keeps a balance between several mediators 
and hormones, any imbalance per se – perhaps caused by inflammation – would result in 
adverse effects.   
C-reactive protein (CRP) is robust marker of inflammation and is an important predictor of 
cardiovascular events. Reports of significant elevation in OSA population led to discover that 
CRP reduces NO synthase levels, supporting the role of inflammation in development of 
endothelial dysfunction [Shamsuzzaman et al 2002][Venugopal et al 2002].  Indeed there are 
other operating mechanisms too such as asymmetric dimethylarginine (ADMA), an endogenous 
NO antagonist is greater in OSA patients [Ohike et al 2005], suggesting yet another route to the 
development of endothelial dysfunction. 
Whether endothelial dysfunction is the cause or the effect of cardiovascular problems (such as 
hypertension) remains ambiguous in OSA.  Nevertheless, a strong link has been demonstrated
between OSA and markers of endothelial dysfunction, even in normotensive population [Ip et 
al 2004].  Furthermore randomized CPAP trials have reported a healthy impact of endothelial 
status in OSA [Lattimore et al 2006].  
1.1.3.2 Autonomic dysregulation
A dysfunctional autonomic system has been reported in OSA [Balachandran et al 2012]. 
Several components of autonomic nervous system mediate cardiovascular changes in OSA; 
however role of sleep related parasympathetic activity is yet to be proved.  Regardless of 
causative mechanisms, deranged autonomic cardiovascular regulation is predictive of worse 
prognosis in high risk patients, ie with diabetes, heart failure, and myocardial infarction 
[Kataoka et al 2004][ Hadase et al 2010]. Increasingly, dysfunctional autonomic system is 
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being regarded as an independent risk factor in normotensives and hypertensive subjects [solin 
et al 2009]. This may be the case also for patients with OSA, who are characterized by diurnally 
increased plasma levels of norepinephrine, elevated muscle sympathetic nerve activity, and 
altered heart rate variability [Singh et al 2008]. Arguably, dysfunctional autonomic system 
could be secondary to obesity, although robust data are limited [Narkiewicz et al 1998(a)].  
Furthermore, repetitive hypoxia in OSA patients may also cause overactivation of sympathetic 
system [Somers et al 1995]. Similarly, central and peripheral chemorecepters have a close yet 
complex relationship with ventilation/breathing [Duffin et al 2010] and the overactivation of 
such receptors has been found in OSA patients nocturnally as well as during the day hours 
[Narkiewicz et al 1998(b)] [Tilkian et al 1976]. On the same note, hypertension and blood 
pressure oscillations in OSA are regarded as poor prognostic signs and predictors of target 
organ damage [Frattola et al 1993]. 
Available evidence suggests that long-term treatment with continuous positive airway pressure
(CPAP) significantly improves autonomic indices in OSA patients [Narkiewicz et al 1998 (b)]. 
Notably, treatment of OSA with 100% oxygen (not necessarily with CPAP) corrects the 
hypoxia results in chemoreceptor deactivation, thus reducing sympathetic activity and 
normalizing hemodynamic parameters. Larger studies are required to assess the effects of 
interventions for OSA on autonomic function.
1.1.3.3 Haemostasis
Coagulopathy and abnormal platelet aggregability play important roles in the pathogenesis of 
atherothrombotic disease [Lurie et al 2011][Kannel et al 1987]. The impact of OSA on platelets 
per se is controversial; such effect may be secondary to endothelial dysfunction, raised 
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nocturnal catecholamine levels, or be simply a response to apnoeic episodes [Sanner et al 
2000][Pearson et al 2010].  Regardless of the aetiology of platelet dysfunction, studies have 
noted improvements in platelet status with the correction of hypoxia using CPAP [Bokinsky et 
al 1995]. 
The effects of sleep disturbed breathing on red blood cells are less well studied. In an 
observational study of 624 OSA patients, small yet significantly higher hematocrit levels were 
reported in patients with lower nocturnal oxygen saturations [Hoffstein et al 1994 (a)]. Finally, 
other coagulation factors, such as plasma fibrinogen, are elevated in OSA and long term CPAP 
appears to reduce coagulation factor VII activity [Wessendorf et al 2010][Chin et al 2007]. 
Indeed this evidence is available but this does not overwhelmingly support the notion of 
disturbed coagulation in OSA. Therefore in summary, the effect of OSA on haemostasis and 
thrombosis remains a controversial territory due to inadequate evidence [Robinson et al 2004].
1.1.3.4 Oxidative stress 
OSA is a state of oxidative ‘stress’ and the latter has a diverse role in the development of 
cardiovascular disorders [Lurie A et al 2011][Lavie et al 2003]. Repetitive hypoxic episodes 
lead to intra-cellular structures to adapt to lower oxygen levels. Therefore, the availability of 
normal oxygen concentration to these cells during the normoxic phase leads to the production 
of reactive oxygen species (ROS), which have the ability to oxidize cellular products, lipids and 
proteins. ROS from neutrophils and monocytes is augmented in OSA patients and has a close 
relationship with classical inflammatory mediators (such as bradykinin), which also suggests 
that systemic inflammation is one of the contributory factors in endothelial dysfunction. ROS 
upregulate adhesion molecules and diminish NO synthase activity, thus augmenting NO 
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breakdown and ultimately, diminished NO levels [Deanfield et al 2005]. If not corrected, the 
resultant endothelial damage/dysfunction may lead to atherosclerosis [Harrison et al 2003]. 
Case control studies have shown the tendency of neutrophils to produce more ROS in OSA, a 
phenomenon which is reversible with CPAP therapy [Schulz et al 2000]. Similarly, an 
enhanced expression of adhesion molecules in monocytes and an increased ROS production in 
OSA patients also responds to CPAP [Dyugovskaya et al 2002].  Both experimental and human 
studies are consistent with the concept that intermittent hypoxia in OSA  represents a form of 
oxidative stress and may lead to dysfunctional endothelium. 
1.1.3.5 Inflammation
Observational studies have shown that various vascular disorders as well as OSA are associated 
with sub-clinical inflammatory processes [Garvey et al 2009] [Ridker et al 2003][Danesh et al 
2000]. It is believed that some of the inflammatory mediators/markers may induce 
vasculopathy through endothelial dysfunction. For example, raised CRP levels result in the 
direct as well as indirect (by monocytes activation) reduction of NO synthase [Venugopal et al 
2002][Woollard et al 2002]. OSA increases levels of inflammatory mediators such as inter-
cellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) [Ohga et al 
1999][Ohga et al 2003], in endothelial cells as well as in neutrophils, thus promoting 
endothelial cell adhesiveness and oxidative stress. The underlying mechanisms is believed to be 
OSA associated hypoxia and sleep deprivation which modulates the expression of 
inflammatory mediators, particularly interleukins and tumor necrosis factor alpha [Vgontzas et 
al 1997]. CPAP therapy reduces various circulating inflammatory mediators such as ICAM-1, 
Interleukin-8 (IL-8) [Ohga et al 2003] and C-reactive protein [Minoguchi et al 2006].
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1.1.3.6 Metabolic dysfunction
There is a well-recognized association of insulin resistance with OSA as well as with 
atherosclerosis [Grebe et al 2006][Punjabi et al 2002], suggesting that metabolic disturbances 
may well be a significant link between OSA and CVD.  The severity of sleep apnea appears to 
correlate with the degree of insulin resistance.  Unsurprisingly, severe OSA is accompanied by 
a 5-fold increase in the risk of overt diabetes mellitus [Spiegel et al 1999]. Conversely, high 
insulin levels in non-obese OSA patients have been reported and worsen with increasing AHI 
and oxygen desaturation levels [Punjabi et al 2002][Elmasry et al 2001 (a)]. Thus, obesity per 
se may not the sole determinant of insulin resistance, as previously believed [Vgontzas et al 
2000]. 
Leptin is a hormone involved in satiety, body weight control and fat distribution is also 
regarded as an independent risk factor for CAD [Caro et al 1996][ Wallace et al 2001]. 
Although leptin is also elevated in obese individuals it increases platelet aggregability 
regardless of the body fat distribution [Considine et al 1996][ Davi et al 2002]. Correction of 
OSA reduces leptin levels, as well as intra abdominal fat levels [Chin et al 1999]. However, 
treatment with CPAP does not show any consistent improvement in glucose tolerance [Elmasry 
et al 2001 (b)].
Despite regional variations in the prevalence of coronary disease, men are consistently at a 
greater risk of developing and dying from CAD than women, and the gender-specific effects of 
sex hormones are implicated in this inequality. Serum testosterone levels have been observed to 
be negatively correlated with the severity of OSA [Canguven et al 2010]. Some studies 
observed an inverse relationship between testosterone levels and not only coronary disease and 
coronary risk factors but also with mortality [Park et al 2012]. There is no evidence to suggest 
that CPAP treatment improves testosterone levels in OSA. Perhaps testosterone level may be an 
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additional indicator in determining severity and in follow-up of OSA, although this hormone is 
strongly affected by a number of physical and physiological factors. 
1.1.4 Obstructive sleep apnea and cardiovascular diseases
The most serious complications of OSA include heart failure, coronary artery disease (CAD),
arrhythmias, stroke, systemic hypertension and pulmonary hypertension. Animal as well as 
human studies have revealed that OSA induced intermittent intra-thoracic pressure changes are 
associated with acute hemodynamic disturbances in physiological parameters and adverse 
effects on left ventricular pressures and dimensions [Bradley et al 1992][Sajkov et al 1994][ 
Virolainen et al 1995][White et al 1995].
1.1.4.1 Hypertension 
Large epidemiological studies have demonstrated a strong and consistent link between OSA 
and hypertension [Table 1-1]. A vast proportion of OSA population (upto 95%) has been 
reported to have some degree of high blood pressure [Marin et al 2012][Lavie et al 2000]. 
Though the causative pathways remain debatable; cross sectional analyses of several studies 
suggest that OSA is an independent risk factor for high mean, systolic and diastolic blood 
pressures [Table 1-1]. Therefore, hypertension management guidelines acknowledge OSA as an 
independent cause of hypertension and recommends blood pressure screening amongst OSA 
patients [Chobanian et al 2003]. 
There are several theories on the underlying mechanisms of raised blood pressure in OSA. 
Increases sympathetic activity secondary to aponeaic/hypopnoeic hypoxia and cortical micro-
arousal [Solin et al 2003][Narkiewicz et al 1998 (a)][Singh et al 1998] and nocturnal 
fluctuations in catecholamines [Fletcher et al 1987][Baruzzi et al 1991] are some of the more 
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prominent factors in the causation of hypertension. Carlson et al reported augmented 
sympathetic activity in non-hypoxic OSA patients even during day hours, which were later 
supported by other studies [Carlson et al 1993][Somers et al 1995].  Finally, endothelial 
dysfunction - leading to failure of endothelial dependent and independent vasodilatation of 
resistant vessels – results in raised peripheral vascular resistance and consequently, 
hypertension.
Increasing evidence suggests that CPAP therapy in OSA could improve blood pressure in part 
by improving endothelial dysfunction as well as the correction of triggering factors, such as 
sympathetic system overactivation and hypoxia [Table 1-2][Bazzano et al 2007][Mills et al 
2006][Faccenda et al 2001]. For example improved nocturnal catecholamine with concomitant 
improvement in nocturnal and daytime blood pressures has been demonstrated with the use of 
CPAP [Mills et al 2006].  Others CPAP studies have also shown to improve autonomic balance 
in small OSA cohorts [Imadojemu et al 2007]. Whilst antihypertensive effect of CPAP has been 
questioned by some [Robinson et al 2006], others suggest that beneficial effect of CPAP on 
lowering blood pressure extends beyond pharmacological therapy [Table 1-2]. 
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Table 1-2: Randomized clinical trials of use of continuous positive airway pressure in obstructive sleep apnea patients with hypertension
Reference Study design Findings Comment 
Mills et al 2006 50 patients were randomised to therapeutic 
or sub-therapeutic CPAP for 2 week, to 
detect any effect on catecholamine 
clearance
Significant reduction in 
systolic as well as diastolic 
blood pressure and concurrent 
increased nor epinephrine 
clearance in CPAP arm 
suggest role of latter in 
hypertension in OSA
Single blinded study, short duration, manual blood 
pressure recordings
Faccenda et al 
2001
Placebo controlled
cross-over study of the effects of 4 wk of 
CPAP or oral placebo on 24-h blood
pressure in 68 patients (predominantly 
male)
Improvement in diastolic 
blood pressure (p=0.04) was 
noted especially in patients 
with nocturnal desaturation or 
with prolonged CPAP use. 
Daytime sleepiness also 
improved
Normotensive study population, Deduction of 
mild OSA from study, lack of washout period and 
short study duration
Robinson et al 
2006
Double blind trial randomising 35 patients 
to either therapeutic or sub-therapeutic 
CPAP for 2 months with ambulatory blood 
pressure monitoring
CPAP does not reduce mean 
blood pressure in non sleepy  
hypertensive OSA patients
Small study, does not individually comment on 
systolic and/or diastolic blood pressue.  Does not 
involve mild OSA
Becker et al 32 patients were randomized to therapeutic Interestingly reduction in AHI First study to suggest drop in blood pressure with 
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2003 or sub therapeutic CPAP.  For 9 weeks. was noted in both groups 
however significant drop in 
mean, systolic and diastolic 
blood pressure was only noted  
in therapeutic CPAP arm
CPAP, good compliance in groups, small study 
size, however ambulatory Blood pressure 
monitoring may give spuriously low readings
Dorkova et al 
2008
32 OSA patients were given CPAP for 8 
weeks with pre and post CPAP assessment 
of various inflammatory and endothelial 
dysfunction markers with blood pressure 
changes 
Reduction in systolic as well 
as diastolic blood pressures 
was noted
Small study, investigated the role of metabolic 
syndrome, oxidative stress and inflammation in 
the causation of CVD
Vgontzas et al 
2008
In this study of 16 obese OSA patients 
several plasma markers and blood pressure 
were assessed with its response to CPAP
Improvement in overall blood 
pressure was recorded after 3 
months on CPAP
Small study, emphasis of the link between OSA 
and inflammation
Barnes et al 
2004
Comparison of the effects of CPAP and oral 
placebo or mandibular device (MAS) 
among 110 OSA patients, for 3 months. 
Objectives were to observe any 
improvement in sleepiness and quality of 
life
Small nocturnal reduction of 
blood pressure noted with 
MAS compared to CPAP 
besides symptomatic 
improvement 
Considerable female population, this is one of the 
first studies to show significant improvement in 
OSA hypertensive patients with MAS, though the 
correct method to use was questioned in some. 
Included mild OSA as well.
Campos -
Rodriguez et al 
2006
In this double blind trial 4 weeks 
randomisation of OSA patients with treated 
hypertension, to therapeutic CPAP verse 
sub-therapeutic CPAP was done 
Statistically insignificant drop 
in mean blood pressure in 
CPAP group but no change in 
systolic, diastolic or nocturnal 
Reasonable size double blind study, short 
duration, inadequately powered to detect blood 
pressure variations
34
blood pressure.
Hla et al 2002 24 men with hypertension and with or 
without OSA were randomized to CPAP for 
3 weeks. 
CPAP arm showed reduction 
in nocturnal systolic and 
diastolic blood pressure.  
Small study, only male investigated, 
Barnes et al 
2002
28 predominantly male patients with mild 
to severe OSA randomized to CPAP or oral 
placebo for 8 weeks to assess 
neurobehavioral improvement and 
reduction in blood pressure. 
Neurobehavioral indices 
improved in both arms 
however subsidiary analysis 
for blood pressure did not 
show significant difference.
Single blinded study, high rate of patients 
withdrawal and doubts about CPAP compliance. 
only 7 patients were hypertensives and analysis 
failed to show significance of CPAP is such a 
small group.
Barbé et al 2001 To detect the effect of CPAP on blood 
pressure and quality of life of non sleepy 
OSA patients, 54 patients with severe OSA 
were randomised to nasal CPAP or sham 
CPAP for 6 weeks
Non-sleepy patients with 
severe OSA do not get 
worthwhile benefit from CPAP 
such as reduction in blood 
pressure and improvement in 
cognitive impairment
Multicenter placebo controlled blinded study, 
short CPAP duration,, 
Campos -
Rodriguez et al 
2007
In this prospective long term trial (24 
month follow up) ambulatory blood 
pressure monitoring was carried out to 
investigate any improvement in blood 
pressure parameters
CPAP has a dose dependent 
response with reduction in 
blood pressure
Small study, same group published opposite 
findings in a double blinded but similar trial in 
short term (4 weeks of CPAP)
CPAP= continuous positive airway pressure; MAS= mandibular advancement splint; OSA= Obstructive sleep apnea; CVD= cardiovascular disease
Indeed, owing to the link between severity of OSA and incidence of hypertension [Table 1-1], 
CPAP therapy has been extensively studied in patients with moderate to severe OSA [Table 1-
2]. Although mild OSA is also linked with elevated blood pressure, limited evidence reveals no 
significant decline in the blood pressure with of CPAP treatment [Monasterio et al 2001].
1.1.4.2 Coronary artery disease (CAD)
Many epidemiological studies consistently report a close and strong presence of CAD in OSA 
population regardless of other risk factors [Martinez et al 2012][Table 1-1]. Circulatory 
physiology is greatly affected by change in sleep pattern, OSA related hypoxia, hypercapnia, 
blood pressure surges, sympathetic overactivation, and the acute imbalance of vasoactive 
hormones [Peker et al 1999]. These changes can not only provoke acute coronary syndromes 
but also, their persistence ultimately leads to chronic consequences such as heart failure [Gami 
et al 2004 (a)]. Interestingly, reversible electrocardiogram (ECG) changes can be noted in OSA 
patients without significant CAD [Hanly et al 1993]. The use of CPAP in OSA patients reduces 
incidence of new coronary events compared to controls, as observed by a large prospective trial 
[Milleron et al 2004]. Moreover, in a randomised study, CPAP has been found to reduce 
mortality [Mooe et al 2000], though the mechanism largely remains unknown. 
1.1.4.3 Heart failure
Many observational studies have linked OSA with systolic as well as diastolic impairment of 
the left ventricle [Table 1-1] [Carr et al 2012] [Artz et al 2006].  Moreover patients with heart 
failure per se have a higher prevalence of sleep disordered breathing [Javaheri et al 1998].  The 
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precise reasons are uncertain but odema of neck soft tissues makes pharyngeal tissue prone to 
collapses thereby leading to further tightening of airways [Shepard et al 1996]. 
In health, during the inspiration the right ventricular output increases whilst the left ventricular 
(LV) output slightly decreases, leading to respective changes in their stroke volumes [Kasai et 
al 2011]. These subtle respiratory variations in ventricular volumes become more pronounced 
with apnoeas/hypopnoeas, due to accentuated negative intra-thoracic pressure induced by 
marked and forceful inspiratory efforts. Increased venous return, augmented right sided preload 
shifts the septum to the left (during diastole) impairs LV filling and diminishes LV preload and 
ejection pressure. Furthermore, transient and intermittent airway obstructions and changes in 
intra-thoracic pressure significantly increase LV transmural systolic pressures. Ultimately these 
haemodynamic stresses translate into cardiac remodelling, LVH and ultimately arrhythmias and 
heart failure [Kasai et al 2011]. In addition, OSA associated hypertension, exaggerated 
adrenergic responses and hormonal imbalance may all predispose to hypertensive heart failure 
[Tanriverdi et al 2006 (a)]. Normalization of left ventricular (LV) function with CPAP 
treatment has been reported in OSA patients [Mansfield et al 2004].
Mechanisms leading to diastolic dysfunction in OSA are less clear. Myocardial hypertrophy 
and persistently high blood pressure [Kasai et al 2011][Cloward et al 2003] and adverse 
changes in LV dynamics (a rise in after-load and a reduction in fractional shortening) in 
response to intermittent airway collapse, can also lead to impaired relaxation [Parker et al 
1999]. Some studies based on the echocardiographic findings have concluded that OSA 
independently does not show any adverse impact on ventricular function in OSA [Hanly et al 
1992]. 
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Right ventricular hypertrophy, reduced contractility and ejection fraction (EF) [Sanner et al 
1997] have all been reported in OSA patients. These findings may be a direct consequence of 
OSA related disturbed haemodynamics or secondary to pulmonary hypertension, which itself is 
prevalent in OSA [Chaouat et al 1996][Alchanatis et al 2001]. Successful treatment of OSA 
also improves right ventricular function [Nahmias et al 1996], and improvement in LV 
dimensions and contractility have been noted after CPAP [Table 1-3]. 
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Table 1-3: Studies using Continuous Positive Airway Pressure in Obstructive Sleep Apnea patients with Heart Failure
Reference Study design Conclusion Comments
Mansfield et al 
2004
Open trial using CPAP for 12 weeks in 
OSA patients in middle aged population 
to detect improvement in heart failure
Substantial improvement in cardiac 
failure and quality of life
predominantly male, large number of drop 
outs, manual blood pressure recording,  
diastolic dysfunction not assessed
Kasai et al 2008 Aim of the study was to detect any 
prognostic benefits of CPAP in heart 
failure with OSA. 88 OSA patients with 
moderate to severe disease were 
randomized to CPAP or observations
CPAP treatment group significantly 
reduces morbidity and mortality 
depending upon strict compliance
Good comparative study for assessing the 
prognostic significance of CPAP in this 
particular group
Kaneko et al 
2003
24 OSA patients were randomized to 
either CPAP with medical therapy or 
medical therapy alone for one month
CPAP significantly reduced heart 
rate, blood pressure and left 
ventricular dimensions and  ejection 
fraction
Well conducted open study,  inclusion of 
ischaemic and non ischaemic patients, small 
study
Wang et al 2007 To see any effect of CPAP on mortality in 
heart failure patients with OSA, 164 
patients were recruited and control group 
involved untreated OSA patients
Untreated OSA with heart failure is 
high risk for mortality
A good prospective study with median follow 
up of over 7 years
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Alchanatis et al 
2000
CPAP was randomized again observation 
in fifteen of twenty six patients for three 
months with regular transthoracic 
echocardiogram
CPAP significantly improves 
ventricular function especially 
diastolic, also drop systolic blood 
pressure
Small study. Echocardiography induced 
possible observer bias, control group 
comprised of non OSA individuals, mild 
disease excluded from study
Arias et al 2005 In this study of 42 patients sham CPAP 
against effective CPAP in moderate OSA 
patients for 12 weeks
Impaired relaxation is a prominent 
finding in OSA patients. Effective 
CPAP treatment improves E/A ratio 
Double blind yet small study, only male 
population included, echocardiography 
related observer bias may be another factor
OSA= obstructive sleep apnea; CPAP= continuous positive airway pressure
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The effect of CPAP on exercise capacity in OSA patients with heart failure has not been studied 
extensively. However in some small studies CPAP seems to increase exercise capacity in heart 
failure patients regardless of coexistence of OSA [Schlosser et al 2006]. 
In most studies transthoracic echocardiography has been used as diagnostic tool, however in 
OSA patients where obesity is commonly prevalent, the efficacy of echocardiography has been 
questioned. Nevertheless, Laaban et al [Laaban et al 2002] studied a large cohort of OSA 
patients without known coronary artery disease and investigated cardiac functions using 
multiple-gated equilibrium cardiac imaging (MUGA) reporting poor LV systolic function.
1.1.4.4 Cardiac Arrhythmias 
A wide spectrum of conduction disturbances ranging from premature ventricular contractions 
(PVCs) to complex arrhythmia such as complete heart block and ventricular tachycardia, have 
been reported in OSA [Harbison et al 2000].  In one small study (n=71), there was a higher 
incidence of life threatening ventricular arrhythmias amongst patients with sleep disordered 
breathing [Harbison et al 2000]. In heart failure patients with implantable cardiac defibrillators,
device discharges occurred more frequently in OSA patients than those without, particularly 
nocturnally, suggesting a link between OSA and nocturnal malignant arrhythmias [Serizawa et 
al 2008].  Epidemiological studies demonstrating the arrhythmia burden of OSA are 
summarized in Table 1-4. 
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Table 1-4: Obstructive Sleep Apnea and association with Cardiac Arrhythmias
Reference n Tachyarrhythmias 
%
Bradyarrythmias 
%
Ectopics %
Guilleminault et al 
1983
400 3 19 0
Becker et al 1995 239 0 10 0
Flemons et al 1993 76 0 6 1
Miller et al 1982 23 0 13 9
Bolm-audorff et al 
1984
20 15 0 36
Tilkian et al 1977 15 13 46 67
Intermittent hypoxia can cause HR to decrease, increase, or remain constant depending upon 
status of autonomic system [Leung et al 2009]. In canine models, right atrial pacing augments 
the autonomic activity of the right pulmonary arterial sympathetic nerve endings during apnoea, 
and may induce atrial fibrillation (AF) [Cagirci et al 2011][Gami et al 2004][Ghias et al 2009]. 
Therefore, stimulation of such ganglionated plexi during obstructive apnoeas may be one of the 
mechanisms of AF in OSA. Myocardial stretch caused by the mechanical effects of OSA, 
myocardial ischaemia and activation of cardiac inflammatory pathways may also precipitate 
atrial and ventricular arrhythmias [Kasai et al 2011]. The mechanisms described above operate 
in parallel in OSA where a marked negative intrathoracic pressure impacts heavily on the LV 
leading to cardiac remodelling (LVH and LA dilatation) ultimately increasing risk of atrial 
arrhythmias and thromboembolism.
.Studies in heart failure patients suggest an increased prevalence of AF in patients with sleep
apnea [Javaheri et al 1998]. Additionally the presence of OSA predicts pre-discharge recurrence 
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of AF after cardiac surgery [Mooe et al 1996] and post ablation [Jongnarangsin et al 2008]. 
Although CPAP treated OSA patients have better outcomes with regards to reduced risk of 
recurrent AF after electrical cardioversion [Kanagala et al 2003], the role of CPAP in primary 
prevention of AF in OSA patients is unknown.
It is clear now that OSA has a profound impact of LV function, promotes stasis and carries a 
high risk of AF. There is no direct study investigating threshold to prescribe oral 
anticoagulation in OSA subjects. Recently, a joint consensus document from the European 
Society of Cardiology (ESC) Heart Failure Association and the ESC Working Group on 
Thrombosis has been published [Lip et al 2012]. This report suggests that, in patients 
(regardless of the OSA status) with AF, oral anticoagulation is recommended, and the 
CHA(2)DS(2)-VASc and HAS-BLED scores should be used to determine the likely risk-
benefit ratio. However, in heart failure patients with impaired LV and sinus rhythm, there is no 
evidence of an overall benefit of vitamin K antagonists (e.g. warfarin) on mortality, with 
excessive risk of major bleeding. Therefore, there is currently no compelling reason to use 
warfarin routinely for OSA patient with heart failure but in sinus rhythm.
Bradycardia is also highly prevalent in OSA patients [Guilleminault et al 1983][Flemons et al 
1993]. Although pauses up to 2 seconds can be observed in apnea episodes in otherwise healthy 
individuals [Becker et al 1995], the prolongation of pause duration has been noted in OSA 
patients [Tilkian et al 1977]. Some degree of conduction block has been described in up to 10% 
of OSA patients, especially during REM sleep [Koehler et al 1998].  Recently a small study 
using insertable loop recorder in 23 moderate OSA patients questioned the usefulness of 24-
hour holter monitor. The results seem to suggest bradyarrythmias are more frequent in OSA 
and loop recorder is superior to 24-hours holter in detecting the significant pauses (longer than 
3 seconds) (p=0.03) [Simantirakis et al 2004]. Further more consistent with the most available 
data, CPAP significantly ameliorates these arrhythmias [Simantirakis et al 2004].
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Hypoxia probably plays an important role in the genesis of bradycardia with improvement in 
heart rate on oxygen administration [Zwillich et al 1982]. CPAP - even in the absence of sinus 
or AV nodal disturbances - reduces apnea associated bradyarrythmias [Harbison et al 2000]. 
Atrial overdrive pacing [Garrigue et al 2002], perhaps by reducing the number of arrhythmias, 
significantly reduces these episodes in OSA as well as CSA, further lowering the risk of sleep 
associated rhythm disturbances.  
1.1.4.5 Cerebrovascular disease 
Epidemiological studies link OSA with escalated risk of stroke [Table 1-1] [Das et al 
2012][Partinen et al 1995]. Unsurprisingly, OSA is also regarded as a poor prognostic marker 
in stroke patients [Good et al 1996] partly due to poor ventilation secondary to posture related 
problems amongst stroke patients. A small study of 24 stroke presence of OSA was 
significantly associated with adverse prognosis [Sahlin et al 2008]. Nevertheless further data is 
needed to determine whether OSA is related to cerebrovascular morbidity independent of other 
vascular risk factors. On a different note, sleep disordered breathing is also highly prevalent 
amongst stroke patients [Good et al 1996] due to associated sub-total/total paralysis of facial 
and pharyngeal muscles.
Hypertension, atherogenesis, hypercoagulability, impaired endothelial dysfunction, strong 
association with AF and changes in cerebral haemodynamics may all contribute [Ficker et al 
1997].  In some instances the dramatic changes in haemodynamics may cause up to 80% fall in 
cerebral blood flow [Netzer el al 1998] contributing to cerebrovascular events in the OSA 
population.  Currently there are little data on the effect of CPAP in OSA in post stroke settings 
to establish any symptomatic and/or prognostic benefits. Limited data indicates poor outcome 
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with CPAP use in OSA [Scala et al 2003]. Larger studies targeting primary risk reduction of 
stroke with the use of CPAP in OSA patients are much required.
1.1.5 Management strategies 
OSA is an emerging health challenge partially because of its strong association with many 
cardiovascular disorders but more importantly due to its’ individual recognition as an 
established cardiac risk factor. Close involvement of OSA in the development of heart failure 
and hypertension might suggest that treatment of OSA might ameliorate these secondary 
conditions. The current general consensus is that OSA should be treated with CPAP for 
ventilatory support as well as a tool for the secondary prevention of cardiac problems [Table 1-
2; 1-3]. Whilst limited data suggest reduction in the incidence of cardiac manifestations with 
early use of CPAP [Dursunoglu et al 2007]; existing and/or secondarily induced cardiovascular 
diseases should still be treated on their own merit [Eastwood et al 2010]. 
OSA is a relatively under-diagnosed condition and hence, the majority of OSA patients would 
have developed a cardiovascular condition before a formal diagnosis of OSA is made. Indeed 
CPAP emerged as a novel therapeutic tool; its prognostic advantages have also been 
demonstrated in recent trials [Kasai et al 2008]. From the cardiac perspective, most of the 
studies on OSA have been done in population with preexisting hypertension or other 
cardiovascular disorders.  The efficacy of CPAP in hypertension in some open, single and 
double blind studies has been challenged by some, whilst investigating a range of blood 
pressure parameters such as systolic, diastolic, mean 24-hours, nocturnal and day time blood 
pressure [Robinson et al 2006][Becker et al 2003]. Indeed most of the current evidence 
supports the use of CPAP in reduction of blood pressure with concomitant improvement in 
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patients’ cognition and daytime sleepiness [Mills et al 2006][ Dorkova et al 2008][Vgontzas et 
al 2008][Dursunoglu et al 2007][Good et al 1996].
In the last decade, various studies have determined the effect of nasal CPAP on heart failure 
associated with OSA [Mansfield et al 2004][Kaneko et al 2003]. Although most were of a small 
size, they have shown improvements in symptoms, LV dimensions and systolic (as well as 
diastolic) cardiac function. However, assessments were based on TTE which is not infallible; 
also, there were significant gender differences and in some, mild OSA was excluded. Few 
studies have focused on the prognostic significance of nasal CPAP but the results are 
promising, with a reduced mortality and hospitalization in patients treated with nasal CPAP 
[Kasai et al 2008][Wang et al 2007].
Compliance with CPAP is a well recognized issue [Weaver et al 2006] which necessitates an 
acceptable alternative with at least similar or more advantages.  Barnes et al [Barnes et al 2004] 
have used a mandibular assisted splint (MAS) with improvements shown in clinical outcomes, 
although this was not superior to nasal CPAP, and the impact on prognosis has not been 
determined.  The oral appliances have also been studied in 28 OSA patients to determine the 
impact on brain natriuretic peptide (BNP) and left ventricular dimensions [Hoekema et al 
2008]. Though the author concluded significant reduction in elevated BNP levels, these benefits 
do not seem to translate into echocardiographic ventricular improvement in this small study. 
Surgical treatment of OSA [Won et al 2008] has not gained much popularity, due to potential 
operative risks and no prognostic value. 
Antihypertensive drugs have shown to have beneficial effects on endothelium, whether directly 
or indirectly [Koh et al 1999][Li-Saw et al 2001]. As inflammation and coagulopathy caused by 
OSA induced hypoxia leads to atherogenesis, the use of aspirin and statins may help [Kennon et 
al 2001][Albert et al 2001].
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1.1.6 Conclusion 
Observational studies have demonstrated that OSA is a highly prevalent condition across all 
age and gender groups, carrying a serious risk of cardiovascular morbidity and mortality. Now 
regarded as an independent cardiac risk factor, OSA also leads to the development of other 
cardiovascular risk factors, such as hypertension.  Although hypoxia, oxidative stress and 
autonomic dysfunction have all been implicated in the development of CVD in OSA 
population, the dysfunctional endothelium plays a pivotal role, by hormonal imbalance and 
impairment of vasomotion which lays the foundations for vascular disoders. Moreover, the 
coexistence of OSA with metabolic syndrome, obesity and diabetes mellitus makes 
cardiovascular complications a logical consequence.  
OSA related symptoms such as insomnia, day time somnolence and poor exercise capacity 
could profoundly affect individual daily life. Therefore early recognition and treatment of OSA, 
supplemented by educational, behavioral and supportive interventions, may improve clinical 
status as well as the long term outcome. Further understanding of basic pathophysiology behind 
the generation of cardiovascular disorders in OSA patients may identify possible new targets 
for adjunct therapies such as use of anti-inflammatory drugs. 
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1.2 Endothelial Dysfunction, its assessment and Prognostic implications
1.2.1 Introduction
The endothelium is a thin mono-cellular layer lining the entire vascular system, separating 
blood from the interstitium. It plays a core role in vascular tone by releasing various types of 
vasoactive substances, such as nitric oxide (NO). In addition to regulating vasomotion, the 
healthy endothelium also has anti-thrombotic (through prostacyclins), anti-inflammatory 
(through developmental endothelial locus-1{Del-1}) and anti-proliferative (through NO and 
prostaglandin I2) properties. All such mechanisms are regulated by a strict balance amongst 
several agonist and antagonist biochemical substances secreted by the endothelium [Choi et al 
2009][ Butt et al 2010][Stamler et al 1994]. 
Endothelial dysfunction (ED) is a systemic process wherein the endothelium loses the ability 
to maintain the vascular equilibrium, and is characterized by abnormal vascular homeostasis, 
a prothrombotic coagulation profile and vasoconstriction. Given the close association between 
ED and cardiovascular risk factors or overt cardiovascular disease per se, the presence of ED 
is, unsurprisingly, a crucial step in the development of atherosclerosis [Figure 1-2] [Hamasaki 
et al 2000][Butt et al 2010]. 
Over the last few years, the use of several invasive and non-invasive methods of assessment 
of ED has led to a better understanding of endothelial pathophysiology and mechanisms of 
disease development.  Also a number of studies have shown that persistent ED is associated 
with adverse prognosis [Halcox et al 2002][Heitzer et al 2001]. More importantly, it has been 
proposed that strict physiological and/or pharmacological management of cardiovascular risk 
factors improves the functional status of the endothelium and reduces the risk of future 
cardiac events [Modena et al 2002].    
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Figure 1-2: The interaction between the Endothelium and Cardiovascular risk factors
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In this chapter I have discussed modern perception of endothelial biology and provided an up-
to-date overview of methods for the assessment of ED. I have also appraised the clinical and 
prognostic significance of the ED in relation to cardiovascular diseases and its major risk 
factors.
1.2.2 The Healthy Endothelium – A Brief Overview
The endothelium is the largest organ and gland of the human body and it produces a variety of 
vasoactive molecules under different stimuli [Table 1-5]. During health, these substances 
balance each other (such as pro- and anti-inflammatory substances) to maintain the vascular 
equilibrium. 
Majority of endothelial functions are mediated thorough NO. It is derived from L-arginine 
and as a biologically active gas it is abundantly present in all tissues [Moncada et al 1993]. Its 
production requires involvement of the NOS enzyme family and several coenzymes 
[Moncada et al 1991]. Three different isoforms of NOS are known, NOS-I, NOS-II and NOS-
III and although are present in endothelial cells. NOS-II that synthesizes NO for longer 
periods is important in maintaining the basal vascular tone whilst NOS-I and NOS-II produce 
short bursts of NO [Jones et al 1996]. Although, a variety of various physiological, chemical 
and pathological mechanisms can accentuate the production and release of NO, shear stress is 
probably the most notable stimulus for NO release [Cooke et al 2001]. Upon appropriate 
stimulation, special endothelial channels in the endothelial cell membrane open, causing an 
influx of calcium that activates nitric oxide synthase (NOS)-III leading to the production of 
NO [Miura et al 2001]. NO crosses the endothelial layer and diffuses into vascular smooth 
muscles and through a series of complex molecular reactions, produces cyclic guanyl 
monophosphate (cGMP). The latter subsequently modulates the influx of intracellular calcium 
causing smooth muscle relaxation and thus vasodilatation [Ohno et al 1993]. 
50
The vasodilatory reaction of endothelium (such as reactive hyperemia) is directly proportional 
to released NO concentration. Since the NO is directly released by the endothelial cells during 
reactive hyperemia, this response is known as endothelial dependent vasodilatation (EDV). 
Extrinsic nitrates such as Nitroglycerine bypasses the endothelium to act directly on smooth 
muscle cells to induce vasodilatation, and is referred to as endothelial independent 
vasodilatation (EIV). Both the EDV and to an extent EIV are attenuated in ED and the 
magnitude of this reduction correlates with the severity of the ED. 
The leukocyte adhesion to endothelium is fundamental in leukocyte recruitment, which 
occurs during inflammatory, autoimmune and infectious settings. The interaction between 
leukocytes and endothelial cells requires numerous adhesion molecules expressed both on 
leukocytes and endothelial cells, thus accentuating leukocyte recruitment into sites of 
inflammation and tissue injury. However, accurate and functionally important 
endogenous/endothelial inhibitors of leukocyte adhesion have remained debatable, thereby 
questioning the anti inflammatory properties of the endothelium. Del-1 is a glycoprotein that 
is secreted by endothelial cells and is regulated upon hypoxia or vascular injury and has been 
implicated in vascular remodeling [Choi et al 2009]. Animal studies suggest that endothelial 
Del-1 acts as an anti-adhesive factor that interferes with the integrin LFA-1- receptor 
dependent leukocyte-endothelial adhesion. Endothelial Del-1deficiency increases LFA-1-
receptor dependent leukocyte adhesion both in vitro and in vivo. This fact is supported by the 
findings that Del-1 (-/-) mice displayed significantly higher neutrophil accumulation in 
induced lung inflammation in vivo [Choi et al 2008]. Thus, it can be derived that endothelial 
Del-1 is an endogenous inhibitor of inflammatory cell recruitment and could provide a 
foundation for targeting leukocyte-endothelial interactions in disease. More importantly, since 
inflammatory processes are pivotal in the pathogenesis of atherosclerosis and mediate many 
stages of plaque formation and destabilization, the anti-inflammatory properties of the healthy 
endothelium could be crucial in the retardation of atherosclerosis [Crea et al 1997]. 
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In addition to NO, prostaglandin I2 (PGI2) released by vascular endothelium has a profound 
negative impact on vascular smooth muscle proliferation [Stamler et al 1994][Sinzinger et al 
1987]. A histological examination of vascular tissue revealed significantly lower number of 
activated smooth muscle cells in patients treated with PGI2 than in untreated ones, across all 
the age groups. A comparable suppression was demonstrated in the intima and the media of 
the vascular segments as well. PGI2 inhibits smooth muscle cell proliferation most probably 
by inhibiting platelet derived growth factor release from the platelets and stimulation of 
vascular smooth muscle cell Camp [Sinzinger et al 1986]. 
1.2.3 Assessment of Endothelial Dysfunction
Due to the intense focus on the endothelium, demand for a cost-effective, non invasive, 
reliable, reproducible, and easily available technique to assess endothelial functions has 
grown tremendously [Table 1-5].
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Table 1-5: Examples of Studies investigating Endothelial Dysfunction in Populations with Cardiovascular Risk Factors
Reference Study design Results and Comments
n ED marker CV risk factor Protocol
Al Suwaidi et 
al 2001
397 Coronary studies Obesity Obese (BMI>30) versus over 
weight (BMI 25-30) and normal 
weight subjects (BMI<25)
Obesity is associated with and is an 
independent predictor of poor ED. Patient has 
angiographically normal coronary arteries, 
DM and HTN excluded 
Lip et al 1997 225 vWF, P-sel, 
Plasma 
Fibrinogen levels, 
PAI
Essential HTN 178 hypertensive compared with 
47 controls
Larger study showing higher levels of ED 
markers in hypertensives and suggesting links 
between ED, blood pressure and cardiac 
remodeling
Celermajer et al 
1993 
200 Brachial artery 
FMD
Smoking Healthy smokers versus healthy 
non-smokers
FMD was significantly lower in smoking 
group (4±3.9% versus 10±3.3%; p<0.0001). 
large group with stringent exclusion criteria
Sibal et al 2009 123 FMD, ADMA, 
ICAM, VCAM, 
E-sel
IDDM 61 IDDM patients versus 62 
healthy subjects
FMD, ADMA were lower and adhesion 
molecules were higher significantly in IDDM 
patients (both p<0.001). coexisting 
confounding factors in study group
Taddei et al 
1995
110 Plethysmography Age Middle aged hypertensive subjects 
were compared matched 
normotensives
An inverse correlation noted between age and 
EDV. Mean age (46 years) of study group 
may be considered ‘too young’ 
Meyer et al 107 FMD, capillary NIDDM 63 NIDDM versus 44 healthy Both FMD and capillary blood flow were 
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2008 blood flow controls impaired in DM (Both p<0.05) coexistence of 
confounders in study group where female 
gender was under-represented
Lip et al 2001 102 vWF, P-sel, 
Plasma 
Fibrinogen levels
Malignant HTN Malignant HTN (n=18)  compared 
with healthy and disease controls,  
6 month follow up 
Patients with blood pressure dependent 
elevated levels of VWF and plasma 
fibrinogen levels in small malignant HTN 
group 
Hamburg et al 
2004
62 Brachial artery 
FMD
Family history of 
premature CAD
34 healthy subjects with parental 
history of CAD compared with 28 
healthy individuals with no FH.
Impaired FMD was demonstrated only in 
men with parental history of CAD in this non 
blinded study. Matched female 
representation. 
Maas et al 2008 36 FMD, NO assays Dyslipidemia 24 hypercholesterolemic subjects 
versus 12 healthy controls. 
Diminished NO excretion (p=0.003) and 36% 
reduction in FMD ((p=0.027) noted in 
hypercholesterolemia. Use of NO as a 
validated ED marker is questionable.
CV: cardiovascular, ED: endothelial dysfunction, CAD: coronary artery disease, FH: family history, BMI: body mass index, FMD: flow mediated dilatation, EDV: 
endothelial dependent vasodilatation, DM: diabetes mellitus, IDDM: insulin dependent diabetes mellitus, NIDDM: Non-insulin dependent diabetes mellitus, HTN: 
hypertension, NO: nitric oxide, ADMA: Asymmetric dimethylarginine, VWF: von Willebrand factor, P-sel: P-selectin, E-sel: E-selectin, ICAM: intercellular adhesion 
molecule, VCAM: Vascular cell adhesion molecule,PAI: plasminogen activator inhibitor 
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Historically, invasive methods were amongst the first to be developed. For example, coronary 
angiography has been utilized extensively for endothelial assessment [Ludmer et al 1986]. 
Changes in the luminal diameter of a coronary artery in response to intra-coronary infusions 
of pharmacological agents such as acetylcholine (ACH) or adenosine were an important 
method for coronary endothelial assessment. Ludmer et al first reported coronary 
vasodilatation post-intracoronary ACH infusion in healthy coronary arteries. In contrast, ACH 
induced paradoxical vasoconstriction in diseased (atherosclerotic) coronaries, which is due to 
relative unavailability of NO [Ludmer et al 1986]. Indeed previous coronary studies do not 
provide a direct evidence of impaired NO release from coronary endothelium; however it 
must be noted that ACH induced endothelial responses are predominantly NO dependent. 
Therefore, the vasoconstrictor response in coronary arteries has been regarded as a useful 
indirect tool for identification and/or risk stratification of ED and early atherosclerosis 
[Anderson et al 1999]. 
Currently, ED can also be assessed by quantifying coronary blood flow and diameter through 
intra-coronary Doppler techniques in response to pharmacological stimuli. In this method, 
once a coronary artery is engaged with a guide catheter, a Doppler wire is introduced, usually 
in left anterior descending coronary artery. Once basal flow tracing is obtained, further signals 
are recorded after an intracoronary ACH or adenosine infusion. Coronary blood flow can be 
calculated by analyzing the peak flow velocity and coronary diameter. The invasive nature 
and potential complications of coronary angiography precludes this as routine method of ED 
assessment [Al Suwaidi et al 2001]. 
Flow Mediated Dilatation 
Flow mediated dilatation (FMD) is amongst the most common techniques for endothelial 
assessment. In this method, the response of the endothelium in a large artery to changes in 
blood flow is to mediate the relaxation of smooth muscle cells, possibly via NO. This requires 
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specialized high resolution vascular ultrasound, in addition to a trained operator, to produce 
valid and reproducible results. Mean basal arterial diameter is measured using high frequency 
ultrasound. Inflation of a sphygmomanometer cuff  (to a pressure level that will prevent blood 
flow) distal to the point of measurement for more than 4 minutes will, upon release of the 
cuff, induce shear stress, which will in turn releases NO, thus  causing vasodilatation. EIV can 
also be determined by measuring mean arterial diameter post nitroglycerine administration 
sublingually [Celemajor et al 1992].  
FMD is most commonly performed on brachial artery although femoral and radial arteries can 
also be used. One big problem with the use of a variety of vascular beds in various research 
laboratories is the different reference ranges for different beds. Reassuringly, most studies 
report FMD as an accurate and reproducible method of ED assessment [Hijmering et al 2001]. 
To ensure reproducible results the test should be performed in a controlled environment (such 
as quiet environment and within a controlled room temperature). Several factors such as food, 
drugs and temperature influence FMD, therefore the test should be performed after at least 8-
12 hour fasting, abstaining from caffeine, smoking and drugs which could potentially 
influence the results. To standardize this technique the International Brachial Artery 
Reactivity Task Force has recommended guidelines to ensure reproducibility and accuracy 
[Corretti et al 2002]. 
1.2.3.2 Other Imaging Methods 
Cardiac Positron Emission Tomography (PET) has the distinctive ability to assess coronary 
flow reserve and coronary endothelial function, based on response of blood flow to 
pharmacological stress (intravenous adenosine or dipyridamole) and the cold pressor test. 
Quantitative analysis of coronary vasomotor function is valuable for accurate estimation of 
function and treatment monitoring in the presence of a number of coronary risk factors [Rosas 
et al 2008]. Recent data supports predictive value of PET assessment of coronary vasomotor 
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imaging in subjects with coronary artery disease [Uren et al 1994]. In addition, this technique 
has shown to demonstrate vasomotor dysfunction in asymptomatic young hypertensives 
and/or dyslipidemic patients [Rosas et al 2008]. Hence, quantitative analysis using PET has a 
great prospect of wide application in recognizing microvascular dysfunction and 
"individualized" monitoring of the outcomes of primary or prophylactic medical interventions 
to optimize cardiovascular outlook.
Similar to PET, Myocardial Resonance Imaging (MRI) also estimates the coronary blood 
flow and coronary flow reserve non-invasively yet without any associated radiation exposure 
[Hirsch et al 2008][Wöhrle et al 2006]. With MRI coronary artery flow indices can be 
measured with either a breath-hold or a respiration-triggered acquisition; however in the 
breath-hold MRI measurements, cardiac output are significantly depressed during breath-
holding phase after deep inspiration, but the advantage is that the breath-hold method requires 
lesser scan time. If coronary sinus blood flow and LV mass is estimated using phase-contrast 
cine MRI, both the blood flow per gram of myocardial tissue and coronary flow reserve can 
be precisely quantified. Coronary flow reserve, with quantitative MRI flow measurement, is 
measured to be between four to five folds. The MRI quantification of coronary flow reserve 
and other flow indices seems to be an ideal method for evaluating coronary hemodynamics 
and may be valuable in evaluating endothelial dysfunction of the coronary circulation [Hirsch 
et al 2008][Wöhrle et al 2006]. 
Nevertheless, whilst both the imaging techniques have their relative pros and cons, the 
expense and limited availability of these modalities render these techniques unsuitable for 
routine use to assess endothelial status.
Lately, myocardial contrast echocardiography (MCE) has been gaining popularity as an 
imaging tool to assess the integrity of the myocardial microcirculation [Dwivedi et al 
2007][Di Bello et al 2004]. This approach provides an estimation of the two crucial 
components of capillary perfusion: Blood volume fraction and flow velocity, unlike other 
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experimental and clinical methods that only measure myocardial blood flow (MBF). The 
latter can be used to accurately calculate of CFR providing information about the functional 
consequences of ED. This technique utilizes inert microbubbles that possess similar 
rheological properties as red blood cells and remain entirely within the vascular space 
[Jayaweera et al 1994]. During the intravenous infusion of these microbubbles and following 
attainment of a steady state in the myocardial tissue, the microbubbles are destroyed using 
high energy ultrasound and the rate of bubble replenishment is measured (represents mean red 
blood cell velocity) [Wei et al 1998]. Under resting conditions and if resting flow is normal, 
this replenishment is completed within 5 seconds. However, it takes longer to fill if resting 
flow is reduced. The rate of filling is faster after stress which is usually induced by 
intravenous dipyridamole or dobutamine. After full replenishment, the ultrasound signals 
represent the relative blood volume within the beam, which correlate to the blood volume 
within the myocardium itself. Normalizing this value to the signals from the left ventricular 
cavity provides a value of blood volume fraction. The product of the blood volume fraction 
and flow velocity is equal to MBF which could be utilized for the measurement of CFR [Wei 
et al 1998]. In addition, not only is MCE a useful tool for the non invasive assessment of ED, 
but it can also be used in evaluating cardiovascular prognosis in selected cohorts [Dwivedi et 
al 2007]. 
Peripheral endothelial function can also be assessed by venous impedance plethysmography 
which quantifies local blood flow in response to intra-arterial drug administration [Taddei et 
al 1995]. However, due to the partially invasive nature of this (administration of intravascular 
infusions) precludes its common use. Similarly, laser Doppler flowmetry (LDF) coupled with 
iontophoresis, which measures endothelial function at capillary level by scanning red cell flux 
in a small tissue sector is another method of ED assessment [Yoshida et al 2010]. 
1.2.4 Plasma Markers 
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The endothelium secretes a number of substances and logically it raises the question if these 
substances can act as surrogate markers for ED [Table 1-5].  Lately, several endothelial 
products have been successfully utilized for this purpose; for example, plasma Von 
Willebrand factor (VWF), have been used as marker of ED in a number of studies [Yaqoob et
al 1993]. More recently, quantitative and qualitative analyses of certain endothelial cell 
strains have also been reported to be useful as putative ED markers [Shantsila et al 2007 (a)].  
The routine use of such substances has their individual pros and cons and is discussed in this 
section.
1.2.4.1 Von Willebrand Factor (VWF)
This glycoprotein is released from endothelial cells and, as demonstrated by severe von 
Willebrand’s disease (which resembles haemophilia), has an integral role in thrombogenesis 
[Vischer et al 2006].  As a strong association has been reported between ED and VWF levels 
[Figure 1-3]; the latter has been meticulously investigated in recent years and can be regarded 
as a surrogate marker for the presence as well as progression of ED [Lip et al 1995][Jansson 
et al 1991].  However, plasma VWF levels are greatly affected by genetic (ABO blood group 
and VWF gene mutations) and non-genetic factors (ageing, diabetes and oxidative stress). 
Therefore, the future role of VWF as a ‘gold standard’ biomarker of ED greatly depends upon 
validation studies of such genetic and non-genetics determinants [Vischer et al 2006]. Finally, 
the acute phase response of VWF results in high levels of this protein in inflammatory 
disorders and malignancy, and in such disease groups VWF can not be utilized as a robust ED 
biomarker [Pottinger et al 1989]. Despite these limitations, the results from studies predicting 
stroke risk in the elderly are promising and similar studies might further refine the role of 
VWF in ED [Conway et al 2003]. 
1.2.4.2 Endothelin (ET)
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Endothelin (ET) is a 21-amino acid vasoconstrictor peptide and was first described to have a 
vital role in vascular homeostasis in 1988 [Yanagisawa et al 1988]. Later, genetic analysis 
demonstrated three distinct genes encoding for three structurally and pharmacologically 
distinct ET isoforms named ET-1, ET-2, and ET-3 [Inoue et al 1989]. The vasoconstrictor 
effect of ET is mediated by ET-A and ET-B receptors located on vascular smooth muscles. 
ET is a mitogenic, vasoconstrictor and pro-inflammatory molecule and is found elevated in 
diseases associated with ED such as hypertension (HTN), diabetes mellitus (DM) and 
coronary artery disease (CAD) [Kishimoto et al 1995]. The association of endothelins with 
ED is also supported by data demonstrating reversal of ET mediated actions by blocking ET-
A receptors in patients with atherosclerosis [Bohm et al 2002]. In addition, ET correlates well 
with other markers of ED [Vancheeswaran et al 1994]; however, limited understanding of the 
subcellular interaction(s) between ET and endothelial functions makes its use as biomarker of 
ED ambiguous at present.   
1.2.4.3 Adhesion Molecules 
These are a family of molecules that are located on the surface of endothelial cells, as well as 
various other cells. The origin and function of these circulating and soluble adhesion 
molecules are largely unclear, but they most likely originate from shedding or proteolytic 
cleavage from the cell surface and promote leukocyte adhesion. 
Vascular cell adhesion molecule-1 (VCAM-1], endothelial–leukocyte adhesion molecule-1 
(E-selectin) and intercellular adhesion molecule-1 (ICAM-1] are some of the more 
extensively studied molecules [Blann et al 1998 & 1999]. E-Selectin is exclusively expressed 
on endothelial cells and due to this exclusivity, could be used as a surrogate marker of ED 
[Newman et al 1993]. High levels of soluble E-selectin have been observed in conditions 
associated with ED such as HTN, cancer, DM and sepsis [Newman et al 1993]. Nevertheless, 
soluble E-selectin levels often fail to correlate with VWF levels in atherosclerosis or 
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connective tissue diseases [Blann et al 1994 & 1995] and therefore its precise role as a plasma 
marker of ED remains unclear.  Plasma adhesion molecules, ICAM and VCAM, are also 
found on other cells in addition to endothelial cells, such as lymphocytes and fibroblasts, and 
hence not specific for the endothelium [Gearing et al 1993].
1.2.4.4 Soluble Thrombomodulin 
Thrombomodulin is an integral membrane protein expressed on the surface of endothelial 
cells [Maruyama et al 1985].  It functions as a cofactor in the ‘thrombin-thrombomodulin 
complex’, leading to inhibition of fibrin formation, as well as platelet activation and 
activation of circulating protein C [Mitchell et al 1986]. Like soluble adhesion molecules, a 
truncated form of membrane thrombomodulin can be found in plasma (i.e. soluble 
thrombomodulin). Given the lack of correlation between soluble thrombomodulin levels, 
cytokines and fibrinogen, this proteoglycan is believed to reflect ‘endothelial damage’ rather 
than ‘endothelial activation’ [Seigneur et al 1993]. Whilst soluble thrombomodulin have been 
reported in the plasma and urine of healthy subjects, levels are grossly deranged in conditions 
associated with ED, such as sepsis, chronic renal failure, cancer and connective tissue disease 
[Gearing et al 1993][Newman et al 1993].
1.2.4.5 Nitric Oxide (NO) 
As described before, majority of vasomotive endothelial functions are predominantly 
mediated through NO. Additionally, owing to its intracellular production, quantitative and/or 
qualitative analysis of NO could make this molecule an accurate surrogate marker for ED.  
However, complex sub cellular biochemical NO synthetic reactions render accurate 
laboratory measurement extremely complex. Although by-products of endogenous NO, found 
in plasma and urine, can be measured, these methods are indirect, expensive and of poor 
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reproducibility. A major problem with a commonly used biochemical method is that increased 
consumption of nitrate rich foods can also result in spuriously high levels [Ignarro et al 
1990][Saccani et al 2006]. These facts, whilst supporting easy availability of NO, indicate 
that the reliability of measuring NO as diagnostic plasma/serum/urine marker of ED is still 
uncertain. 
1.2.4.6 Asymmetric Dimethylarginine (ADMA)
ADMA is a competitive NO antagonist. It is produced as a metabolic by-product of a 
complex proteolytic cleavage process in human cell cytoplasm and is detected in the plasma 
and urine. There is ample evidence supporting the presence of elevated ADMA levels in 
conjunction with ED [Abbasi et al 2001]. In addition, its close biochemical link with 
homocystiene indicates the potentially significant contribution of ADMA in the initiation of 
ED and manifestations of atherosclerosis [Abbasi et al 2001]. Of note, folic acid induced 
endothelial improvement also supports the same notion [Holven et al 2003]. 
Hence, when considering the available data, ADMA seems to be emerging as a novel marker 
of ED; however, rapid fluctuations in plasma ADMA levels in response various factors such 
as high-salt diet, fatty meal consumption, pregnancy and renal impairment [Fard et al 2000]
Holden et al 1998][Vallance et al 1992] are the major limitations to its routine use. 
1.2.5 Cell Markers
1.2.5.1 Circulating Endothelial Cells (CECs)
Circulating endothelial cells (CECs) represent mature endothelial cells driven from the vessel 
wall in response to endothelial injury, and rarely exist in healthy individuals in detectable 
quantities [Erdbruegger et al 2006]. As quantitative assays of CECs have been shown to have 
a linear correlation with endothelial integrity; these cells could be regarded as a novel and 
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reliable surrogate biomarker of endothelial integrity [Lee et al 2005][ Erdbruegger et al 2006]. 
High CEC counts are found in a number of disease states associated with ED. Enumeration of 
elevated CECs levels in acute coronary syndrome, stroke, DM, and peripheral vascular 
disease could act as a diagnostic marker in addition to reliably indicating disease severity and 
prognosis [Lee et al 2005][ Nadar et al 2005][ Sinzinger et al 1986]. Although estimation and 
enumeration of CECs is complex, technologies such as immunobeads isolation and 
fluorescence-mediated flow cytometry have made this a plausible proposition.  
1.2.5.2 Endothelial Progenitor Cells (EPCs)
Bone marrow-derived circulating endothelial progenitor cells (EPCs) help maintaining 
vascular integrity by restoring endothelial continuity and neo-vascularization of ischaemic 
tissues [Kawamoto et al 2007]. Although the exact mechanism resulting in the mobilization of 
EPCs largely remains unknown, a spectrum of biochemical substances such hypoxia and 
vascular endothelial growth factor (VEGF) have been described as mediators of this process 
[Hristov et al 2004]. EPCs not only mediate neovascularization having been demonstrated in 
transplanted limbs but have also been useful in predicting cardiovascular prognosis 
[Kawamoto et al 2007]. 
These concepts have led to further improvements in efficient isolation, mobilization, 
recruitment, and transplantation of EPCs as a therapeutic approach. Since these cells are 
related to endothelial repair and regeneration, depletion of EPCs in conditions associated with 
ED, leads to impairment of the repair process and thus promote endothelial and vascular 
damage. Of note, the extent of EPCs paucity can also be correlated with disease severity 
[Valgimigli et al 2004]. Therefore, depletion or extremely low EPCs levels in smoking, DM, 
and atherosclerosis suggests that EPCs may be a consistent and robust in vivo early marker of 
ED [Tepper et al 2002][ Kondo et al 2004] [Vasa et al 2001]. However, since EPCs diminish 
with age, the correlation with ED may not be possible in the elderly population [Scheubel et 
al 2003]. 
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1.2.6 Inter-relationships between different Methods of Endothelial Assessment
The availability of a wide variety of ED assessment tools introduces a possibility of wide 
variability among different methods. As yet, there are very few randomized and blinded data 
comparing invasive and non invasive methods to demonstrate agreement between these 
techniques. 
Coronary vaso-reactivity and brachial artery FMD were compared in a study on subjects with 
angiographically normal arteries [Teragawa et al 2005]. The results suggested that brachial 
FMD significantly correlates with coronary diameter and flow changes indicating reasonable 
agreement between the methods. Similarly, FMD has also been compared with plasma 
markers such as VWF [Chong et al 2004][Figure 1-3]. Here again, authors reported a 
significant inverse correlation between FMD and VWF (p=0.001). 
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Figure 1-3: Correlation between von Willebrand factor and Flow Mediated Dilatation
Correlation line between FMD and vWf shown, with 95% confidence intervals [FMD= flow mediated 
dilatation; VWf=von Willebrand factor] Correlation between FMD and vWf: r=-0.517, p<0.001. 
Reproduced from Felmeden DC et al., Blood Coag Fibrinolys 2003; 14: 425-431, with permission
                                                
.
Further larger studies using newer methods (such as new biological and biochemical marker) 
are needed to test the correlation between the different methods of endothelial assessment.
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1.2.7 Endothelial dysfunction in relation to cardiovascular risk factors
Endothelial dysfunction (ED) has been demonstrated in prominent prognostic cardiovascular 
risk factors such as DM, HTN) and smoking [Figure 1-2] [Table 1-5], leading to the 
hypothesis that ED could be the final common pathway for major cardiovascular risk factors. 
However as yet, it is largely unclear if the prognostic power of these risk factors is secondary 
to the presence of ED.  
1.2.7.1 ED and Demographic variables 
The effects of ageing on endothelial functions have been investigated in human models and 
generally the results seem to support that ageing is associated with attenuated NO production 
[Toda et al 2012][Taddei et al 1995]. For example, ACH induced changes in coronary artery 
diameter were investigated in an elderly cohort and the results seem to suggest that ageing is
associated with attenuated EDV [Taddei et al 1995]. Age related attenuation of the NO levels 
is probably the consequence of the ‘vascular senescence’ phenomenon [Minamino et al 2004]. 
The latter is described as a stage when the vascular cell growth is arrested after completing 
their life span. These senescent cells are abundantly present in atherosclerotic lesions, express 
proinflammatory molecules reducing the in vivo NOS levels, and thus contribute to impaired 
NO production [Minamino et al 2004]. In addition, evidence from animal studies suggests 
that age related enhanced oxidative stress could also be another contributing factor [Blackwell 
et al 2004].
Obesity also has a profound impact on endothelial function as demonstrated in a large study 
(n=397) investigating the impact of body mass index (BMI) on coronary vasomotor response 
[Campia et al 2012][Al Suwaidi et al 2001]. In multivariate regression analysis, obesity was 
found an independent predictor of poor coronary blood flow and vasoreactivity [Al Suwaidi et 
al 2001]. Although pathophysiological pathways explaining this association largely remain 
obscure; intracellular accumulation of certain fatty acids could augment the oxidative stress 
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and cause ED [Bakker et al 2000].  Long chain fatty acyl co-enzymes-A esters may also 
inhibit endothelial mitochondrial function, resulting in impaired adenosine translocation 
leading to over production of ROS, ultimately resulting in manifestations of ED [Bakker et al 
2000].  
1.2.7.2 ED and Smoking
Active or passive, smoking has an independent and dose-dependent relationship with ED and 
atherosclerosis [Celermajer et al 1993 & 1996]. Nicotine is converted by the liver into various 
metabolites such as cotinine, cotinine-N-oxide, nicotine-1'-N-oxide and norcotinine. These 
metabolites increase the expression and the activity of angiotensin converting enzyme 
[Ljungberg et al 2008] which subsequently promotes the over production of angiotensin II. 
The latter result in the production of superoxide ions and enhances vasoconstriction 
[Rajagopalan et al 1996] and may be responsible for the development of ED. Interestingly, 
smoking causes raised VWF [Lip et al 1995], and also predisposes to the formation of white 
thrombi (platelet thrombus) which, though clinically quiescent [Hung et al 1995], are 
frequently reported on atherosclerotic plaques [Davies et al 1988]. In an environment of 
impaired coagulation (such as ED), these so called ‘benign white thrombi’ might proliferate 
leading to an acute coronary occlusion. 
1.2.7.3 ED and Diabetes Mellitus
ED is dominantly reported in association with insulin dependent (IDDM) and independent 
diabetes (NIDDM), and indicates a high risk of developing micro- and macro-angiopathic 
complications [Johnstone et al 1993]. Although underlying mechanisms are broadly similar, 
ED is more frequently associated with angiopathic complications in NIDDM [Neri et al 
1998]. In a large cohort (n=209) of IDDM patients, for example, those who developed 
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microalbuminuria after a 10 year follow up had significantly impaired endothelial functions 
compared to those patients who did not develop microalbuminuria [Myrup et al 1994]. 
Similarly, in a relatively smaller study of 70 IDDM patients, ICAM and VCAM levels were 
substantially raised in patients with retinopathy compared to those without diabetic eye 
disease [Fasching et al 1996]. 
It is believed that persistently elevated blood glucose levels cause glycosylation of the 
phospholipids and proteins inducing increased intra-cellular oxidative stress. These 
glycosylated products are initially reversible but after undergoing complex biochemical 
reactions, they transform into more stable and irreversible molecules which generate ROS and 
increase oxidative burden [Calles-Escandon et al 2001]. Additionally, the role of ED in 
intracellular depletion of nicotinamide adenine dinucleotide phosphate (NADPH) and over 
expression of growth factors in subject with DM could also provide insight into diabetes 
related neovascularization and atherogenesis [Calles-Escandon et al 2001]. 
1.2.7.4 ED and Hypertension
ED has been demonstrated in the peripheral as well as coronary circulation of hypertensive 
patients   In a large study of 111 hypertensive patients, coronary Doppler recordings showed 
significantly diminished coronary vasoreactivity to both, ACH and adenosine infusions, 
indicating dysfunctional endothelium [Hamasaki et al 2000]. FMD of the brachial artery in 
hypertension may be less sensitive than in-vitro measurement in resistance arteries, whilst 
EDV in the human forearm and coronary vasculature are strongly correlated [Teragawa et al 
2005]. Another indirect method of endothelial assessment is to visualize the intima and media 
thickness (IMT) of the carotid artery [Sramek et al 2000]. Strictly speaking, this is not a 
routine test of assessment of “endothelial function”, but IMT measurement is believed to 
reflect the global endothelial state and overall atherosclerotic burden on the large arteries. 
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Similar to the FMD, IMT measurement also has issues regarding observer dependency, but a 
good correlation has also been shown between IMT and FMD [Hashimoto et al 1999]. 
Other tests such as response of blood flow as measured by plethysmography to intra-arterial 
infusions such as, acetylcholine, methacholine or nitroprusside, are also frequently used to 
study the effect of drugs on vascular and endothelial function in hypertension. Unsurprisingly, 
the use of anti-hypertensive therapy is associated with an improvement of endothelial 
function [Nadar et al 2004].
ED per se could even lead to HTN and vice versa and there are several explanations for this 
[Figure 1-2].  Clearly, strong and well documented evidence supports the concept of 
endothelial disturbance in hypertension [Spencer et al 2002][Panza et al 1993] with 
relationships to the severity of carotid artery atherosclerosis and abnormalities in coagulation 
profile, which may contribute to an accentuated risk of stroke [Lip et al 1994]. However, it is 
unclear if these changes are of aetiological nature or simply the consequences of hypertension 
[Luscher et al 1994].  
With the constant exposure to high blood pressures in HTN, certain changes occur in 
endothelium that ‘activates’ it. However, endothelial activation, regardless of different 
versions of its definitions by molecular biologists and immunologists, ultimately leads to the 
enhanced production of procoagulant and inflammatory agents [Blann et al 2000][Harrison et 
al 2003]. Hence, with persistent exposure to the high-pressure blood flow, accentuated 
inflammatory mediators and the effects of the neutrophils and platelets adhered to the 
endothelium; the latter becomes damaged [Pearson et al 1994]. This ‘damaged’ or 
‘dysfunctional’ endothelium then participates in a vicious cycle whereby the blood pressure 
tends to remain elevated due to consistent changes in NO and endothelin bioavailability. 
Conversely, ED related lack of NO, oxidative stress, impaired coagulation profile and 
exaggerated vascular smooth muscle proliferation could lead to increased peripheral vascular 
resistance [Buga et al 1991]. As the blood pressure is directly related to cardiac output and 
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peripheral vascular resistance, the hemodynamic effects of the latter could contribute to the 
development of HTN. It has been reported that cyclooxygenase dependent vasoconstrictor 
pathway contributes to the development of ED in essential hypertensive patients [Taddei et al 
1993].  Others, whilst investigating the vascular effects of NG monomethyl L arginine (an 
arginine analog) in essential hypertension, report a defect in the endothelium-NO system as a 
root cause of ED development in HTN [Panza et al 1994]. 
1.2.7.5 ED and Dyslipidemia
There is a linear relationship between dyslipidemia and CAD risk [Multiple Risk Factor 
Intervention Trial Group 1982]. Studies carried out to determine statin’s abilities 
demonstrated they have multiple pleiotropic effects (i.e. cholesterol-independent benefits). 
These properties are highly diverse and assume such effects such as the improvement of 
endothelial status-damaged by multiple pathologic conditions- with secondary increase in 
plasma NO bioavailability [Agewall et al 2006]. Enhanced production of reactive oxygen 
species (ROS) due to hypercholesterolemia, and in conditions with increased low density 
lipids (LDL) and/or reduced high density lipids (HDL) levels could impair endothelial 
functions [Casino et al 1993]. In addition, oxidized LDL also down- regulates the activity of 
endothelial NOS, and thereby induces ED [O’Driscoll et al 1997]. Antioxidant ability of the 
statins manifests in various ways, such as reduction in the ROS production, fact that makes 
them useful in the treatment of the conditions like dyslipidemia or cardiovascular diseases 
[Agewall et al 2006]. 
1.2.8 Role of Endothelial Dysfunction in Cardiovascular Prognosis 
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It is evident that a variety of cardiovascular risk factors significantly contribute to the 
development of ED [Table 1-6]. Based on such links, ED could be the final common pathway
shared by most cardiac risk factors and could have a crucial role in the cardiovascular 
prognosis. 
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Table 1-6: Important Prognostic Studies on Endothelial Dysfunction
Reference                                            Study design Conclusion
n ED assessment 
Method 
ED marker Follow up Primary end points
Modena et al 
2002
400 Brachial FMD EDV and EIV 67 months Any cardiovascular 
events (non 
specified)
Highly significant event rate in patients 
with poor FMD (p< 0.0001), inclusion of 
only post menopausal women was a 
limitation
Halcox et al 
2002
308 Intracoronary 
studies
Coronary 
response to 
ACH
46 months Cardiovascular 
events
11% event rate, ACH induced coronary 
vasoconstriction is predictive of CV events
Heitzer et al 
2001
281 Brachial FMD EDV and EIV 4.5 years Death, MI, stroke, 
PTCA, CABG
Worse outcome in patients with poor ED 
(p<0.001) and EIV (p<0.05). Significant 
improvement in vasomotor response was 
noted with vitamin C (p=0.001)
Perticone et al 
2001
225 Brachial FMD EDV and EIV 31.5 months Any vascular event 
(MI, stroke, PVD)
8.17% event rate, observer bias can not be 
ignored in FMD
Gokce et al 
2003
199 Brachial FMD EDV and EIV 1.2 years Death, MI, USA, 
stroke, PTCA, 
CABG
FMD markedly reduced in patients with 
events (4.4 ± 2.8% compared with those 
without an event 7.0 ± 4.9%, p < 0.001). 
Suwaidi et al 
2000
157 Intracoronary 
studies 
Coronary 
response to 
28 months Cardiac death, MI, 
PCI
Presence of ED is significantly associated 
with future risk of adverse cardiac events 
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ACH (p<0.05)
Schächinger et 
al 2000
147 Intracoronary 
studies 
Coronary 
response to 
ACH, CPT
7.7 years Cardiac death, MI, 
PCI, CABG
19% event rate, vasomotor responses are 
predictive of cardiac events
ED: endothelial dysfunction, ACH: acetylcholine, USA: unstable angina, MI: myocardial infarction, PCI: percutaneous coronary intervention, PTCA: percutaneous 
Transluminal coronary angioplasty, CABG: coronary artery bypass grafting, CPT: cold pressor test, CV: cardiovascular, PVD: peripheral vascular disease, FMD: flow 
mediated dilatation, EDV: endothelial dependent vasodilatation, EIV: endothelial independent vasodilatation
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In order to test this concept, a number of invasive and noninvasive studies have investigated 
the relationship between ED and cardiovascular prognosis [Table 1-5, 1-6]. Halcox et al 
investigated the coronary endothelial function invasively and noted the occurrence of 
unpredictable cardiovascular events (cardiovascular death, myocardial infarction, stroke, and 
unstable angina) in healthy subjects and patients with CAD on follow up [Halcox et al 2002]. 
The authors reported that coronary EDV response to ACH was a strong and independent 
predictor of future cardiovascular events (p=0.003); although EIV was not associated with 
worse cardiovascular outcome.  Similar results were also reported by Schächinger et al, who 
observed a 19% relative increase in the risk of cardiovascular events in patients with CAD 
and poorer endothelial dependent responses [Schächinger et al 2000]. 
Thus, the existence of ED in coronary arteries is associated with poor cardiovascular outcome. 
However, whether the severity and extent of ED would have an impact on clinical outcome, 
remained unclear. To address this issue, Suwaidi et al compared patients with different 
grades/severity of ED (on the basis of their response to ACH) and found significantly higher 
incidence of cardiac events in patients with severe ED compared to those with the milder 
form (P<0.05) [Suwaidi et al 2000]. These findings reinforce the general belief that the extent 
of ED has an additional impact on cardiovascular prognosis.
Similar to the invasive techniques, the non-invasive methods of ED assessment have also 
been used to predict adverse cardiovascular prognosis in a number of studies.  In one study by 
Perticone et al, endothelial status was investigated in 225 hypertensive patients using brachial 
FMD [Perticone et al 2001]. The patients in the lowest FMD tertile had the worst prognosis, 
demonstrating a link between occurrence and severity of ED with cardiovascular prognosis. 
Similarly, in another study using FMD with prolonged follow up (4.5years), higher rates of 
cardiovascular events (32%) were noted in patients with poor ACH induced vasodilatory 
response [Heitzer et al 2001]. 
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Similarly, plasma indices have also been utilized in a number of recent studies investigating 
cardiovascular prognosis. For example, VWF levels were found profoundly and significantly 
elevated in patients admitted with acute coronary syndromes and levels were independently 
predictive of major adverse cardiovascular events (MACE) [HR 1.02 (95% CI 1.005-1.040); 
P = 0.009][Boos et al 2008]. Earlier, Lip et al also concluded that hypertensive patients who 
experienced new cardiovascular events had more ED, as demonstrated by elevated D-dimer 
and VWF levels [Lip et al 2002]. Finally, these observations were also supported by findings 
from Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) where among high risk patients 
with hypertension, raised levels of P-selectin were found predictive of myocardial infarction 
[Varughese et al 2007].  
As a close agreement exists between invasive and no invasive methods as described above 
[Teragawa et al 2005][Chong et al 2004], a variety of non-invasive methods can be reliably 
utilized for the assessment of cardiovascular prognosis. Further larger studies using newer 
methods (such as new biological markers) are needed to test the prognostic value of ED. 
1.2.9 Management of Endothelial Dysfunction
ED is potentially a reversible condition. Several physiological and pharmacological 
therapeutic strategies have proven to improve ED. These include, for example exercise, folic 
acid, ACE inhibitors, statins and antidiabetic drugs [Table 1-7]. It can be hypothesized that 
the prognostic benefits of some pharmacological agents (such as statin, ACE Inhibitors) may 
secondary to endothelial improvement with the use of these agents. 
75
Table 1-7: Important Interventional (Physiological and Pharmacological) Studies on Endothelial Dysfunction
Reference Study Design Results and Comments 
n Intervention Study groups ED markers Follow up
Mancini et al 
1996
155 ACEI 51 patients were randomized 
to 40mg quinapril compared 
to placebo (n=54) 
Intra coronary studies 6 months In this double blinded study, Quinapril group 
showed significant improvement in coronary 
dynamics versus placebo. This was possibly 
due to better oxidative profile
Böger et al 
1998
80 L-Arginine 49 hypercholesterolemic 
versus 31 healthy subjects
ADMA Nil In this double blinded trial, ADMA levels 
were found raised in disease group (p<0.05). 
Levels normalized after L-arginine 
administration (p<0.01). 
De Souza et 
al 2000
68 Exercise Healthy men underwent a 
home-based aerobic exercise 
Plethysmography 3 months 30% increase in ACH-mediated 
vasodilatation after exercise (p<0.01) 
Suggested  regular aerobic exercise can 
retard age-related attenuation in vascular 
responses EDV
Dupuis et al 
1999
60 Statins ACS patients (n=30) versus 
healthy volunteers (n=30)
FMD 6 months Compared to placebo, EDV improved 
(p=0.02) with no concurrent changes in 
coagulation profile or endothelin levels,  in 
statin group 
Ziaccardi et 
al 2002
56 Weight 
Reduction 
Obese females underwent 
strict weight reduction 
TNF-α, IL-6, ICAM-1, 
VCAM-1 and P-sel
12 months 10% weight reduction significantly reduces 
cytokines (p<0.01) and adhesion molecules 
(p<0.02). However exclusively young 
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programme female included. Obese group have higher 
levels at baseline
Mather et al 
2001
44 Metformin 1gram/day Metformin in 29 
DM patients versus placebo 
(n=15) 
Plethysmography 12 weeks Subjects randomized to Metformin 
demonstrated marked improvement in ACH-
stimulated flows compared to other group 
(p= 0.002). Insulin resistance was found to 
be the sole predictor of EDV
Quyyumi et 
al 1997
39 L-Arginine 32 CAD patients compared 
with 7 healthy volunteers
Intra coronary studies Nil Intracoronary infusion of L arginine 
enhanced EDV significantly (p<0.001). 
however, small and non-blinded study
Prasad et al 
2000
31 ARB Effects of Losartan were on a 
cohort of patients with 
atherosclerosis
FMD 8 weeks Small study yet showed improvement in 
FMD after ARB therapy (1.4±0.9% to 
3.2±0.8%, P=0.03)
Ting et al 
1997
23 Vitamin C Dyslipidemic (n=11) versus 
healthy subjects (n=12) 
Plethysmography Nil Vitamin C improves EDV in dyslipidemic 
(p=0.001) supporting anti-oxidant actions of 
Ascorbic acid
Husain et al 
1998
19 Aspirin 19 patients with documented 
CAD and/or coronary risk 
factors.  
Doppler flow 
velocities
Nil Intravenous Aspirin significantly improved 
ACH-mediated femoral vascular resistance 
index (19 ±5%, p=0.002).  intravenous use is 
exceedingly rare in practice
Pistrosch et 
al 2004
12 Rosiglitazone 12 Patient received 
Rosiglitazone and  
Plethysmography 12 weeks Small double blind study demonstrating 
increased forearm blood flow post 
Rosiglitazone significantly (12.8 ± 1.3 
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Nateglinide  versus. 8.8 ± 1.3 ml/100 ml;  P < 0.05)
ED: endothelial dysfunction, ACH: acetylcholine, SNP: sodium nitroprusside, FMD: flow mediated dilatation, EDV: endothelial dependent vasodilatation, EIV: endothelial 
independent vasodilatation, DM: diabetes mellitus, ACS: acute coronary syndrome, ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blockers, 
CAD: coronary artery disease, ADMA: Asymmetric dimethylarginine, MDT: multidisciplinary team, TNFα: tumor necrosis factor α, IL-6: interleukin-6, ICAM-
1:intercellular adhesion molecule-1, VCAM-1: vascular cell adhesion molecule-1, P-sel: P-selectin
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Several possible mechanisms have been postulated to explain how such pharmacological 
interventions improve the endothelium. For example, therapeutic use of L-Arginine 
(precursor of NO) is believed to increase the concentration and activity of endothelial NO. In 
addition, reduction in plasma ET-1 levels, enhanced apoptosis of vascular lesion cells and 
normalization of elevated ADMA levels have been described as supplementary benefits of L-
Arginine [Böger et al 1998]. Other agents such as ACE inhibitors and statins may to improve 
ED possibly by reduction in superoxide ions, attenuation of contractile effect of angiotensin 
and enhanced increase in NO release from endothelial cells [O’Driscoll et al 1997][ Mancini 
et al 1996]. Such improvement in oxidative stress by statins is in addition to its cholesterol 
lowering effects [Dupuis et al 1999]. 
Furthermore, the evidence from the last two decades strongly support the prognostic benefits 
obtained in different populations with ACE inhibitors and statins [ONTARGET Investigators 
2008][Yusuf et al 2000]. Whilst evidence as described above clearly demonstrates 
improvement in endothelial status with the use of these agents, how much of such endothelial 
improvement translates into the prognostic benefits remains largely unclear. Larger 
prognostic studies investigating pharmacological interventions with set primary and 
secondary end points and concomitant endothelial assessment are needed to settle this debate. 
1.2.10 Conclusion 
The endothelium is a unique vasoregulatory organ which secretes a number of molecules to 
achieve and maintain the vascular equilibrium. Any derangement in the endothelium has 
significant negative consequences. Ample evidence suggests that major cardiovascular risk 
factors impair endothelial function inducing a state of ED and this could predispose to the 
development of atherosclerotic plaques if left unchecked. Since ED holds such a critical 
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position in the development of various cardiovascular disorders, this demands its accurate 
assessment for risk stratification. Over the years, a large number of useful invasive and 
noninvasive techniques have been utilized to assess ED accurately. Endothelial functional 
status can be improved by using a number of physiological and/or pharmaceutical agents. 
Improved prognosis with primary prevention strategies could suggest that improved ED could 
lead to better outcome. However, data supporting this point are not only limited but also 
indirect. The answer probably lies in further large studies with cardiovascular primary and 
secondary end points and prolonged follow up. 
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Section 2 Hypotheses and Methodology 
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2.1 Hypotheses
The aims of the present study were to test the following three hypotheses:
1. Significant perfusion abnormalities are demonstrable in OSA using MCE, compared with 
disease and healthy controls.
2. Degree of perfusion abnormalities demonstrated in OSA with MCE correlates with 
established markers of endothelial damage/dysfunction.
3. Myocardial perfusion and endothelial abnormalities in OSA patients improve with 
prolonged CPAP therapy.
2.2 Subject Recruitment
2.2.1 Study Population
Forty five stable, newly diagnosed moderate/severe (apnoea hypopnoea index>15 diagnosed 
by multi channel polysomnography [FSI Grey Flash recorder, Stowood Scientific Instruments 
Ltd, Oxford UK]) OSA patients were selected from sleep laboratory at City Hospital 
Birmingham, UK. These patients were compared with 45 healthy controls and 45 stable, 
treated hypertensive controls (disease controls). OSA was excluded from both control groups 
using multi channel sleep study. The hypertensive subjects were recruited from hypertension 
clinic whilst healthy subjects were selected from patients’ relatives, staff and from the 
hospital records of sleep study negative patients [Table 2-1]. 
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Table 2-1: Clinical Characteristics of Obstructive Sleep Apnoea patients, Hypertensive 
and Healthy Controls 
Variable OSA HTN Healthy p
n 45 45 45
Male/Female 34/11 30/15 30/15 0.21
Age (years) 50(9) 49 (12) 46(7) 0.120
Aponea 
Hypopnea index
33 (21-50) 
*Ψ
4(1.2-5.8)Ψ 3(0.9-5)* <0.01
Body mass 
index (Kg/m2)
34(8) 32(6) 32(6) 0.118
Systolic Blood 
pressure 
(mmHg)
142(16) 150(21)^ 135(15)^ <0.01
Diastolic Blood 
pressure 
(mmHg)
83(11) 85(10) 82(9) 0.22
No. of current 
smokers
14 12 16
Comorbidities 
Treated 
hypertension
0 45 0
Treated 
dyslipidemia 
0 0 0
Known coronary 
artery disease
0 0 0
Diabetes 
Mellitus
0 0 0
Past stroke/TIA 0 0 0
Current drug therapy
ACE inhibitors 0 23 0
ARB 0 20 0
Calcium channel 
blockers
0 20 0
Beta blockers 0 15 0
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Aspirin 0 34 0
Diuretics 0 7 0
Values are described as Mean (Standard Deviation) and Median (Inter-quartile Range). P <0.05 was 
considered statistically significant.
* Significance between OSA and Healthy subjects 
^ Significance between Hypertensive and Healthy subjects
Ψ Significance between OSA and Hypertensive subjects
OSA= Obstructive Sleep Apnoea, HTN= Hypertension, TIA= Transient Ischemic Attack, ACE= 
Angiotensin Converting Enzyme, ARB= Angiotensin Receptor Blockers
All study participants were deemed otherwise healthy after careful interview, detailed clinical 
examination, baseline blood tests (Full blood count, renal function tests, liver function tests, 
inflammatory markers, blood glucose, thyroid and cholesterol profile) electrocardiogram 
(ECG) and transthoracic echocardiography. 
All study subjects fasted for 12 hours and abstained from smoking, alcohol, tea and coffee for 
24 hours prior to the study. Hypertensive subjects were advised to omit their medications on 
the study day, as prolonged treatment omission was deemed unethical. All scans were 
performed in a quiet, darkened, temperature controlled room after patient rested for 15-20 
minutes. Blood pressure (BP) measurement and baseline venous blood sampling were 
performed prior to any scanning, from the left and right arm respectively whilst subjects were 
rested in supine position. 
After baseline measurements, the OSA subjects were autotitrated with an automated CPAP 
device before being issued with a fixed pressure CPAP (REMstar Pro M Series with C-Flex -
Phillips Respironics, Pennsylvania, USA). CPAP compliance was monitored/recorded 
throughout the study at regular intervals. Satisfactory CPAP compliance was defined as a 
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minimum usage of 4 hours per night for at least 75% of the week’s nights (i.e. more than 5 
nights per week).  After a mean duration of 26 weeks on CPAP therapy, all available OSA 
subjects were followed up. 
Ethical approval was granted by local research ethics committee and written informed 
consent was obtained from all participants.
2.2.2 Exclusion criteria  
Patients with confounding effect on endothelial function such as those with pre-existing 
diabetes mellitus (defined according to WHO criteria; fasting plasma glucose more than 7.0 
mmol/L or 2-hour post-prandial plasma glucose of more than 11.1mmol/L, and/or the patient 
taking on anti-diabetic treatment such as insulin or oral therapy or on dietary management), 
hyperlipidaemia (defined as patients taking antidyslipidemic drugs) and coronary artery 
disease (such as previous myocardial infarction or revascularisation procedure) were 
excluded from this study.  Patients with known acute or chronic conditions such as with 
cardiovasucular disease disease, cerebrovascular disease, malignancy, connective tissue or 
inflammatory disease, hepatic/renal impairment and acute infections were excluded from the 
study.
2.2.3 Study Design
2.2.3.1 Cross-Sectional Study           
I compared ‘OSA patients’, ‘healthy controls’ and ‘disease controls’ in the cross-sectional 
arm.  The three groups were well-matched for age, sex and body mass index and underwent 
the tests as detailed in the next section [Figure 2-1]. 
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2.2.3.2 Longitudinal Study:
All OSA patients were prescribed with CPAP therapy and were followed up after six months 
of treatment [Figure 2-1]. The pressures and compliance was ensured in first month after 
prescription and adequate ventilatory pressures were set. Poorly compliant subjects were 
excluded. 
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Figure 2-1: Study Design 
OSA= Obstructive Sleep apnoea; 2DE=2-dimensional echocardiography;RT3DE=Real time three dimensional 
echocardiography;FMD= Flow mediated dilatation;LDF=Laser Doppler flowmtry;PWA=Pulse wave 
analysis;PWV= Pulse wave velocity;FC= Flow cytometry;CPAP= continuous positive airway pressure
Patients with mod-severe OSA Healthy Controls
Macro/Micro-vascular endothelial function assessment (FMD, LDF,PWA/PWV)
Echocardiography (2DE, RT3DE)
flow cytometry
Myocardial Contrast Echocardiography (MCE)
Repeat (Group A) Laboratory Assessments
Repeat (Group A) MCE
CPAP
Diseased controls
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2.3 Methods for assessment of Endothelial function
2.3.1 Flow Mediated Dilatation (FMD)
All images were acquired with a GE Vingmed System 5 ultrasound system using a hand-held 
10 MHz vascular ultrasound probe in accordance with the international guideline [Corretti et 
al 2002]. High resolution ultrasound scanning of right brachial artery was performed 3-5 cm 
above the antecubital fossa whilst patients lying flat. Anterior to posterior wall diameters 
(leading edge to leading edge) were recorded synchronized by R-wave on the ECG. 
Endothelium-dependent dilation was assessed by response to flow-mediated hyperaemia. The 
sphygmomanometer cuff placed around the right upper arm was inflated above the systolic 
blood pressure for 4.5 minutes followed by prompt deflation and recording of brachial artery 
image for 5 minutes. Once the baseline brachial artery diameter and flow restored, 
endothelium-independent dilation was assessed 3 minutes after administration of 0.4mg 
glyceryl trinitrite (GTN, Nitrolingual Hohenlockstedt, Germany). Endothelial responses 
were estimated as percentage of the brachial diameter changes compared to baseline levels.
2.3.2 Laser Doppler flowmetry (LDF)
Assessment of microvascular endothelial function has been performed using scanning laser 
Doppler flowmeter (Periscan system PIM II, Perimed AB, Stockholm, Sweden, 780 nm red 
laser) with iontophoresis (0.1mA for 60 sec.) of 2% acetylcholine (ACH- to evaluate 
endothelial-dependant response) and 1% sodium nitroprusside (SNP- to evaluate 
endothelium-independent response) [Yim-Yeh et al 2011]. The current was delivered through 
two drug delivery chambers (Model LI 611, Perimed, Sweden) placed on ventral aspect of 
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right upper forearm 5 cm apart, and were connected to current intensity-regulated generator 
(Perilont, Perimed AB). 
Three baseline scans were taken to measure the mean baseline perfusion. 2% ACH (as an 
endothelium-dependent vasodilator) was iontophoresed for 60 sec at 0.1 mA followed by 
pulse scanning (each scan for 38 seconds) for minimum of 7 minutes. Similarly 1% SNP was 
delivered once for 60 seconds at 0.1 mA which was followed by seven minutes of pulse 
scanning. Mean baseline perfusion, mean maximum perfusion and maximum percentage 
change in a region of interest (ROI), were calculated using Perimed software. 
2.3.3 Assessment of Arterial Stiffness using Pulse wave analysis/velocity
Pulse wave analysis and velocity was measured using Sphygmocor (Sphygmocor, Atcor 
medical, Sydney, Australia). Carotid arterial waveforms were recorded non-invasively over 
10 seconds using a high-fidelity hand-held tonometer [Wilkinson et al 1998]. Aortic 
augmentation (AA), augmentation index (AIx), rate adjusted augmentation index (AIx@75) 
and sub-endocardial viability ratio (SEVR) were recorded using sphygmocor CVMS software 
system (Version 8).
After performing the baseline measurements, waveform was recorded every five minutes for 
20 minutes after 2 puffs of Salbutamol (Salamol CFC-free, IVAX pharmaceutical, Ireland). 
Subjects were rested till the pulse wave data returned to baseline, and waveforms were 
recorded again every 5 minutes for 20 minutes after the sublingual GTN administration (0.4 
mg). 
Aortic pulse wave velocity was also recorded by making sequential ECG-gated tonometer 
recordings at the carotid and femoral arteries. The straight-line distances between the sternal 
notch and both waveform measurement sites were determined.  Pulse wave velocity was also 
estimated using sphygmocor CVMS software system (Version 8). 
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2.3.4 Flow cytometry
A fasting venous blood sample was taken from the left antecubital vein prior to any imaging 
and was collected into EDTA vacutainers. The first 10 ml of drawn blood was not used for 
cellular analysis to avoid contamination of the sample by endothelial cells dislodged by 
venepuncture. All samples were analyzed for flow cytometry (FACSCalibur, Becton 
Dickinson, Oxford, UK) within three hours of sampling. A full blood count was obtained 
simultaneously using hematoanalyser (Advia, Bayer).
For EPC and CEC quantification, 200ul of whole EDTA blood was mixed with 500ul of 
phosphate buffer solution (PBS) followed by incubation with fluorochrome-labelled 
monoclonal antibodies anti-CD45-PerCP (Becton Dickinson, Oxford, UK), anti-CD34-PE 
(Becton Dickinson, Oxford, UK), anti-CD146-FITC (Biocytex, France) and KDR-PE (R&D, 
UK) for 20 minutes in the dark at room temperature. The sample was then lysed with BD 
lysing solution® and washed once in PBS. The resultant pellet was then resuspended with 
PBS before running for flowcytometeric analysis.
The samples were analyzed using a 2 laser 4-colour FACSCalibur flow cytometer (Becton 
Dickinson, Oxford, UK). A minimum of 1,000,000 mononuclear cellular events was analyzed 
per sample. Cells were plotted according their forward scatter and side scatter characteristics 
and gated to include only mononuclear cell events, excluding cell doublets, platelets, dead 
cells/debris and high side scatter events. In our project EPCs were defined as cells strongly 
positive for CD34++/KDR++ antibodies and CECs as cells strongly positive for 
CD34++/CD146++ antibodies.  
Figure 2-2 illustrates flow cytometry immunophenotyping of circulating EPCs and CECs. A 
population of cells with distinct forward-scatter and side-scatter characteristics (R1) was 
shown to be strongly positive for CD34 expression, yet bearing low levels of CD45 [Figure 
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2-2A]. CD45 negative and positive events are plotted along the X-axis [Figure 2-2B]. A 
subset of R1 cells labelled as R2, demonstrating high levels of CD146, yet negative for KDR 
represented CECs [Figure 2-2C]. Similarly, EPCs were highly positive for KDR with little or 
no expression of CD146 [Figure 2-2D].  
2.3.5 Echocardiography 
In all subjects, 2DE, RT3DE and MCE was performed using Phillips iE33 ultrasound 
machine (Bothel, WA, USA). A modern off-line QLAB software [Xcelera, Phillip (iE33) 
Ultrasound Quantification Module, USA] was used for RT3DE volumetric assessment and 
estimation of myocardial perfusion. 
2.3.5.1 Two Dimensional Echocardiography (2DE)
Para-sternal long axis, para-sternal short axis (at aortic valve level, mitral leaflet level, 
papillary muscle level and at apex) and standard apical views (4-chamber, 5-chamber, 2-
chamber and 3-chamber) were acquired. The aortic root and valvular assessment was 
performed according to the American Society of Echocardiography’s (ASE) 
recommendations [Quiñones et al 2002]. The ASE 16-segment LV model was used for 
analysis. LV diastolic dimensions, LV mass index, Left ventricular ejection fraction (LVEF) 
and left ventricular systolic/diastolic volume (LVESV/LVEDV) were assessed by using M-
mode and the modified Simpson’s biplane method [Senior et al 1994]. All above parameters 
and mitral annular systolic velocity (S’) surrogated LV systolic function.
Assessment of the markers of acute diastolic function was performed by evaluating trans-
mitral flow and tissue Doppler imaging (TDI). For every parameter, at least three samples of 
flow direction were taken sequentially and then the average was calculated. Trans-mitral flow 
was obtained in the apical 4-chamber position, where the pulsed Doppler and the sample 
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volume cursor were in parallel with the flow direction. Mitral early inflow peak velocity (E), 
late inflow peak velocity (A), deceleration time of E wave (DT) and A wave duration were 
calculated with conventional Doppler measurement technique. Colour-mapped tissue Doppler 
images (TDI) were obtained on apical 4-chamber view with a frame rate exceeding 175 
frames/seconds. After TDI preset was activated, sample volume of pulsed Doppler was 
located at the corner of mitral annulus and septal wall and then lateral wall in apical four-
chamber position. Peak velocities of early (E’), late (A’) diastolic, systolic (S’) wave and iso-
volumetric relaxation time (IVRT) were calculated [De Boeck et al 2003]. 
The left atrial (LA) volume surrogates chronic diastolic dysfunction and was calculated as 
below: 
1- Ellipse formula – (πxD1xD2xD3)/6, where D1=longitudinal dimension of LA in the 4-
chamber view, D2=horizontal dimension of LA in the 4-chamber view, D3=vertical 
dimension of LA in para-sternal long axis view. 
2- Area-length formula – (0.85 x 4-chamber LA area x 2-chamber LA area)/common length
3- Using RT3DE planimetry
Left atrial volume index was obtained by dividing left atrial volume by body surface area 
(Mosteller formula).
2.3.5.2 Real time Three Dimensional Echocardiography (RT3DE)
RT3DE dataset was acquired in apical windows. LV and LA images were taken by wide-
angled acquisition (full-volume method) during end expiration. Using QLAB software the 
LV/LA volume was measured using a semiautomatic tracing of endocardial border at each 
frame during one cardiac cycle [Anwar et al 2008]; however automatic tracings were 
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manually modified if necessary. Papillary muscles, LA appendage and pulmonary vein 
apertures were excluded during analysis. Stroke volume (SV), LVEF and LVESV/LVEDV
were recorded. 
2.3.5.3 Myocardial Contrast Echocardiography (MCE)
Advances over the past fifteen years in the development of contrast agents and ultrasound 
equipment technology have allowed myocardial contrast echocardiography (MCE) to evolve 
from the experimental laboratory into clinical practice for the evaluation of ischaemic heart 
disease.
MCE utilises acoustically active gas filled microspheres (microbubbles) which have rheology 
similar to that of red blood cells, and are small enough to traverse capillaries, these unique 
properties allow assessment of the myocardial microcirculation which provides information 
about the epicardial coronary arteries.
2.3.5.3.1 Contrast agents 
Contrast agents are typically 2 to 4 microns in size and consist of a gas encapsulated by a 
stabilising outer shell [Grayburn et al 2002]. To ensure successful negotiation of the 
pulmonary microvasculature and adequate visualisation of the myocardium, microbubbles 
have undergone a number of modifications over recent years. The prolonged survival of 
microbubbles has been achieved primarily through the use of stable outer shells and the 
substitution of air with a high density; high molecular weight gas both of which confer 
improved stability. Table 2-2 summarises the currently available contrast agents and their 
physical properties.
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Table 2-2 Currently available ultrasound contrast agents
Agent
Bubble 
size
Gas Shell composition
Albunex 4.5 m Air Albumin
Levovist 2-3 m Air
None – bubbles adhere 
to galactose 
microparticles
EchoGen 2-5 m Perfluoropentane Stabilised surfactant
Sonogen 2-5 m Perfluoropentane Anionically charged 
surfactant
Optison 4.7 m Perfluoropropane Albumin
Definity 1.5 m Perfluoropropane Phospholipid
Sonovue 2.5 m Sulphur 
hexafluoride
Phospholipid
AI-700 2 m Perfluorocarbon Synthetic polymer
The significant acoustic difference created between microbubbles and blood allows easy 
detection by specific ultrasound imaging techniques. Importantly, microbubbles oscillate at a 
rate of several million times per second in response to ultrasound waves, the same frequency 
used for echocardiography. Therefore, microbubbles not only act as passive reflectors but 
also as strong sources of sound. Oscillations generated thereby, have characteristics in 
received waves which are not present in transmitted waves. These signal characteristics are 
critical for effective separation of microbubble signals from tissue signals. Microbubbles are 
haemodynamically inert and remain entirely within the intravascular space. These two 
properties differentiate it from tracers used in other forms of cardiac imaging (such as PET, 
SPECT and CMR). 
2.3.5.3.2 Principles of Myocardial Contrast Echocardiography
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When insonated, gas bubbles pulsate with compression and expansion at the peak and trough 
of the ultrasound wave respectively. In an ultrasound beam with a frequency of 3MHz, 
bubble oscillation will reach three million times per second which is significantly more than 
the oscillation produced by the red cells. With this movement sound is generated and, 
combined with that of thousands of other bubbles it results in the scattered echo from the 
contrast agent. Characterising this echo, such that it can be differentiated from that of tissue, 
improves the sensitivity of contrast ultrasound and is the basis for new contrast specific 
imaging modes. Unlike solid tissue, gas bubbles have acoustic properties that vary with the 
strength of the insonating signal. With increasing power, insonation of gas bubbles can result 
in linear oscillation, non-linear oscillation or bubble destruction [Stewart et al 2003].
Insonated gas bubbles display the physical property of resonance - a frequency of oscillation 
at which the absorption and scattering of ultrasound is particularly efficient. Insonation of gas 
bubbles at their resonant frequency results in non-linear oscillation of the bubble, whereby 
the alternate expansion and contraction of the bubble is not equal. This results in the 
generation of harmonics - ultrasound produced at a frequency which is a multiple of the 
insonating frequency [Stewart et al 2003]. Recognition of this property of contrast media led 
to the development of harmonic imaging [Burns et al 1996]. With the receiver tuned to 
receive double the transmit frequency, an image is generated predominantly from the first 
harmonic signal, greatly improving the signal-to-noise ratio. Although initially developed as 
an aid to contrast echo, tissue also generates harmonics and the ability to enhance 
conventional grey scale imaging was rapidly appreciated. Harmonic imaging is now a 
standard feature on most echocardiography machines.
2.3.5.3.3 Assessment of Myocardial perfusion
For MCE studies, acoustic power and compression were maximized, and gain settings were 
optimized at the onset of each study and held constant throughout. The focus was initially set 
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at two-thirds of the depth of the image and then moved at the level of myocardial segment to 
be examined. Mechanical index was set at 0.9 for flash images. The definitive setting of the 
ultrasound images was optimized after initial contrast infusion, kept constant throughout the 
study, and matched at follow-up MCE study. Fifteen consecutive heart beats after the flash 
were acquired in digital format for subsequent off-line analysis. The intravenous contrast 
used in this study was Sonovue (Bracco Research SA, Geneva, Switzerland), a second-
generation ultrasound contrast agent that consists of microbubbles containing sulfur 
hexafluoride surrounded by a phospholipid shell. It is reconstituted by the addition of normal 
saline to the final solution of 5 ml. Sonovue was administered intravenously at the rate of 1 
ml/min using a VueJect (BR-INF 100, Bracco Research SA, Geneva, Switzerland) infusion 
pump. Contrast images were acquired in apical 4-chamber, 2-chamber, and 3-chamber views. 
As soon as myocardial video intensity had reached a plateau, a flash of ultrasound with a high 
mechanical index was given to destroy microbubbles in the sector and then the replenishment 
of bubbles was observed, digitally acquired and stored onto a magneto optical disk. 
For stress, study subjects were then infused with dipyridamole (0.56 mg/kg over 4 min) 
followed by re-administration of intravenous contrast and acquisition of stress contrast 
images.
MCE was analysed using modern QLAB software. Basal segments, segments with poor 
image quality and frames showing wide variations in contrast intensity were excluded from 
analysis. On average, 4 segments per study were measured. After setting the background 
frame (frame immediately following microbubbles destruction) a region of interest (ROI) was 
mapped within a specific myocardial segment in background frame as well as frames 
showing replenishment of microbubbles. After full replenishment, the ultrasound signals 
represent the relative blood volume () within the beam, which correlate to the blood volume 
within the myocardium itself. Plateau myocardial contrast intensity () representing 
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myocardial blood flow volume, the rate of rise of signal intensity (β), representing mean 
myocardial blood flow velocity, and their product, myocardial blood flow (‘’ x ‘β‘) at rest 
(FR) and after stress (FS) were measured, enabling calculation of mean MBFR (ratio of FS 
and FR) for each subject [Wei et al 1998].
2.4 Power Calculations
As my project is about vascular function, I decided to take a commonly used index of this 
function as my test statistic – the change is arterial diameter after reactive hyperaemia, known 
by many as flow mediated dilatation. This method is accepted and widely used in 
cardiovascular research [Cooke et al 2001] [Corretti et al 2002]. In addition, the department 
has a long history of using this method [Chong et al 2004][Felmeden et al 2003][Foster et al 
2010]. Tanriverdi et al reported a significant difference in FMD in 40 OSA patients [mean 
(SD) FMD change 4.6 (1.3)%] compared to 24 controls [6.3 (0.8)%], a relative reduction of 
over 25% [Tanriverdi et al 2006].
Nevertheless, it is my hypothesis that that magnitude of the change in FMD in OSA is of the 
same order as the well-known abnormality in FMD in patients with hypertension, effectively 
a positive control group, and is inferior to that in healthy controls. Impaired FMD is 
hypertension is established [Muiesan et al 2001][Felmeden et al 2003]. Accordingly, my 
sample size calculation is for 40 subjects per group. This brings the 1-beta power of 0.8 for a 
difference of at least 0.05 between the groups, with an overall p value of <0.001. This is 
summarized in the following Minitab ANOVA printout of a possible model of changes in 
FMD in OSA and hypertension (HT) compared to controls. 
This model is actually more conservative than that of Tanriverdi et al, who found FMD to be 
73% lower in OSA compared to controls. My model is that FMD in OSA is only 83% of that 
of controls. 
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Minitab printout of my Model - One-way ANOVA: All groups versus C10 
One-way ANOVA: All groups versus C10 
Source   DF       SS      MS      F      P
C10       2   22.400  11.200  16.63  0.000
Error   117   78.799   0.673
Total   119  101.199
S = 0.8207   R-Sq = 22.13%   R-Sq(adj) = 20.80%
                                 Individual 95% CIs For Mean Based on
                                 Pooled StDev
Level         N    Mean   StDev  ------+---------+---------+---------+---
1: Controls  40  5.8120  0.8207                           (-----*------)
2: HT        40  5.0120  0.8207       (-----*------)
3: OSA       40  4.8120  0.8207  (-----*------)
                                 ------+---------+---------+---------+---
                                     4.80      5.20      5.60      6.00
Pooled StDev = 0.8207
However, with three groups I require more power, and so aimed to collect data from 45 
subjects per group, giving extra confidence, both scientifically and statistically. As it 
happened, in reality, FMD in OSA was marked 54% lower (when assessed as  arterial 
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diameter in mm or as percentage) and compared to the healthy controls [Table 3-3], a much 
greater difference than that of Tanriverdi et al. This validates my sample size calculation.    
2.5 Statistical Analyses
Minitab-15 (Minitab Ltd. Coventry, UK) statistical software was used to perform statistical 
analysis. Data are expressed as mean ± standard deviation (SD) for normally distributed data; 
or median and inter-quartile range (IQR) for descriptive and/or non-normally distributed data.  
For categorical data, chi-squared test was used. Data among three groups (OSA, hypertensive 
and healthy controls) were analyzed by one way analysis of variance (ANOVA) or Kruskall-
Wallis test depending upon distribution, whilst Paired t test or Wilcoxon test was used for 
paired analysis. A post-hoc Tukey test was performed where to assess inter-group differences 
(with Log transformation where appropriate). Two-way ANOVA was used to investigate the 
longitudinal influence of time on the parameters of pulse wave analysis and pulse wave 
velocity. Pearson correlation was used for normally distributed data whilst non-normally 
distributed data was log transformed before the correlation analysis.  A value of p<0.05 was 
considered statistically significant. The influence of independent variables (age, body mass 
index, blood pressure, total cholesterol, glucose, Epworth score, AHI) on a given parameter 
was explored using univariate analysis; only the statistically significant variables were then 
entered into a stepwise multivariate linear regression analysis.
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Figure 2-2: A typical Fluorescence-activated cell-sorting (FACS) analysis for a subject. (A) 1% of events, 
plotting forward scatter (FSC) vs. side scatter (SSC). R1 selects all presumed cellular CD positive events; 
(B) A region of R1 showing CD45 negative (in bottom left box) and CD45 positive cells (bottom right box 
showing); (C) A region of R1 that expresses CD34 and CD146 highly and CD45 to a lesser degree, labelled 
as R2 (shaded box) is representing Circulating Endothelial Cells; (D) Sequential analysis of cells from R1 
from (A) showing cells staining positively for both CD34 and KDR yet negative for CD45. These cells 
represent Endothelial Progenitor Cells and are labelled as R3. A representative FACS analysis is shown 
below:
(A)
(B)
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Section 3 Validation and Clinical Studies 
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3.1 Validation Studies 
I assessed inter- and intra-observer variability, on 10 subjects for each of the techniques described 
in ‘Hypotheses and Methodology’’.  These subject numbers are a quarter of the study group and 
hence 10 subjects were recruited only. For inter- and intra-observer variability study, I analysed 
the data for Coefficient of variation using Minitab. Using standard deviation of the difference 
between two groups and dividing this standard deviation by the mean of the study group, I 
obtained the percentage for the inter- and intra-observer variability.
These subjects were specifically recruited for this purpose and were not a part of the main study 
recruitment. They were recruited in the same manner as described in the section ‘Hypotheses and 
Methodology’ and provided informed consent.  During intra-observer variability, I compared my 
method outcome when it was performed at two different times. During inter-observer variability 
my results were compared against an expert technician. Standard statistical tests were used as 
described in section ‘Statistical analyses’. Following table represent the percentage difference in 
the variability for each technique. 
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Table 3-1: Percentage inter- and intra-observer variability
Technique Inter-observer variability 
(n=10)
Intra-observer variability
(n=10)
FMD 2.7% 1.9%
LDF 6.3% 8%
Flow Cytometry 1.9% 8.2%
Pulse wave analysis 9% 5.1%
2DE 1.4% 5.9%
RT3DE 11% 6.8%
MCE 6.1% 7.3%
FMD: Flow mediated dialatation, LDF: Laser Doppler flowmetry, 2DE: 2-dimensional echocardiography, 
RT3DE: Real time 3-dimensional echocardiography, MCE: Myocardial contrast echocardiography
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3.2 Cross sectional studies 
     
3.2.1 Assessment of Macro-vascular Function using Flow Mediated Dilatation in 
Moderate to Severe Obstructive Sleep Aponea compared with hypertensive and 
healthy controls  
3.2.1.1 Abstract
Background: OSA is associated with a wide variety of cardiovascular diseases and increased 
cardiovascular morbidity and mortality. Impaired flow mediated dilatation (FMD) has been 
utilized to demonstrate endothelial dysfunction (ED) in several cardiovascular diseases. I
hypothesized that ED could exist in conjunction with moderate to severe OSA contributing to its 
cardiovascular complications.
Methods: I compared FMD of the brachial artery in untreated moderate to severe OSA patients 
with hypertensive and healthy control subjects (n=45, in each group) without sleep-disordered 
breathing. Endothelial-dependent vasodilatation (EDV) was assessed by establishing reactive 
hyperaemia and endothelial-independent vasodilatation (EIV) was determined by using 
sublingual Glyceryl trinitrate (GTN).
Results: Baseline brachial artery diameter was comparable in all three groups. Both EDV and 
EIV were significantly impaired in OSA and hypertensive cohorts compared to healthy subjects.
Conclusion: Macro-vascular dysfunction, as demonstrated by impaired FMD, is present in 
otherwise healthy patients with moderate-severe OSA. This may indicate potential 
pathophysiological mechanisms leading to ED, impaired smooth muscle function and untimately
increased cardiovascular risk in normotensive subjects with moderate to severe OSA. 
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3.2.1.2 Introduction 
Over the past decade, FMD has evolved as a non-invasive and reproducible technique of 
endothelial assessment [Corretti et al 2002]. The stimulus in the form of reactive hyperaemia, 
induced by arterial occlusion, provokes the endothelium to release nitric oxide (NO), with 
subsequent vasodilatation which can be ultrasonographically acquired and quantified as a 
surrogate of vasomotor function [Dijkhorst-Oei et al 1999]. This technique has been validated 
and standardized according to the recommendations of the International Brachial Artery 
Reactivity Task Force [Corretti et al 2002]. 
Impaired endothelial dependent and -independent responses have been reported in OSA using 
FMD [Celermajer et al 1992][ Corretti et al 2002][ Tanriverdi et al 2006 (a)][ Bayram et al 
2009][Amra et al 2009]. However these studies have important limitations, such as inclusion of 
milder form of the disease. Since only moderate to severe OSA is the primary target for CPAP
and presence of mild OSA could have diluted the results. Secondly, high frequency of 
confounding variables such as hypertension and diabetes mellitus in these studies may suggest 
that the reported ED may only be a reflection of coexisting diseases. Additionally, in some
previous studies, presence of the OSA in the control (non-OSA) group has not been meticulously 
excluded. Finally, lack of adequate power to detect a statistically significant change has also been 
an issue previously. Given strong bond between OSA and cardiovascular disorders, it is 
imperative to determine the varcular functional viability in OSA, however in the presence of 
above mentioned limitations, the answer remains ambiguous. 
The purpose of this study was to assess endothelial-dependent and -independent dilatation in 
otherwise healthy patients with moderate to severe OSA.  I hypothesized that ED exists in 
otherwise healthy normotensive OSA individuals and can be demonstrated using FMD.  I tested 
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this by perforimg FMD in otherwise healthy untreated moderate to severe OSA subjects who 
were compared against hypertensive and healthy subjects. 
3.2.1.3 Methods
The methods have been described in details under section ‘hypotheses and methodology’.  
3.2.1.4 Results
Table 3-2 depicts the baseline demographic, anthropomorphic and polysomnographic data whilst 
Table 3-3 shows brachial artery measurement data including absolute and percentage changes in 
brachial artery diameters in response to reactive hyperaemia and sublingual nitrates. 
FMD was performed on all of 135 study patients (OSA=45, hypertensive=45, healthy=45). All 
three groups were matched for age, sex and body mass index. On average, patients were middle 
aged (50±9 years) with comparable female gender representation (32%). OSA patients had 
greater median apnoea-hypopnoea index compared to both hypertensive and healthy subjects 
(both p<0.0001). In the hypertensive cohort, systolic blood pressure was higher compared to 
healthy group (p<0.0001) [Table 3-2].   
Mean baseline brachial artery diameter was comparable amongst three groups (p=0.138) [Table 
3-3]. Following forearm ischaemia, endothelium dependent FMD was significantly impaired both 
in OSA and hypertensive groups compared with healthy individuals (p for both 
comparisons<0.0001). However no difference was found between OSA and hypertensive subjects 
(p=0.51) [Table 3-3].
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EIV, measured following the sublingual administration of GTN spray was also significantly 
attenuated in OSA cohort compared with healthy subjects (p=0.02).  Again, no difference was 
found between OSA and hypertensive subjects (p=0.59) [Table 3-3].  
On Univariate analysis, no relationship was found between arterial responses and age, BMI, AHI, 
Blood pressure, glucose and total cholesterol [Table 3-4] 
3.2.1.5 Discussion
To the best of my knowledge, this is the first study reporting impaired endothelium-dependent 
and endothelial independent brachial artery responses in otherwise healthy patients with moderate 
to severe OSA compared with healthy and hypertensive subjects without OSA. 
Endothelium-dependent dilatation results from the release of nitric oxide (NO) from endothelial 
cells, in response to stimuli such as shear stress or acetylcholine infusion. Arterial dilatation in 
response to NO donors such as GTN is dependent upon normal vascular smooth muscle function.
These results provide first evidence that impaired FMD responses in OSA subjects cannot be 
attributed solely to decreased brachial artery NO bioactivity, but is a function, at least in part, of 
downstream vascular reactivity. 
I noted impaired EDV in OSA and a smaller ratio of EDV to EIV compared with the healthy 
subjects. This suggest endothelial dysfunction and these findings of are consistent with most 
studies [Bayram et al 2009][ Amra et al 2009][ Tanriverdi et al 2006 (a)][Ip et al 2004][ Kraiczi 
et al 2001]. Impaired FMD has traditionally been recognized as an indirect marker of NO 
bioactivity. The exact mechanisms responsible for determining the magnitude of the FMD 
response are complex and incompletely understood. FMD may directly reflect brachial artery NO 
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bioavailability, but it also depends on baseline brachial artery diameter [Lockhart et al 2011]. 
Endothelium-dependent FMD has been shown to be a homoeostatic response to short-term 
increases in local shear stress, which is known to be critically dependent on the magnitude of the 
imposed stimulus and status of the distal forearm microcirculation [Lockhart et al 2011]. Finally, 
recurrent exposure to hypoxia-reoxygenation during apnoea/hypopnoea is believed to reduce 
endothelial NO synthesis and/or accentuating its degradation by production of reactive oxidative 
species [Lavie et al 2003][ Busse et al 1995]. It is worth mentioning that ED is being regarded as 
a final common pathway, mediated by several cellular (inflammation, NO release dysfunction, 
coagulopathy), metabolic (metabolic dysfunction) and nervous (autonomic dysregulation) 
mechanisms which may contribute to variable extent in different patient population. Indeed a 
range of coaguopathies, metabolic syndrome and over driven sympathic system have been 
reported, but this study does not clearly show if either of above mentioned mechanisms are 
responsible and to what extent. 
I also noted that brachial artery dilatation measured in response to sublingually administered 
GTN was impaired in OSA patients compared with healthy control subjects. This endothelium 
independent response reflects arterial smooth muscle function and can be impaired in 
asymptomatic subjects with coronary risk factors [Zhang et al 2000]. 
Exogenous organic nitrates, such as GTN, produce vasodilation by entering smooth muscle cells 
and undergoing conversion to NO. Sulfhydryl groups, in antioxidant compounds such as 
glutathione and cysteine, are important in the formation of active intermediates [Torfgård et al 
1994]. Inflammation and/or oxidative stress may result in reduced bioconversion of GTN to NO, 
within smooth muscle cells, producing impaired GTN mediated response [Mülsch et al 2001]. In 
a recent study, higher hs-CRP was associated with lower GTN induced vascular response [Ayer 
et al 2011]. CRP has direct pro-inflammatory effects and is associated with markers of oxidative 
stress [Abramson et al 2005]. Furthermore, there is evidence for impaired endothelium-
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independent responses in patients with Type 2 diabetes, proposing that increased oxidative stress 
associated with the diabetic state may impair the biochemical conversion of organic nitrates into 
NO [Abramson et al 2005]. It is thus possible that inflammation, associated with obesity, results 
in a relative overabundance of reactive oxygen species in the vessel wall, which in turn reduces 
the bioconversion of GTN to NO, representing as smooth muscle dysfunction and impaired EIV. 
However, the design of the present study did not permit to directly determine the relative 
importance of impaired generation of endothelium-derived NO and the smooth muscle response 
to NO in contributing to the magnitude of vasodilatation. However, at the very least this can be 
postulated that, as previously believed, impaired brachial reactivity is not purely NO related, and 
vascular components may have strong contribution in impaired vasoreactivity. 
Several other factors such as dysfunctional autonomic nervous system are also crucial in the 
endothelial responsiveness. Over-activation of sympathetic system has been well reported in 
obese patients with and without OSA [Narkiewicz et al 1998(b)]. A recent study tested vascular 
endothelial function whilst investigation sympathetic activity simultaneously [Kaplon et al 2001]. 
An inverse relationship has been demonstrated with between FMD and the sympathetic drive 
surrogated by plasma epinephrine levels. Considering previously reported sympathetic over drive 
and higher epinephrine levels in OSA population [Narkiewicz et al 1998(b)], it can be derived 
that my results are likely to be secondary to dysfunction autonomic system, instead of endothelial 
dysfunction. However I did not have the mandate to investigate autonomic system as per the 
mandated by the study design.
Limitations
The observational model is one important limitation of this study. However, these data are 
relevant to human health, risk stratification and disease development. In order to ensure 
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uniformity, the tests were performed and analyzed by single operator and was validated with 
excellent inter- and intra-observer variability. It must be noted that these observations are limited 
to healthy middle aged subjects with moderate to severe OSA and cannot be extrapolated to OSA 
patients with milder form disease or subjects with coexisting cardiovascular disease/risk factors.
The blood pressure was significantly higher in hypertensive group compared with healthy 
controls. Blood pressure was also modestly elevated in OSA subjects compared with healthy 
controls but it did not reach statistical significance. In deed it can be argued that the vascular 
changes noted in the present study could just be a reflection of underlying hypertension in OSA 
subjects. Although my OSA subjects were not known hypertensives and blood pressure was 
monitored on several occasions to ensure normotensive recruitment. However, I did not perform 
24 hour blood pressure monitoring due to logistical limitations. An element of white coat 
response can not be ignored although the patients were rested prior to all blood pressure 
recordings. Due to well known over active sympathetic drive in OSA subjects, it is quite possible 
the morning blood pressure was temporarily yet mildly elevated during the study period. Finally 
as described in the results I did not find a statistical relationship between the blood pressure and 
the vascular reactivity. Regardless of these arguments, there is no doubt that more stringent 
screening is required to exclude undiagnosed hypertensive cohorts and for this purpose use of 24-
hour blood pressure monitoring is crucial. This is one big limitation of my study and this aspect 
should be taken care of in future studies.
3.2.1.6 Conclusion 
In conclusion, this study submits the findings of impaired macro-vascular endothelial dependent 
and independent vasoreactivity in OSA subjects compared with healthy and hypertensive controls
and is due to a combination of endothelial and vascular smooth muscle dysfunction.
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Table 3-2: Clinical Characteristics of Obstructive Sleep Apnoea patients, Hypertensive 
and Healthy Controls 
Variable OSA Hypertensive 
controls
Healthy 
controls
p
n 45 45 45
Male/Female 34/11 30/15 30/15 0.54
Age (years) 50 (9) 49 (12) 46 (7) 0.120
Aponea 
Hypopnea 
index
33 (21-
50) *Ψ
4(1.2-5.8)Ψ 3(0.9-5)* <0.0001
Body mass 
index 
(Kg/m2)
34(8) 32(6) 32(6) 0.118
Systolic 
Blood 
pressure 
(mmHg)
142(16) 150(21)^ 135(15)^ <0.0001
Diastolic 
Blood 
pressure 
(mmHg)
83(11) 85(10) 82(9) 0.220
No. of 
current 
smokers
14 12 16 0.452
Values are described as Mean (Standard Deviation) and Median (Inter-quartile Range). P <0.05 was 
considered statistically significant.
* Significance between OSA and Healthy subjects 
^ Significance between Hypertensive and Healthy subjects
Ψ Significance between OSA and Hypertensive subjects
OSA= Obstructive Sleep Apnoea
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Table 3-3: Brachial Artery reactivity data in Obstructive sleep apnoea, Hypertensive and 
Healthy subjects
OSA HT Healthy p
Baseline 
Brachial 
artery 
diameter 
(mm)
4.5±0.6 4.5±0.6 4.2±0.7 0.138
Absolute 
change in 
diameter 
after reactive 
hyperaemia 
mm)
0.26 (0.19-
0.41)*
0.33 (0.16-0.46)^ 0.48 (0.34-
0.63)*^
<0.0001
Percentage 
change after 
reactive 
hyperaemia
6 (4-9)* 7 (3.4-9.5)^ 11 (9-15)*^ <0.0001
Absolute 
change in 
diameter 
after GTN
0.50 (0.40-
0.63)
0.51 (0.36-0.58) 0.59 (0.45-
0.67)
0.05
Percentage 
change after 
GTN (mm)
11 (7-15)* 11 (8-14)^ 14 (10-17)*^ 0.018
EDV/EIV 
ratio
0.54* 0.63^ 0.78*^ 0.02
*Significance between Obstructive Sleep Aponea and Healthy subjects
^Significance between Hypertensives and Healthy subjects
OSA= Obstructive Sleep Apnoea; GTN= Glycerol Trinitrate; HT= Hypertension 
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Table 3-4: Univariate analyses of Pre-CPAP brachial artery reactivity in Obstructive Sleep 
Apnoea 
FMD hyperaemia %change GTN %change
r p r p
Age -0.168 0.270 -0.103 0.500
Height 0.205 0.176 0.047 0.759
Weight 0.133 0.386 0.075 0.685
BMI -0.002 0.989 -0.096 0.531
AHI 0.102 0.506 -0.091 0.551
Epworth score -0.278 0.096 -0.036 0.833
Systolic BP 0.082 0.594 0.103 0.499
Diastolic BP 0.162 0.288 -0.004 0.989
Glucose -0.394 0.872 -0.325 0.657
Total cholesterol 0.239 0.318 0.735 0.159
r=correlation coefficient; AHI= Apnoea Hypopnoea Index; FMD= Flow mediated Dilatation; BP= Blood 
Pressure; CPAP= Continuous Positive airway pressure; GTN= Glycerol trinitrite; BMI= Body mass index
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3.2.2 Microvascular Reactivity assessed by Laser Doppler Flowmetry in Moderate to 
Severe Obstructive Sleep Aponea compared to Hypertensive and Healthy 
controls
3.2.2.1 Abstract
Background: Micro-vascular dysfunction has been implicated in the pathogenesis of 
cardiovascular complications of obstructive sleep apnea (OSA). I investigated micro-vascular 
function in moderate to severe OSA using laser Doppler flowmetry (LDF). I hypothesized that 
LDF derived ED exists in OSA compared with matched healthy and hypertensive controls.
Methods: Otherwise healthy patients with moderate to severe OSA were compared with non-OSA
hypertensive and healthy controls. Micro-vascular reactivity was assessed by LDF, which 
allowed the measurement of the response to iontophoretically applied acetylcholine 
(endothelium-dependent vasodilatation {EDV}) and sodium nitroprusside (endothelium-
independent vasodilatation {EIV}). 
Results: Both endothelial dependent and independent responses were blunted significantly in 
OSA and hypertensive patients compared to healthy subjects. Both EDV and EIV were 
comparable between OSA and hypertensives. 
Conclusion: Impaired endothelial microvascular function exists in otherwise healthy 
normotensive subjects with moderate to severe OSA. 
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3.2.2.2 Introduction
There are a variety of non invasive methods to estimate endothelial function in macrovasculature 
such as flow-mediated vasodilatation. In microcirculation, ED can be noninvasively measured in 
the forearm cutaneous vasculature using laser Doppler flowmetry (LDF). This technique has been 
successfully utilized in a number of disease states and has proven to be a reproducible tool 
[Gomes et al 2008][Beer et al 2008][ Kubli et al 2000]. This device allows monitoring of the 
changes in cutaneous perfusion precipitated by the iontophoresis of acetylcholine (ACH) and 
sodium nitroprusside (SNP).  
Microvascular endothelial status has been rarely assessed in OSA using this technique. There are
significant limitations even in the sparcely available data [Friberg et al 1998][Trzepizur et al 
2009]. Also, no previous study has used this method in otherwise healthy subjects with moderate 
to severe OSA. It must be understood that the understanding of microvascular endothelial 
integrity is particularly important, as moderate to severe form of OSA is an emerging and widely 
acknowledged risk factor for cardiovascular health. 
I aimed to assess endothelial-dependent and independent perfusion changes in the forearm skin of 
patients with moderate to severe OSA who were compared with matched non-OSA hypertensive 
and healthy subjects. I hypothesized that ED may exist in the microvasculature of otherwise 
healthy normotensive OSA patients. In order to test this hypothesis I performed LDF coupled 
with iontophoresis in moderate to severe OSA subjects, hypertensive and healthy cohorts. 
3.2.2.3 Methods
The methods have been described in details under section 2 ‘Hypotheses and Methodology’.  
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3.2.2.4 Results
45 subjects with moderate to severe OSA were recruited after the diagnosis was established with 
polysomnography but only 31 patients were available for LDF scanning prior to the initiation of 
the CPAP treatment. In total, the LDF was performed on 98 patients (OSA=31, hypertensive=34, 
healthy=33). All three groups were matched for age, sex and BMI. On average, OSA patients 
were middle aged (50±10 years) with similar proportion of female gender representation (30%). 
OSA patients has greater median AHI compared to both, hypertensive and healthy subjects 
[p<0.0001] [Table 3-5].
Mean baseline perfusion was comparable amongst the three groups [Table 3-5]. ACH induced 
increase in cutaneous blood flow was significantly impaired in OSA and hypertensive groups 
compared to healthy individuals [p<0.0001] [Table 3-6]. However, the EDV was comparable 
between OSA and hypertensive cohorts (p=0.22).
Following iontophoresis of SNP, endothelium independent percentage perfusion was significantly 
impaired in OSA and hypertensive groups compared with healthy subjects, with median increase 
of 96% (IQR 58-151) and 103% (IQR 69-139) in OSA and  hypertensive groups respectively, 
versus 180% (IQR 125-237) in healthy subjects {both p <0.0001} [Table 3-6]. Again there was 
no significant difference in EIV, between the OSA and hypertensive cohorts (p=0.43).  
On Univariate analysis, no relationship was found between microvascular responses and age, 
BMI, AHI, Blood pressure, glucose and total cholesterol [Table 3-7]
3.2.2.5 Discussion
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In this study, I demonstrated for the first time that microvascular endothelial activity, represented 
by cutaneous perfusion, is significantly impaired in patients with moderate to severe OSA who 
are otherwise healthy and free from any cardiovascular history and/or risk factors, compared to 
healthy subjects. Impaired EDV can be explained by impaired NO release from endothelial cells 
but EIV is predominantly controlled by smooth muscles in vascular wall. Hence impairment of 
EIV may represent smooth muscle dysfunction alongside the ED, which has never been described 
in moderate to severe OSA before. 
. 
LDF in combination with iontophoresis is a validated and reproducible technique for the 
assessment of ED [Pellaton et al 2002][Rousseau et al 2008]. Although LDF has not been studied 
widely in OSA population, my results are consistent with the published data. Trzepizur et al has 
recently reported impaired endothelial dependent (ACH induced) micro-vascular function in OSA 
patients compared with healthy controls [Trzepizur et al 2009]. Additionally, these findings are 
consistent with previous OSA studies, where alternative techniques were used instead of LDF 
[Carlson et al 1996][ Kato et al 2000][ Kraiczi et al 2001]. 
Sleep deprivation, impaired sympathetic responses and hypoxia- all of which are widely prevalent 
in OSA- have been implicated in the impairment of endothelial dependent vasoreactivity  [Gokce 
et al 2002][ Morris et al 1996][Bonetti et al 2003][ Amir et al 2004][ Phillips et al 2000][ Phillips 
et al 2004]. For example, Amir et al reported vascular malfunction in subjects with fewer sleeping 
hours [Amir et al 2004]. Indeed sleep deprivation induces surges in the systolic blood pressure 
due to autonomic disturbances releasing endothelial inflammatory mediators and causing ED 
[Phillips et al 2000][Pagani et al 2009] [Chae et al 2001]. Similarly, a close relationship has been 
demonstrated between serum nitrites/nitrates concentrations and oxygen desaturation may offer 
another explanation of severely blunted endothelial dependent responsiveness in OSA [Phillips et 
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al 2004]. In a study investigating cardiovascular morbidity, has reported autonomic dysfunction 
as a major causative factor [Okano et al 2010]. This study was carried out using LDF in high risk 
patients. There is also some evidence that improvement in metabolic profile translates into better 
vascular responsiveness [Forst et al 2008]. Therefore this can be concluded that some 
mechanisms over and above ED also exist and may operate in OSA. 
I also demonstrated impaired endothelial independent functions in moderate to severe OSA 
compared to healthy subjects. Although these findings are in contrast to the data reported by 
Trzepizur et al, my data are consistent with LDF studies in smokers and diabetic subjects 
[Trzepizur et al 2009] [Morris et al 1995][Lim et al 1999][Caballero et al 1999][ Pellaton et al 
2002]. 
Impaired endothelial independent vasoreactivity at arteriolar/capillary level could be linked with 
smooth muscle dysfunction secondary to sub-clinical inflammatory processes in OSA subjects 
[Bravo et al 2007]. Up-regulation of certain cytokines such as Interleukin-1β, interleukin-6, 
Interleukin-10 and tumor necrosis factor-α, may modulate micro-vascular smooth muscle tone by 
reducing SNP induced cGMP levels [Ferrell et al 2002][ Meier-Ewert et al 2004][Iversen et al
1999] [Papapetropoulos et al 1996]. The reduction in cGMP levels is also reported to be due to 
hypoxia driven attenuated nitric oxide synthase activity [Orshal et al 2004].  Nevertheless, this 
cumulative reduction in cGMP may limit the biological effect of extrinsic nitrates on smooth 
muscles expressed as impaired endothelial independent vasoreactivity [Papapetropoulos et al 
1996]. 
. 
These finding of impaired endothelial dependent responses in hypertensive patients compared 
with healthy controls is consistent with the available data [Farkas et al 2005][Lindstedt et al 
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2006][Cupisti et al 2000]. However no previous study has demonstrated impaired endothelial 
independent response in healthy hypertensives as observed in the present study. This could be 
explained by the smaller study sizes and the co-existence of important confounding factors (such 
as renal failure) in the studied hypertensive patients which could restrict SNP mediated response 
markedly [Nakanishi et al 2002][Lindstedt et al 2006]. 
Hence it can be concluded that the findings of impaired EDV and EIV in OSA population, in fact, 
represent a more general vascular abnormality comprised of endothelial activation as well as 
smooth muscle dysfunction. 
Limitations
Open study design and relatively smaller numbers are important limitations.  I excluded milder 
form of OSA and our findings are limited to healthy middle aged subjects with moderate to 
severe OSA and cannot be extrapolated to patients with milder severity or OSA with coexisting 
disease causing altered vascular function (such as with atherosclerosis). A modestly elevated 
blood pressure was noted in OSA compared with healthy subjects, in spite of strict recruitment. 
As shown in the Table, no relation was found between the blood pressure and the LDF and hence 
it can be assume that such a modestly elevated BP is not the mediator of vascular responsiveness. 
This is one important limitation and should be focussed at in future larger studies.
3.2.2.6 Conclusion
In conclusion, ED exists at microciculatory level in moderate to severe OSA even in the absence 
of confounding cardiovascular factors. These changes may be subtle initially however I propose 
that repetitive transient ventilatory loss could lead to key changes in cellular physiology and 
thereby priming the development of future cardiovascular disease.
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Table 3-5: Clinical characteristics of Obstructive Sleep Apnoea patients and the Controls 
Variable OSA Hypertensive 
controls
Healthy 
controls
p
n 31 34 33
Male/Female 24/7 23/11 22/9
0.364
Age (years) 50(10) 49(11) 46(9) 0.087
Aponea Hypopnea 
index
33 (20-48) *Ψ 3(2-4)Ψ 3(2-4)* <0.0001
Body mass index 35(8) 31(6) 32(8) 0.084
Systolic Blood 
pressure (mmHg)
145(17) 149(20)^ 137(14)^ <0.0001
Diastolic Blood 
pressure (mmHg)
83(12) 85(9) 83(10) 0.771
No. of current 
smokers
10 12 11 0.561
* Significance between OSA and healthy subjects 
^ Significance between hypertensive and healthy subjects
Ψ Significance between OSA and hypertensive subjects
OSA= obstructive Sleep Aponea
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Table 3-6: Changes in Micro-Vascular reactivity in response to Acetylcholine and Sodium 
Nitroprusside; values in Median (Inter-quartile Range)
OSA Hypertensive 
Controls 
Healthy 
Controls
p
Mean 
Baseline 
perfusion 
(PU) pre-
ACH
0.69 (0.62-
0.78)
0.75 (0.6-0.87) 0.58 (0.44-0.8) 0.101
Mean 
maximum 
perfusion 
post-ACH 
(PU)
1.3 (1.1-1.7) 1.3 (1.1-1.7) 1.4 (1.1-2.1) 0.449
Mean 
percentage 
increase 
post-ACH 
(%)
101 (52-135)* 76 (51-109)^ 234 (120-305)*^ <0.0001
Mean 
Baseline 
perfusion 
pre-SNP 
(PU)
0.74 (0.65-
0.82)
0.72 (0.62-0.85) 0.62 (0.56-0.81) 0.061
Mean 
maximum 
perfusion 
post-SNP 
(PU)
1.3 (1.2-1.7) 1.5 (1.3-1.9) 1.5 (1.3-1.9) 0.350
Mean 
percentage 
change 
post-SNP 
(%)
96 (58-151)* 103 (69-139)^ 180 (125-237)*^ <0.0001
* Significance between Obstructive Sleep Aponea and Healthy subjects
^ Significance between Hypertensive and Healthy subjects
OSA= Obstructive Sleep Aponea, ACH= Acetylcholine, SNP= Sodium Nitroprusside, PU= perfusion unit
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Table 3-7: Univariate analyses of the Pre-CPAP micro-vascular reactivity in Obstructive Sleep 
Apnoea 
ACH %LDF change SNP LDF %change
r p r p
Age -0.137 0.461 0.174 0.349
Height -0.289 0.215 -0.343 0.06
Weight -0.034 0.854 -0.116 0.535
BMI 0.107 0.567 0.109 0.559
AHI 0.133 0.477 -0.185 0.318
Epworth score -0.269 0.193 -0.174 0.406
Systolic BP -0.138 0.459 0.081 0.661
Diastolic BP 0.205 0.269 0.065 0.730
Glucose -0.003 0.989 0.091 0.632
Total cholesterol 0.292 0.111 0.197 0.287
r=correlation coefficient; AHI= Apnoea Hypopnoea Index; FMD= Flow mediated Dilatation; BP= Blood 
Pressure, LDF= Laser Doppler flowmetry, CPAP= Continuous Positive airway pressure; ACH= Acetylcholine; 
SNP= Sodium nitroprusside; BMI= Body mass index
125
3.2.3 Endothelial Progenitor Cells and Circulating Endothelial Cells in Moderate to 
Severe Obstructive Sleep Aponea Compared to Hypertensive and Healthy 
Subjects
3.2.3.1 Abstract
Background: Obstructive sleep apnea (OSA) is associated with endothelial damage/dysfunction 
(ED) and enhanced cardiovascular risk. Increased circulating endothelial cells (CECs) have been 
reported in conditions with ED, such as coronary artery disease. Similarly lower endothelial 
progenitor cell (EPC) counts have been observed in patients with cardiovascular risk factors. I 
hypothesized that a similar distribution of CECs and EPCs might exist in moderate to severe 
OSA.  
Methods: In the present study, CECs and EPCs were enumerated using flow cytometry in 
peripheral blood sample of 40 otherwise healthy untreated patients with moderate to severe OSA 
and compared with hypertensive and healthy subjects (n=40, in each control groups) without 
sleep-disordered breathing.
Results: Subjects in all three groups were age, sex and body mass index matched. OSA patients 
had significantly higher aponea-hypopnoea index (AHI) score compared with controls. There 
were no significant differences in CECs, EPCs count or CEC/EPC ratio amongst the three groups.
Conclusion: I found no differences in CECs or circulating EPCs in OSA compared with the 
control groups. Moderate to severe OSA may not be associated with cellular markers of vascular 
endothelial cell damage/repair in subjects with no concomitant vascular disease.
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3.2.3.2 Introduction
Endothelial progenitor cells (EPCs) contribute significantly to vascular homeostasis and may 
represent reparative cells. It is postulated that these special cells replace dysfunctional endothelial 
cells [Khakoo et al 2005][ Hristov et al 2003], and hence, a close association between EPCs, 
endothelial function and atherosclerotic risk factors has been reported [Hill et al 2003] [Chen et al 
2004][ Tepper et al 2002]. For example, patients at risk of atherosclerosis have strikingly reduced 
numbers of circulating EPCs. Additionally, decreased EPC counts have been reported to be 
predictive of future cardiovascular events in patients with stable as well as unstable coronary 
artery disease [Schmidt-Lucke et al 2005] [Werner et al 2006]. On the contrary, increased levels 
of circulating EPCs have been associated with better survival in patients with acute lung injury 
[Burnham et al 2005], indicating that EPCs may be predictive of favourable prognosis after 
vascular injury.
Circulating endothelial cells (CECs) have been described as the apoptotic cells which tend to 
coexist in conditions with vascular damage [Boos et al 2006][Jimenez et al 2003][Gonzalez-
Quintero et al 2003]. Unsurprisingly, markedly elevated levels of these apoptotic CECs have been 
reported in vitro and ex vivo in patients with coronary artery disease [Kavurma et al 2005][Mayr 
et al 2001]. Additionally, CECs counts are increased in a range of conditions where vascular 
damage might be expected, such as acute coronary syndrome, congestive heart failure, both 
primary and secondary pulmonary hypertension and systemic sclerosis [Quilici et al 2004] 
[Chong et al 2004] [Bull et al 2003] [Del Papa et al 2004]. Thus, denuded CECs could be a 
marker for vascular endothelial cell damage, and thus might be increased in the untreated OSA 
population. Likewise, reduced EPC counts could also represent endothelial dysfunction (ED) in 
OSA. 
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I hypothesized that the CECs and EPCs distribution patterns could represent the burden of ED in 
subjects with moderate to severe OSA. I tested the hypothesis by performing flow cytometry on 
peripheral blood sample of modeare to severe OSA subjects and compared with hypertensive and 
healthy controls. 
3.2.3.3 Methods
The methods have been described in details under section 2 ‘Hypotheses and Methodology’.
3.2.3.4 Results
45 subjects with moderate to severe OSA were recruited once the diagnosis was established 
however due to technical reasons only 40 patients were available for flowcytometric analysis 
prior to the initiation of the CPAP treatment. Therefore in total, the flow cytometric analysis was 
performed on 120 patients (OSA=40, hypertensive=40, healthy=40). All three groups were 
matched for age, sex and body mass index [Table 3-8]. On average, patients were middle aged 
(50±9 years) with similar proportion of female gender representation (20%). OSA patients has 
greater median AHI compared to both, hypertensive and healthy subjects (both p<0.001).  In the 
hypertensive cohort, systolic blood pressure was higher compared to healthy group (p<0.0001). 
As shown in Table 3-9, the number of circulating CD34++ cells, both in absolute count (p=0.713) 
and as percentage (p=0.764) of peripheral blood mononuclear cells, was not significantly 
different in OSA patients compared to that seen in both control groups [Table 3-9]. There were no 
statistically significant differences between the groups with respect to numbers of CECs 
(p=0.083) or circulating EPCs (p=0.262) and EPC/CEC ratio (p=0.766) [Figure 2-2] [Table 3-9]. 
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Assessment of correlations between numbers of CECs and circulating EPCs in OSA and age, sex, 
body mass index, smoking, apnoea hypopnoea index, Epworth score and blood pressure yielded 
no statistically significant correlations [Table 3-10]. 
3.2.3.5 Discussion 
In this study, I observed no significant differences in EPCs or CECs counts in the healthy OSA 
patients, compared with of age- and sex- and body mass index matched hypertensive and healthy 
controls. To the best of my knowledge this was the first and largest cross sectional comparison to 
date investigating EPCs/CECs using flow cytometry among patients with moderate to severe 
OSA, hypertension and normotensives.
My findings seem to suggest that OSA may not be associated with ED. Indeed EPCs have been 
proposed as a regenerative tool for treating human vascular disease, but are these cells 
indisputable markers of ED? Conflicting results have been reported in the identification, 
characterization, and precise role of EPCs in vascular biology and true significance of these cells 
in vascular repair and growth is still under scrutiny [Avogaro et al 2011]. Vascular homeostasis 
and specifically repair are complex multicellular processes that require several cellular 
phenotype-like endothelial cells, smooth muscle cells, monocytes, and bone marrow–derived 
cells. Hagensen et al. has recently questioned the role of EPCs in vascular repair by showing that 
bone marrow–derived cells rarely contribute to the endothelium of developing plaques or 
participate in endothelial regeneration after plaque rupture [Hagensen et al 2010]. The authors 
convincingly demonstrate that EPCs rarely contribute to plaque endothelium or regeneration of 
overlying endothelium after plaque disruption. This study indirectly suggests that the local vessel 
is the major source of plaque endothelium and predominantly contributes to regeneration of 
overlying endothelium after plaque rupture. All this is further complicated by the lack of a 
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specific marker and validated methods to unequivocally identify this circulating cell subset and 
by the presence of platelet microparticles in a standard assay for putative EPCs [Prokopi et al 
2009]. Interestingly, a rare population of endothelial colony-forming cells has been identified in 
human umbilical cord blood and adult peripheral blood that embodies all of the properties of an 
EPC; however, there is no proof that the human endothelial colony-forming cells play a role in 
neoangiogenesis in vivo [Yoder et al 2007]. 
CECs are regarded as apoptotic cells and the apoptotic process takes place through a complex 
series of inter- and intra-cellular events [Avogaro et al 2011]. The consequence of the apoptotic 
process is detachment of endothelial cells, which are released into the bloodstream and can be 
recognized and measured as CECs. However, in some circumstances, endothelial cells do not 
detach as entire cells, but as apoptotic endothelial microparticles, which have strong prognostic 
value [Avogaro et al 2011]. Given the complexity of the ultimate so-called ‘arterial denudation’ 
and relative lack of data on this subjects, perhaps it is reasonable to assume that a certain 
threshold exists in the duration or the severity of the OSA, which needs to be reached before the 
apoptotic process could be triggered. 
Nevertheless, my results are consistent with findings reported by Martin et al who investigated 
EPCs and CECs using immunomagnetic beads and flowcytometric techniques in a middle aged 
OSA population [Martin et al 2008].. The authors report no quantitative differences in CECs (7.0 
± 1.5 vs. 4.9 ± 0.9; p=0.18) or EPCs (1077 ± 318 vs. 853 ± 176; p>0.51) between OSA and the 
controls.   
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My findings can be justified by technical, logistical and individual factors. Firstly, the total 
numbers of identifiable EPCs and CECs in peripheral blood are extremely small, even in patients 
with proven ED [Rafii et al 2000]. Although our study design is one of the largest cross sectional 
studies, yet due to the rare event rate, it could have been under powered to detect the difference.  
Secondly, I had stringent exclusion criteria where subjects with conditions known to alter EPCs 
and/or CECs count, were excluded in order to assess the un-confounded effect of moderate to 
severe OSA on these cell strains. Hence, it is plausible that relative changes in EPCs and CECs 
count in OSA might exist distinctively, i.e. in OSA and coexisting cardiovascular diseases. 
Thirdly, depending upon a number of predisposing factors such as severity of OSA and fat 
distribution, individual vulnerability to develop derangement in the cell count could be highly 
discrepant in OSA [Barbe et al 2001] [Schafer et al 2002]. 
In previous OSA studies, exaggerated circadian variability has been indentified in certain 
hemodynamic variables such as blood pressure, the so-called ‘‘nondipping and dipping patterns’’ 
[Akashiba et al 1999]. These circadian fluctuations in endothelial status have been identified 
using more specific tests such as flow mediated dilatation [Maruo et al 2006]. However, the 
existence of circadian variability in EPCs and CECs numbers is not known in OSA and it can be 
hypothesized that these cells may alter transiently or/and intermittently during hypoxia. As I 
obtained blood samples in the morning (0900-1100 AM), I can not exclude the presence or the 
extent of circadian rhythm. 
Limitations 
I enumerated EPCs and CECs using modern flow cytometry alone. The choice between flow 
cytometry and immunobead technique is debatable as both have serious limitations [Shantsila et 
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al 2007 (a)(b)]. Furthermore, I did not perform qualitative analysis of the functional properties of 
these cells, which may have shown more profound impact of OSA compared to mere quantitative 
changes.
Mildly elevated BP, though statistically insignificant compared with healthy group, is another 
limitation of this study. On statistical analyses no correlation was found between the BP and the 
cellular counts. Although the cellular count was comparable amongst the group, it is reasonable to 
challenge the contribution of mildly elevated BP. 
.  
3.2.3.6 Conclusion 
This study did not demonstrate significant differences in EPCs and CECs distribution in 
otherwise healthy subjects with moderate to severe OSA free from confounding vascular disease 
or cardiovascular risk factors, compared with healthy or hypertensive controls. Therefore, I 
suggest that EPCs and CECs may not represent dysfunctional endothelium/endothelial damage, in 
a normotensive subset of moderate to severe OSA patients in the absence of coexisting 
cardiovascular disease or risk factors.
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Table 3-8: Clinical Characteristics of Obstructive Sleep Apnoea patients, Hypertensives and 
Healthy Controls 
Variable OSA Hypertensive 
controls
Healthy 
controls
p
n 40 40 40
Male/Female 31/9 32/8 29/11 0.343
Age (years) 50(9) 49.1(12) 45.8(7) 0.120
Aponea 
Hypopnea 
index
33 (21-50) 
*Ψ
4(1.2-5.8)Ψ 3(0.9-5)* <0.0001
Body mass 
index
34(8) 32(6) 32(6) 0.118
Systolic Blood 
pressure 
(mmHg)
142(16) 150(21)^ 135(15)^ <0.0001
Diastolic 
Blood 
pressure 
(mmHg)
83(11) 85(10) 82(9) 0.22
No. of current 
smokers
14 12 16 0.21
Values are represented as Mean (Standard deviation) and Median (Inter-quartile Range). A p<0.05 was 
considered statistically significant.* Significance between OSA and Healthy subjects; ^ Significance 
between Hypertensive and Healthy subjects; Ψ Significance between OSA and Hypertensive subjects
OSA: obstructive sleep apnoea
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Table 3-9: Endothelial Progenitor Cells and Circulating Endothelial Cell in Obstructive 
Sleep Apnoea patients, Hypertensive and Healthy groups  
OSA Hypertensive 
controls 
Healthy 
controls
p
n 40 40 40
%CD34++ 
count
0.0004 
(0.0003-
0.0007)
0.0005 
(0.0003-0.0007)
0.0004 
(0.0003-0.0007)
0.764
CD34++ 
count (Per 
ml)
3092  
(1756-3891)
2753
(1646-5409)
3144  
(1948-5043)
0.713
Absolute 
EPC count 
(Per ml)
79 (43-149) 104 (64-182) 99 (48-404) 0.262
Absolute 
CEC count 
(Per ml)
81 (41-142) 107 (49-178) 133 (63-274) 0.083
EPC/CEC 
ratio
1 (0.79-1.60) 1 (0.67-1.36) 1.1 (0.54-1.71) 0.766
OSA= obstructive Sleep Apnoea; EPC= Endothelial Progenitor Cell; CEC= Circulating Endothelial Cell
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Table 3-10: Univariate analyses of the Pre-CPAP Cellular count in Obstructive Sleep Apnoea
Abs EPC Abs CEC
r p r p
Age 0.040 0.796 -0.024 0.873
Height 0.184 0.227 0.271 0.072
Weight -0.135 0.377 -0.100 0.514
BMI -0.224 0.140 -0.234 0.122
AHI -0.016 0.917 -0.130 0.395
Epworth score 0.082 0.629 0.093 0.526
Systolic BP 0.025 0.869 0.019 0.902
Diastolic BP 0.160 0.294 0.004 0.979
Glucose -0.108 0.497 -0.058 0.715
Total cholesterol -0.248 0.101 -0.070 0.646
r=correlation coefficient; AHI= Apnoea Hypopnoea Index; FMD= Flow mediated Dilatation; BP= Blood 
Pressure, CEC= Circulating endothelial cells; EPC= endothelial progenitor cells; BMI= Body mass index
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3.2.4 Assessment of Pulse Wave Analysis and Pulse Wave Velocity in Moderate to 
Severe Obstructive Sleep Aponea compared to Hypertensive and Healthy 
controls
3.2.4.1 Abstract
Background: Moderate–severe obstructive sleep apnea (OSA) is associated with endothelial 
dysfunction (ED) and hypertension. However it is uncertain if moderate-severe OSA in otherwise 
healthy subjects is also associated with increased arterial stiffness and impaired macro-vascular 
function.
Method: In 35 patients with moderate to severe OSA [Aponea-hypopnoea index (AHI) 36±20], 
and 35 matched diseased and healthy control subjects without OSA, arterial stiffness was 
assessed by applanation tonometry– derived pulse wave analysis (PWA) and carotid-femoral 
pulse wave velocity (PWV). Baseline and Glycerol trinitrate (GTN)/ Salbutamol induced changes 
in aortic augmentation (AA), aortic augmentation index (AIx), AIx corrected for heart rate of 
75/minute (AIx@75), Sub-endocardial viability ratio (SEVR)] and PWV were recorded in all 
subjects.
Results: Systolic blood pressure (SBP) was higher in hypertensives compared to healthy subjects 
(p=0.001). Indices of PWA or the PWV were not statistically different in OSA patients at 
baseline or in response to GTN/salbutamol, compared with the controls. 
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Conclusion: Systemic arterial function and responses to endothelium-dependent (salbutamol 
induced) and -independent vasodilators (GTN induced) are preserved in patients with moderate to 
severe uncomplicated OSA, indicating preserved macro-vascular endothelial function.
3.2.4.2 Introduction
Multiple causal factors such as OSA related endothelial dysfunction (ED), modulations in 
sympathetic tone, high blood pressure and activation of inflammatory mediators have been 
implicated to cause vascular damage and in the development of atherosclerosis [Somers et al 
1995][Shamsuzzaman et al 2002][Ip et al 2004]. Available evidence suggests that arterial 
stiffness and its interaction with dysfunctional endothelium significantly contribute in the 
accentuation of atherosclerosis and could be associated with cardiovascular risk factors [Koji et al 
2007] [Ross et al 1999][ Shimokawa et al 1999][Celermajer et al 1992][ Schachinger et al 2000].  
Although minimally symptomatic OSA has been shown to be associated increased arterial 
stiffness and hypertension [Kohler et al 2008 (a)], however only a few studies have investigated 
functional deformation in the arterial waveform in moderate to severe OSA [Kohler et al 2008 
(b)][Drager et al 2007][Tomiyama et al 2009]. However, prominent presence of the 
cardiovascular diseases/risk factors in these available data may have heavily confounded the 
outcome [Wilkinson et al 2002] [Zhong et al 2005]. In summary, there are no uniform data 
reflecting early changes in vascular transfer function in otherwise healthy normotensive patients 
with moderate to severe OSA. 
To investigate if arterial stiffness and hence vascular functions are impaired in patients with 
moderate to severe OSA, I conducted a cross-sectional study investigating validated indices of 
arterial stiffness and their responses to glycerol trinitrite (GTN) and Salbutamol to assess 
endothelial dependent- and independent vascular vasoreactivity. I hypothesized that subjects with 
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moderate to severe OSA have enhanced arterial stiffness compared with healthy and hypertensive 
controls.
3.2.4.3 Methods
The methods have been described in details under section 2 ‘Hypotheses and Methodology’.
3.2.4.4 Results
Although 45 subjects with moderate to severe OSA were recruited after the diagnosis was 
established with polysomnography but due to certain reasons only 35 OSA patients were 
available for assessment of arterial stiffness prior to the initiation of the continuous positive 
airway pressure (CPAP) treatment. These subjects were compared with equal number of age-, 
sex- and BMI-matched healthy and hypertensive controls [Table 3-11]. On average, OSA patients 
were middle aged (49±10 years) with similar proportion of female gender representation (25%). 
OSA patients has greater mean AHI compared to both, hypertensive and healthy subjects {both 
p<0.0001}; AHI was comparable between hypertensive and healthy individuals.   In the 
hypertensive cohort, systolic blood pressure was higher compared to healthy subjects (p=0.002) 
partly due to omitting antihypertensive drugs for at least 12 hours before test.  
Arterial stiffness assessed using AA, AIx, AIX@75, SEVR and PWV was comparable at 
baseline, amongst the three groups [Table 3-12; 3-13]. The endothelial-dependent (induced by 
systemic application of Salbutamol) and -independent changes (induced by sublingual application 
of GTN) in these parameters were not significantly different in OSA patients compared with 
control groups. During longitudinal analyses, only healthy subjects demonstrated normal 
endothelial dependent responses (Salbutamol use) whilst endothelial independent responses 
(GTN induced) were preserved in all three groups as shown below [Table 3-14; 3-15; 3-16].  
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On Univariate analysis, no relationship was found between vascular responses and age, BMI, 
AHI, Blood pressure, glucose and total cholesterol [Table 3-17]. 
3.2.4.5 Discussion
To the best of my knowledge, this is the first well-controlled, cross-sectional study on the 
assessment of vascular elastic properties in otherwise healthy patients with moderate to severe 
OSA. I demonstrated that patients with moderate to severe OSA had preserved vascular transfer 
function compared with matched control subjects without OSA. 
I used a number of surrogate markers for arterial stiffness and pressure waveform reflection. For 
example, the AIx and SEVR are accurate surrogates for vascular elasticity and excellent predictor 
of adverse cardiovascular events [Wilkinson et al 2002] [Weber et al 2004][Noon et al 2008]. 
However, according to recent CAFÉ (Conduit Artery Function Evaluation) study, AIx@75 (AIx 
corrected for heart rate of 75 beats per minute) is a better and sensitive surrogate of central 
arterial stiffness [Williams et al 2009]. Finally, PWV is regarded as a superior marker of arterial 
stiffness in middle aged population [Zoungas et al 2007] [Drager et al 2007 (a)]. 
These data are in contrast with the findings from previous OSA studies; however, most of 
available data carry notable limitations. For example, considering dominant use of radial 
approach in most previous studies, physiological consequences of ‘site-dependent heterogeneity’ 
and ‘amplification phenomenon’ can not be ignored [Phillips et al 2005][Zhong et al 2005][Jelic 
et al 2002][Kohler et al 2008 (a)][Laurent et al 2006]. I used carotid approach based on the 
consensus from ‘European Network of non-invasive investigations of large arteries’ which
concluded that the carotids artery may provide more accurate information of the transfer function 
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compared to the radial artery [Kelly et al 1989][O'Rourke et al 1992][O'Rourke et al 1999]. My
PWV measuring technique (carotid-femoral) could also account for our findings of preserved 
PWV which is contrary to available data where ankle-brachial technique was used [Kitahara et al 
2006] [Tomiyama et al 2009] [Drager et al 2010 (a)] [Drager et al 2007]. 
Hypertension has prominently coexisted in OSA subjects in previous investigation and could be 
an important confounder [Zhong et al 2005].  It must be noted that hypertension on its own merit 
increases arterial stiffness independent of OSA. Jelic et al, reported higher AIx in hypertensive 
OSA patients compared to normotensive OSA subjects (p<0.001) [Jelic et al 2002]. Therefore 
due to presence of hypertension and other cardiovascular disorders with concurrent use of 
antihypertensives, the reported vascular changes cannot be attributed entirely to the OSA [Kohler 
et al 2008][Noon et al 2008][Drager et al 2007][ Zhong et al 2005]. 
I also did not demonstrate difference in GTN or Salbutamol induced changes in the indices of 
PWA or PWV, amongst the groups. This is consistent with the blinded data by Waring et al 
[Waring et al 2006]. In this investigation comparing hypertensive and healthy subjects, Waring et 
al reported comparable GTN-induced and salbutamol-induced responses in OSA patients and 
controls [Waring et al 2006]. Our study is novel as the effects of GTN and salbutamol on PWA 
indices have not been tested previously in the moderate-severe form of OSA. 
This study was carried out at the time of diagnosis of OSA and it is unknown how long the 
disease had existed in these individuals. It can be assumed that certain threshold duration of OSA 
is necessary to observe any changes in pressure waveform. 
Limitations 
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The existence of circadian variability in indices of arterial stiffness is not known in OSA and may 
be important factor. In order to reduce these variations, vascular scanning was performed at fixed 
times (0900AM-1100AM). 
Hypertension has a close correlation with arterial stiffness and has been reported by several 
investigators as above. In my OSA population the systolic as well as diastolic blood pressure was 
higher than healthy subjects, but did not reach statistical significance. It can be argued that con 
existing hypertension may have a significant impact on the investigated parameters. I have 
described the recruitment process in details, under the METHODS section. There are several 
reasons why my OSA subjects still had modestly elevated BP, such as white coat hypertension, 
autonomic dysregulation and indeed under lying hypertension. I did not investigate the BP by 24 
monitoring due to unfavourable logistics and neither the autonomic dysregulation was 
investigated. Due to a strong and close interaction between the two, I acknowledge slightly 
elevated BP as one of the most important limitations of the present study. Indeed, BP needs to be 
studied in OSA subjects with appropriate tools in order to rectify such bias. Having said that, I 
did not notice a statistical relation between markers of arterial stiffness and recorded BP. This is 
given in the Table below, showing univariate analyses [Table 3-17]. 
3.2.4.6 Conclusion
This cross-sectional study has demonstrated that in otherwise healthy patients with moderate to 
severe OSA, indices of arterial stiffness and hence macro-vascular functions are preserved, when 
compared with well-matched diseased and healthy control subjects without OSA. It can also be 
derived that only OSA patients with cardiovascular diseases/risk factors may have increased 
arterial stiffness and hence enhanced cardiovascular risk. 
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Table 3-11: Clinical Characteristics of Obstructive Sleep Apnoea Patients, Hypertensive 
and Healthy Controls 
Variable OSA Hypertensive 
controls
Healthy 
controls
p
n 35 35 35
Male/Female 25/10 26/9 23/12 0.128
Age (years) 49(10) 48(11) 47(9) 0.654
Body mass 
index
32(6) 30(5) 31(6) 0.364
Waist 
circumference 
(cm)
110(16)* 105(14) 98(14)* 0.003
Aponea 
Hypopnea 
index
36 (20) *Ψ 4(2)Ψ 3(1)* <0.0001
Systolic 
Blood 
pressure 
(mmHg)
141(17) 150(20)^ 135(16)^ 0.002
Diastolic 
Blood 
pressure 
(mmHg)
83(12) 85(9) 80(8) 0.113
No. of current 
smokers
7 7 9 0.147
Values expressed as Mean (Standard Deviation) or Median (Inter quartile range). P<0.05 is considered 
statistically significant
* Significance between OSA and healthy subjects 
^ Significance between hypertensive and healthy subjects
Ψ Significance between OSA and hypertensive subjects
OSA: obstructive sleep apnoe
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Table 3-12:  Indices of Pulse Wave Analysis and Pulse Wave Velocity before and after systemic 
administration of Salbutamol, as Median (Inter-quartile range)
Index OSA HT Healthy P
Baseline 1
AA 15 (9-21) 15 (9-23) 13 (10-21) 0.800
AIx 26 (20-32) 29 (16-35) 27 (17-34) 0.893
AIx@75 18 (11-31) 22 (14-30) 21 (13-28) 0.777
SEVR 162 (138-
194)
167 (147-188) 164 (145-
191)
0.930
PWV 6 (5-7) 5 (5-7) 5 (5-6) 0.138
After 5 Minutes
AA 13 (7-22) 14 (7-25) 14 (3-16) 0.170
AIx 25 (12-35) 28 (12-39) 21 (7-31) 0.154
AIx@75 21 (8-27) 19 (11-30) 17 (5-22) 0.141
SEVR 157 (146-
183)
161 (142-182) 155 (142-
187)
0.946
PWV 6 (5-7) 5 (4-6) 5 (5-6) 0.499
After 10 Minutes
AA 13 (7-20) 14 (5-23) 12 (6-15) 0.554
AIx 25 (14-33) 26 (9-34) 22 (10-30) 0.642
AIx@75 18 (7-29) 21 (6-28) 16 (7-27) 0.522
SEVR 159 (143-
176)
161 (144-179) 164 (139-
192)
0.929
PWV 6 (5-7) 6 (5-7) 5 (5-6) 0.286
After 15 Minutes
AA 12 (7-20) 13 (5-21) 14 (7-17) 0.844
AIx 22 (13-33) 26 (9-35) 23 (11-31) 0.890
AIx@75 17 (8-29) 21 (11-27) 17 (12-26) 0.834
SEVR 163 (143-
181)
156 (146-181) 160 (141-
185)
0.829
PWV 6 (5-7) 5 (5-6) 5 (5-6) 0.126
After 20 Minutes
AA 12 (7-21) 11 (4-22) 12 (7-19) 0.942
AIx 23 (15-33) 21 (10-35) 21 (12-32) 0.872
AIx@75 18 (7-28) 19 (6-29) 15 (8-25) 0.868
SEVR 163 (144-
181)
157 (144-174) 150 (140-
190)
0.901
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PWV 6 (5-7) 5 (5-6) 5 (5-6) 0.245
                     OSA= Obstructive Sleep Apnoea, HT=Hypertension, AA=Aortic Augmentation, 
AIx=Augmentation Index, AIx@75=Augmentation Index at heart rate of 75/minute, SEVR=Sub-
Endocardial Viability Ratio, PWV= Pulse Wave Velocity
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Table 3-13:  Indices of Pulse Wave Analysis and Pulse Wave Velocity before and after systemic 
administration of Glyceryl trinitrate, as median (Inter-quartile range)
Index OSA HT Healthy P
Baseline 2
AA 14 (9-21) 15 (8-23) 15 (9-18) 0.956
AIx 26 (19-33) 26 (13-38) 29 (17-33) 0.923
AIx@75 22 (13-31) 22 (9-35) 21 (17-28) 0.934
SEVR 163 (145-187) 156 (139-172) 162 (139-199) 0.451
PWV 5.8 (4.8-7) 5.3 (4.8-6.5) 5.4 (4.8-6) 0.612
After 5 Minutes
AA 3 (-3 - 7) 4 (-2 - 11) 7 (1-11) 0.126
AIx 4 (-4 - 14) 7 (-2 - 16) 12 (3-24) 0.086
AIx@75 0 (-6 - 13) 10 (-3 - 16) 7 (0-17) 0.131
SEVR 160 (145-183) 156 (140-170) 158 (142-191) 0.846
PWV 5.6 (5-8) 5.4 (4.8-6) 5.3 (5-5.9) 0.362
After 10 Minutes
AA 1 (-4 - 8) 6 (-5 - 12) 5 (-1 - 10) 0.322
AIx 2 (-7 - 13) 6 (-9 - 20) 10 (-2 - 17) 0.272
AIx@75 -1 (-9 - 8) 4 (-12 - 17) 5 (-3 - 10) 0.186
SEVR 164 (143-176) 160 (146-174) 158 (142-189) 0.986
PWV 6 (5-7) 5 (5-8) 5.5 (5-6) 0.467
After 15 Minutes
AA 2 (-4 - 7) 5 (-5 - 12) 6 (-1 - 12) 0.320
AIx 2 (-6 - 13) 12 (-7 - 21) 11 (-1 - 20) 0.281
AIx@75 -2 (-12 - 11) 6 (-7 - 18) 7 (-3 - 15) 0.199
SEVR 163 (145-179) 161 (152-182) 150 (148-191) 0.904
PWV 6 (5-7) 5 (5-7) 5 (5-6) 0.486
After 20 Minutes
AA 3 (-3 - 10) 7 (-3 - 15) 5 (0.3-12) 0.669
AIx 5 (-7 - 19) 15 (-5 - 25) 8 (-0.3 - 18) 0.597
AIx@75 -2 (-8 - 16) 8 (-10 - 22) 4 (-3 - 15) 0.510
SEVR 164 (144-178) 163 (152-185) 163 (147-198) 0.984
PWV 6 (5-7) 5 (5-7) 5 (5-6) 0.255
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OSA= Obstructive Sleep Apnoea, HT=Hypertension, AA=Aortic Augmentation, AIx=Augmentation Index, 
AIx@75=Augmentation Index at heart rate of 75/minute, SEVR=Sub-Endocardial Viability Ratio, PWV= Pulse 
Wave Velocity
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Table 3-14: Indices of Pulse Wave Analysis and Pulse Wave Velocity versus time after 
Salbutamol in Pre-CPAP Obstructive sleep apnoea, Hypertensive and 
Healthy Subjects 
Pre Sal 5 min 10 min 15 min 20 min P
OSA
AA 15 (9-21) 13 (7-22) 13 (7-20) 12 (7-20) 12 (7-21) 0.159
AIX 26 (20-32) 25 (12-35) 25 (14-33) 22 (13-33) 23 (15-33) 0.120
AIx@75 18 (11-31) 17 (8-27) 18 (7-29) 17 (8-29) 18 (7-28) 0.440
SERV 162 (138-
194)
157 (146-
183)
159 (143-
176)
163 (143-
181)
163 (144-
181)
0.600
PWV 6 (5-7) 6 (5-7) 6 (5-7) 6 (5-7) 6 (5-7) 0.119
HT
AA 15 (9-23) 14 (7-25) 14 (5-23) 13 (5-21) 14 (4-22) 0.372
AIX 29 (16-35) 28 (12-39) 26 (9-34) 26 (9-35) 25 (10-35) 0.147
AIx@75 22 (14-30) 19 (11-30) 21 (6-28) 21 (11-27) 19 (6-29) 0.380
SERV 167 (147-
188)
161 (142-
182)
161 (144-
179)
156 (146-
181)
157 (144-
174)
0.119
PWV 5 (5-7) 5 (4-6) 6 (5-7) 5 (5-6) 5 (5-6) 0.092
Healthy
AA 13 (10-21)* 10 (3-16)* 12 (6-15) 14 (7-17) 12 (7-19) 0.002
AIX 27 (17-34)* 21 (7-31)* 22 (10-30) 23 (11-31) 21 (12-32) 0.015
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AIx@75 21 (13-28)* 17 (5-22)* 16 (7-27) 17 (12-26) 15 (8-25) 0.025
SERV 164 (145-
191) )*#∞
155 (142-
187)*
164 (139-
192)
160 (141-
185) )#
150 (140-
190) )∞
0.006
PWV 5 (5-6) 5 (5-6) 5 (5-6) 5 (5-6) 5 (5-6) 0.544
Values as Median (Inter-quartile range); p<0.05 is significant
* Significant difference between time 0 and 5 min
^ Significant difference between time 0 and 10 min
# Significant difference between time 0 and 15 min
∞ Significant difference between time 0 and 20 min
OSA= Obstructive Sleep Apnoea, HT=Hypertension, Sal= Salbutamol, AA=Aortic Augmentation, 
AIx=Augmentation Index, AIx@75=Augmentation Index at heart rate of 75/minute, SEVR=Sub-Endocardial 
Viability Ratio, PWV= Pulse Wave Velocity
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Table 3-15: Indices of Pulse Wave Analysis and Pulse Wave Velocity versus time after Glyceryl 
trinitrite in Pre-CPAP Obstructive sleep apnoea patients, Hypertensive and healthy 
controls
Pre-GTN 5 min 10 min 15 min 20 min P
OSA
AA 14 (9-
21)*^#∞
3 (-3 - 7)* 1 (-4 - 8)^ 2 (-4 - 7)# 3 (-3 - 10)∞ <0.0001
AIX 26 (19-33) 
)*^#∞
4 (-4 - 14)* 2 (-7 - 13)^ 2 (-6 - 13)# 5 (-7 - 19)∞ <0.0001
AIx@75 22 (13-
31)*^#∞
0 (-6 - 13)* -1 (-9 - 8)^ -2 (-12 -
11)#
-2 (-8 -
16)∞
<0.0001
SERV 163 (145-
187)
160 (145-
183)
164 (143-
176)
163 (145-
179)
164 (144-
178)
0.651
PWV 5.8 (4.8-7) 5.6 (5-8) 6 (5-7) 6 (5-7) 6 (5-7) 0.388
HT
AA 15 (8-23)*^ 
#∞
4 (-2 - 11)* 6 (-5 - 12)^ 5 (-5 - 12)# 7 (-3 - 15)∞ <0.0001
AIX 26 (13-
38)*^ #∞
7 (-2 - 16)* 6 (-9 - 20)^ 12 (-7 -
21)#
15 (-5 -
25)∞
<0.0001
AIx@75 22 (9-35)*^ 
#∞
10 (-3 -
16)*
4 (-12 -
17)^
6 (-7 - 18)# 8 (-10 -
22)∞
<0.0001
SERV 156 (139-
172)#∞
156 (140-
170)√
160 (146-
174)
161 (152-
182)#
163 (152-
185)∞√
<0.0001
PWV 5.3 (4.8-
6.5)
5.4 (4.8-6) 5 (5-8) 5 (5-7) 5 (5-7) 0.734
Healthy
AA 15 (9-18)*^ 7 (1-11)* 5 (-1 - 10)^ 6 (-1 - 12)# 5 (0.3-12)∞ <0.0001
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#∞
AIX 29 (17-
33)*^ #∞
12 (3-24)* 10 (-2 -
17)^
11 (-1 -
20)#
8 (-0.3 -
18)∞
<0.0001
AIx@75 21 (17-
28)*^ #∞
7 (0-17)* 5 (-3 - 10)^ 7 (-3 - 15)# 4 (-3 - 15)∞ <0.0001
SERV 162 (139-
199)
158 (142-
191)
158 (142-
189)
150 (148-
191)
163 (147-
198)
0.485
PWV 5.4 (4.8-6) 5.3 (5-5.9) 5.5 (5-6) 5 (5-6) 5 (5-6) 0.352
Values as Median (Inter-quartile range); p<0.05 is significant
* Significant difference between time 0 and 5 min
^ Significant difference between time 0 and 10 min
# Significant difference between time 0 and 15 min
∞ Significant difference between time 0 and 20 min
√ Significant difference between time 5 and 20 min
OSA= Obstructive Sleep Apnoea, HT=Hypertension, GTN= Glycerol trinitrite, AA=Aortic Augmentation, 
AIx=Augmentation Index, AIx@75=Augmentation Index at heart rate of 75/minute, SEVR=Sub-Endocardial 
Viability Ratio, PWV= Pulse Wave Velocity
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Table 3.16: Comparison of the Baseline values pre-Salbutamol and pre- Glyceryl trinitrate for 
three groups; as Median (Inter-quartile range)
OSA
B1 (pre Sal) B2 (pre-GTN) P
AA 15 (9-21) 14 (9-21) 0.874
AIx 26 (20-32) 26 (19-33) 0.546
AIx@75 18 (11-31) 22 (13-31) 0.150
SEVR 162 (138-194) 163 (145-187) 0.654
PWV 6 (5-7) 5.8 (4.8-7) 0.798
HT
AA 15 (9-23) 15 (8-23) 0.691
AIx 29 (16-35) 26 (13-38) 0.421
AIx@75 22 (14-30) 22 (9-35) 0.741
SEVR 167 (147-188) 156 (139-172) 0.091
PWV 5 (5-7) 5.3 (4.8-6.5) 0.321
Healthy
AA 13 (10-21) 15 (9-18) 0.165
AIx 27 (17-34) 29 (17-33) 0.446
AIx@75 21 (13-28) 21 (17-28) 0.246
SEVR 164 (145-191) 162 (139-199) 0.812
PWV 5 (5-6) 5.4 (4.8-6) 0.311
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OSA= Obstructive sleep Apnoea; HT= Hypertension; B1= Baseline 1 ; B2= Baseline 2; Sal= Salbutamol; 
GTN= Glycerol trinitrite; AA=Aortic Augmentation, AIx=Augmentation Index, AIx@75=Augmentation Index 
at heart rate of 75/minute, SEVR=Sub-Endocardial Viability Ratio, PWV= Pulse Wave Velocity
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Table 3-17:  Univariate analyses of the Pre-CPAP arterial stiffness markers in Obstructive 
Sleep Apnoea
AIx75 PWV
r p r p
Age 0.199 0.260 0.618 0.010
Height -0.358 0.48 -0.478 0.062
Weight -0.347 0.57 -0.216 0.228
BMI 0.181 0.306 0.048 0.790
AHI 0.109 0.539 -0.197 0.273
Epworth score 0.038 0.845 0.187 0.342
Systolic BP 0.163 0.358 0.552 0.111
Diastolic BP 0.439 0.110 0.311 0.08
Glucose 0.117 0.529 -0.102 0.592
Total cholesterol 0.043 0.809 -0.113 0.532
r=correlation coefficient; AHI= Apnoea Hypopnoea Index; FMD= Flow mediated Dilatation; BP= Blood 
Pressure; PWV= Pulse wave velocity; AIx@75= Augmentation index corrected for heart rate of 75/min; BMI= 
Body mass index
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3.2.5 Left Ventricular Systolic and Diastolic function as assessed by Two- and Three-
Dimensional Echocardiography in Moderate-Severe Obstructive Sleep Apnoea
compared with healthy and hypertensive controls
3.2.5.1 Abstract
Background: Previous studies have yielded incongruent results regarding the effect of moderate 
to severe obstructive sleep aponea (OSA) on left ventricular (LV) function, in the absence of 
pulmonary or cardiac co-morbidity.  In addition, there are limited data on the assessment of LV 
function using real time three-dimensional echocardiography (RT3DE). 
Methods: I performed a prospective cross-sectional study investigating healthy subjects with 
moderate to severe OSA compared with stable hypertensive and healthy controls (n=40 in each 
group). Two-dimensional echocardiography (2DE) and RT3DE were used to measure LV systolic 
function (M-mode and modified Simpson’s method) and acute and chronic indices of diastolic 
function (left atrial volume index, trans-mitral flow patterns and tissue Doppler imaging). 
Results: OSA and hypertensive groups exhibited LV diastolic but not systolic dysfunction 
compared with healthy individuals.  Left atrial (LA) volume and LA volume index was 
significantly greater in OSA compared to the control groups (p<0.001 for all comparisons).
Conclusion: Episodic changes in breathing patterns during sleep (repetitive apnoeas/ hypopnoeas) 
could be significant factors in the LV remodelling leading to LV diastolic dysfunction in non-
hypertensive patients with moderate to severe OSA. 
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3.2.5.2 Introduction
Some obstructive sleep apnoea (OSA) studies have reported left ventricular (LV) systolic 
dysfunction [Krieger et al 1991][ Malone et al 1991]. Although the underlying mechanisms are
largely unclear however a reduced LV output is believed to be due to exaggerated negative 
intrathoracic pressure dynamics, and hypoxia driven augmentation in vascular resistance and rise 
in transmural pressure [Karam et al 1984][Parker et al 1999][Millman et al 1991] [Laks et al 
1995]. Interestingly, some propose that OSA merely interacts with subclinically existing cardiac 
and respiratory diseases and enhances the appearance of heart and respiratory failure [Marrone et 
al 1998]. More importantly, only a few studies have specifically investigated LV function in 
moderate to severe OSA which is the primary target for continuous positive airway pressure 
(CPAP) treatment. Even in the available data, there are important limitation owing to loose 
inclusion criteria and mere use of 2DE techniques [Nahmias et al 1996]. It must be noted that 
RT3DE has been proven useful tool for accurate LV assessment in a number of conditions but 
there is no data on the use of RT3DE in the moderate to severe OSA population. 
In summary, the LV systolic dysfunction is a debatable issue in moderate to severe OSA subjects. 
However, LV diastolic dysfunction has been reported by most OSA subjects with or without LV 
hypertrophy [kim et al 2008][Alchanatis et al 2002][Hedner et al 1990]. 
In this project, healthy OSA patients were compared with patients with stable and treated 
hypertension as well as healthy individuals, using both Two- and Three-dimensional 
echocardiographic techniques.  I tested the hypothesis that ventilatory changes in moderate to 
severe OSA subjects causes LV remodelling manifested as impaired LV systolic and diastolic 
function, compared with healthy and hypertensive controls.
3.2.5.3 Methods
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The methods have been described in details under section ‘Hypotheses and Methodology’. 
3.2.5.4 Results
As shown in Table 3-18, the echocardiography was performed on total of 120 patients (OSA=40, 
hypertensive=40, healthy=40) prior to CPAP treatment. Subjects with suboptimal image quality
were excluded. OSA patients has greater mean AHI compared to both hypertensive and healthy 
subjects (both p<0.0001).  
Left Ventricular Systolic Function
There were no differences in LV volumes and other parameters including ejection fraction (EF), 
stroke volume (SV) and fractional shortening (FS) amongst the 3 groups using M-mode, modified
Simpson’s and RT3DE methods [Table 3-19].
Left Ventricular Diastolic Function
Table 3-20 presents diastolic indices provided by conventional echocardiography and tissue 
Doppler (TDI).  Early and late mitrial inflow velocities and their ratio (E, A and E/A), were 
significantly impaired in both, OSA and hypertensive groups, compared to healthy subjects (p 
<0.001 for both comparisons). OSA and hypertensive patients showed a significantly reduced 
TDI derived E’ velocity (<0.0001 for both) and prolonged iso-volumetric relation time (IVRT) 
than did normal control subjects (p=0.02 for both). Post-hoc analysis showed a significant 
difference in E/E’ between hypertension and healthy controls, but only a non-significant trend 
between OSA and healthy subject (p=0.58). All above diastolic indices were comparable between 
OSA and hypertension [Table 3-20]. 
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Left atrial (LA) volume and LA volume index (LAVI) were significantly greater in OSA and 
hypertensives compared to healthy controls using 2DE and RT3DE [Table 3-21]. On Univariate 
analysis, no relationship was found between ventricular dimensions and age, BMI, AHI, Blood 
pressure, glucose and total cholesterol [Table 3-22]
3.2.5.1 Discussion 
Important findings of this study are following: 1) systolic function is preserved in healthy OSA 
subjects; 2) OSA subjects exhibit LV diastolic impairment; 3) RT3DE derived LAVI is 
significantly greater in OSA compared with healthy controls. This is a novel study as the LV 
function, LA volume and LAVI have not previously been comprehensively explored using 
RT3DE in moderate to severe OSA. Due to high prevalance of atrial fibrillation and stroke in 
OSA subjects, our findings of greater LAVI may have important clinical and prognostic 
implications.    
LV Systolic function
OSA has been described in conjunction with LV systolic dysfunction in a number of 
observational studies. In three large case series, 37%, 11% and 26% of the populations with 
impaired LV systolic function have been reported to have proven OSA [Sin et al 1999] [Javaheri 
et al 1998][Wang et al 2007]. Intesrestingly, LV systolic dysfunction tends to occur less in 
females (men 38% versus women 31%; p<0.05) and in subjects with excessive daytime 
somnolence [Javaheri et al 1998] [Arzt et al 2006][Sin et al 1999]. 
LV function has also been reported to be preserved in OSA patients in several studies and our 
findings are in line with these data [Alchanatis et al 2002] [Kraiczi et al 2001][ Kim et al 2008].  
For example, Kim et al studied 62 patients with mild, moderate and severe OSA and observed 
normal LV dimensions, mass index, LVEF and FS compared to health subjects (p>0.05) [Kim et 
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al 2008]. Similarly, whilst measuring FS (39.4±2.6% versus 39.9±4.1%; p>0.05), septal wall 
(9.2±0.8 mm versus 9.9±1.2 mm; p>0.05) and posterior wall thickness (8.6±1.0 mm versus 
8.3±1.2mm; p>0.05) as a surrogate for LV systolic function, Alchanatis et al observed no 
difference between OSA and healthy subjects [Alchanatis et al 2000]. It is noteworthy that the 
present study is one of the largest to focus on healthy moderate to severe OSA and the first one to 
utilize RT3DE in this particular group. 
Indeed, few have reported impaired LVEF in OSA compared with healthy subjects but the 
techniques used in these investigations was not validated for LV systolic assessment [Alchanatis 
et al 2002]. Repetitive nocturnal blood pressure surges have been reported in OSA patients and 
may be the most likely mechanism by which chronic OSA induce left ventricular systolic 
dysfunction [Portaluppi et al 1997][Levy et al 1996] [Verdecchia et al 1990]. My OSA patients 
were normotensive and although I did not measure nocturnal blood pressure fluctuation, it can be 
derived that only persistently elevated blood pressure would impair LV systolic function. 
Traditional methods of LV systolic function assessment (M-mode and modified Simpson’s 
method), may not be accurate due to sub-optimal image acquisition with 2DE, patient habitus and 
unusual LV geometry in OSA subjects. RT3DE has proven useful in accurate LV assessment 
compared with 2DE and older 3D reconstruction techniques [Von Ramm et al 1990][Smith et al 
1991][ Shiota et al 1998][ Zwas et al 1999]. 
LV Diastolic Function using Conventional Indices
Diastolic dysfunction is regarded as a condition with increased resistance to LV filling, resulting 
in discernible transformations in the diastolic pressure-volume curve, causing symptoms of 
pulmonary congestion at rest and exertion [Brutsaert et al 2000]. The present study shows 
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deranged of markers of diastolic function in moderate to severe OSA and hypertension groups 
compared to healthy subjects. 
Most studies on LV diastolic function in OSA patients have demonstrated impaired LV filling 
patterns [Arias et al 2005][ Kraiczi et al 2001][Fung et al 2002] [Niroumand et al 2001] which are 
consistent with my reported findings. Few have reported preserved LV diastolic function 
[Niroumand et al 2001]. 
Evidence from animal studies suggest that surges in blood pressure, changes in LV 
hemodynamics, left ventricular hypertrophy and their interplay could be potential mechanisms 
leading to diastolic dysfunction in OSA [Flecher et al 1992][Gradman et al 2009]. Although same 
factors seem to induce diastolic impairment in homo sapiens too but it must be borne in mind that 
due to fundamental differences in artificially induced OSA in animals and naturally occurring 
OSA in humans, the presence of an additional perpetrator can not be completely ruled out 
[Stradling et al 1997].  For example, OSA is widely reported to cause ‘endothelial dysfunction’; a 
condition associated with paucity of nitric oxide. Since nitric oxide is a key vasodilator, 
impairment of its secretion results in vasoconstriction and increased peripheral vascular resistance 
which may ultimately contribute to impaired LV filling [Schulz et al 2000][Ip et al 2000]. 
Left Atrial Volume/Left Atrial Volume Index 
LA remodeling is viewed as a surrogate marker for chronic diastolic dysfunction. Notably, 
increased LA volume is an independently predictive of atrial fibrillation, heart failure and worse 
prognosis in asymptomatic populations with preserved LV systolic function [Pritchett et al 2005] 
[Takemoto et al 2005]. In present study of OSA patients without structural heart disease, greater 
LA volume might reflect chronicity of diastolic dysfunction. Due to age related altered flow 
dynamics and remodeling, I corrected LA volume for body surface area and reported as LAVI 
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[Lang et al 2005][Pritchett et al 2003]. My findings of larger LAVI in OSA are in accord with 
limited available data [Otto et al 2007] [Khan et al 2008]. Nevertheless previous studies were 
based on 2DE and were relatively smaller. This study is the first study to report greater LAVI in 
OSA population using RT3DE which may explain high preponderance of AF and stroke in OSA 
subjects. This may also elucidate high AF recurrence rate after cardiovarsion and ablation in OSA 
population [Ng et al 2011]. 
Limitations
Inter- and intra-observer variation in echocardiographic examinations is an important issue.  
However in order to ensure uniformity, all the measurements and recordings were performed and 
analyzed by the same operator. Besides, there was an excellent agreement between 2DE and 
RT3DE results. 
High blood pressure is a well known cause of systolic and diastolic dysfunction. As I have 
demonstrated impaired diastolic function (with enlarged left atrium) with concomitantly high BP 
in OSA population, the effect of the latter on LA and LV dimensions can be questioned. The 
OSA subjects were non-hypertensive and compared to hypertensive cohort their average BP is 
much lower (150 versus 142). Besides OSA group’s average BP is comparable with the healthy 
cohort. Such a modest rise is unlikely to cause a clear and marked diastolic dysfunction and 
subsequent LA dilatation. It’s notable that no correlation existed between BP and the LV 
functional and structural parameters as given in the Table below.
3.2.5.6 Conclusion
In conclusion, this study reports preserved LV systolic yet impaired diastolic function in 
moderate to severe OSA subjects using both 2DE and RT3DE. LAVI have been demonstrated to 
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be significantly greater in OSA population which may have important predicting and managing 
atrial arrythmias.
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Table 3-18: Clinical Characteristics of Obstructive Sleep Apnoea Patients, Hypertensives 
and Healthy controls 
Variable OSA Hypertensive 
controls
Healthy 
controls
p
n 40 40 40
Male/Female 33/7 31/9 30/10
0.647
Age (years) 50(10) 49(11) 46(9) 0.120
Aponea 
Hypopnea 
index
39 (22) *Ψ 4(2)Ψ 3(2)* <0.0001
Body mass 
index
34(8) 32(6) 32(6) 0.118
Systolic 
Blood 
pressure 
(mmHg)
142(16) 150(20)^ 135(15)^ <0.0001
Diastolic 
Blood 
pressure 
(mmHg)
83(11) 85(10) 82(9) 0.22
No. of current 
smokers
16 12 13 0.374
Values are described as Mean (Standard Deviation) and Median (Inter-quartile Range). P <0.05 was 
considered statistically significant.
* Significance between OSA and Healthy subjects 
^ Significance between Hypertensive and Healthy subjects
Ψ Significance between OSA and Hypertensive subjects
OSA= Obstructive Sleep Apnoea
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Table 3-19: Systolic Indices amongst the Obstructive Sleep Apnoea Patients, Hypertensives 
and Healthy controls using M-mode, Modified simpson’s method and real 
time three dimensional echocardiography
OSA Hypertension Healthy p
n 40 40 40
M-Mode
IVSd (cm) 1.2 ± 0.20 1.2±0.28 1.3±2.72 0.763
LVEDV 
(ml)
112.5±37.08 104.3±30.38 111.8±35.80 0.499
LVESV 
(ml)
42±20.22 34.8±16.08 36.7±17.14 0.175
LVEF (%) 64.1±7.84 67.4±8.52 67.4±9.8 0.152
FS (%) 35.3±5.78 37.8±6.64 38±8 0.152
Modified Simpson’s 
LVEDV 
(ml)
87.9±24.18 80.5±19.84 93.2±26.27 0.053
LVESV 
(ml)
30.6±13.04 28.4±12 34.4±14.13 0.113
LVEF (%) 65.9±9.61 65.8±8.92 64±7.77 0.552
RT3DE 
LVEDV 
(ml)
84.2±25.05 87.7±23.29 84.5±24.26 0.779
LVESV 
(ml)
28.9±11.43 28.7±10.24 29.2±11.40 0.979
SV(ml) 54.8±17.27 58.1±16.19 55.2±15.30 0.461
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LVEF (%) 66.3±7.6 67.4±6.59 65.8±6.68 0.574
Values are described as Mean (Standard Deviation). P <0.05 was considered statistically significant.
* Statistical significance lies between hypertensive and Healthy subjects
^ Statistical significance lies between OSA and Healthy subjects
OSA= Obstructive Sleep Apnoea, IVSd=Interventricular Septal thickness in Diastole, PWd= Posterior Wall 
thickness in Diastole, LVEDV= Left Ventricular End-Diastolic Volume, LVESV= Left Ventricular End-
Systolic Volume, LVEF=Left Ventricular Ejection Fraction, FS= Fractional Shortening, SV=Stroke 
Volume
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Table 3-20: Comparison of Diastolic Indices in Obstructive Sleep Apnoea, Hypertension 
and Healthy subjects
OSA Hypertension Healthy p
n 40 40 40
E (m/sec) 51.8±13.48^ 48.2±10.35* 59.5±15.03^* 0.001
A (m/sec) 53±13.37^ 56.7±17.15* 41.5±10.32^* <0.0001
E/A 1.01±0.35^ 1.1±0.89* 1.5±0.45^* <0.0001
E’ (sep) 
(m/sec)
6.1±2.06^ 5.1±1.35* 7.5±2.15^* <0.0001
E/E’(sep) 9.5±3.93 10±3.52* 8.2±2.21* 0.05
IVRT 
(ms)
0.01±0.023^ 0.01±0.028* 0.078±0.021^* 0.002
Values are described as Mean (Standard Deviation). P <0.05 was considered statistically significant.
       * Statistical significance lies between Hypertensive and Healthy subjects
^ Statistical significance lies between OSA and Healthy subjects
OSA= Obstructive Sleep Apnoea, E= Mitral Early Inflow Peak Velocity, A= Late Inflow Peak Velocity, 
sep E’= Septal E prime, IVRT=Iso-Volumetric Relaxation Time
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Table 3-21: Left Atrial Volume Index amongst Obstructive Sleep Apnoea Patients, 
Hypertensives and Healthy controls 
OSA Hypertension Healthy p
n 40 40 40
Ellipsoid 
Method
26.6±9.53^† 22.2±5.48*† 17.1±4.53 ^* <0.0001
Area-
length 
Method
28.1±9.50 ^† 23.7±5.74*† 18.6 ±4.93^* <0.0001
RT3DE 26.3±8.04^ 23.1±5.32* 18.2±4.33^* <0.0001
Values are described as Mean (Standard Deviation). P <0.05 was considered statistically significant.
       * Statistical significance lies between Hypertensive and Healthy subjects
^ Statistical significance lies between OSA and Healthy subjects
† Statistical significance lies between OSA and Hypertensive subjects
        OSA= Obstructive Sleep Apnoea, RT3DE= Real time 3-Dimensional Echocardiography
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Table 3-22:  Univariate analyses of the Pre-CPAP Left ventricular function in Obstructive Sleep 
Apnoea
r=correlation coefficient; AHI= Apnoea Hypopnoea Index; FMD= Flow mediated Dilatation; BP= Blood 
Pressure; LVEF= Left ventricular ejection fraction; LAA= Left atrial area; BMI= Body mass index
3DLAA E/A 3DLVEF
r p r p r p
Age 0.141 0.420 -0.129 0.421 -0.230 0.183
Height 0.124 0.479 0.435 0.064 -0.257 0.137
Weight 0.233 0.179 0.202 0.206 -0.182 0.297
BMI 0.225 0.194 -0.046 0.774 -0.098 0.576
AHI 0.016 0.925 -0.090 0.578 0.299 0.081
Epworth score -0.116 0.443 -0.062 0.727 -0.122 0.521
Systolic BP -0.008 0.948 -0.269 0.089 -0.151 0.387
Diastolic BP -0.140 0.423 -0.292 0.64 0.004 0.981
Glucose 0.199 0.274 0.84 0.616 -0.032 0.861
Total cholesterol0.08 0.646 0.203 0.201 0.104 0.552
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3.2.6 Myocardial Blood Flow Reserve (using Myocardial Contrast Echocardiography) 
in Moderate to Severe Obstructive Sleep Apnoea compared with hypertensive 
and healthy controls 
3.2.6.1 Abstract
Background: Obstructive sleep apnoea (OSA) is associated with a variety of cardiovascular 
diseases and increased cardiovascular morbidity and mortality. It is unknown whether the 
coronary blood flow responses are appropriate for myocardial metabolic requirements in 
otherwise healthy subjects with moderate to severe OSA. In this cross-sectional study, myocardial 
perfusion was assessed in moderate to severe OSA using quantitative myocardial contrast 
echocardiography (MCE).
Methods: Rest and stress MCE was performed in 120 patients (n=40 in moderate-severe OSA, 
hypertensive and healthy cohorts) with normal left ventricular systolic function and no known 
cardiovascular disorder. Real-time MCE dataset were acquired in three apical views at rest and 
after dipyridamole challenge. Myocardial blood flow was quantified in the mid- and apical 
cardiac segments, for the estimation of myocardial blood flow reserve (MBFR) {ratio of 
myocardial blood flow at rest (FR) to myocardial blood flow following stress (FS)}.
Results: All the groups were matched for age, sex and body mass index (BMI). Resting and post 
stress myocardial blood flow and MBFR were significantly attenuated in OSA patients and 
hypertensives compared with healthy subjects.  
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Conclusion: Impaired myocardial perfusion (owing to microvascular dysfunction) is attenuated in 
otherwise normal subjects with moderate to severe OSA and can be demonstrated using MCE. 
This may indicate altered flow-metabolic coupling, which may lead to nocturnal myocardial isch-
emia and other cardiovascular disorders particularly in susceptible individuals with moderate to 
severe OSA. 
3.2.6.2 Introduction
Myocardial blood flow reserve (MBFR) is an established marker of coronary perfusion and has 
been reported to be subclinically impaired in hypertension, diabetes mellitus and heart failure 
[Hamasaki et al 2000][Houghton et al 1992][Moir et al 2006]. The major determinants of MBFR 
- blood flow at rest and at maximum stress- are largely dependent on the endothelial dependent 
coronary microvasculature [Chilian et al 1986]. Since endothelial dysfunction (ED) has been 
consistently reported in obstructive aleep apnoea (OSA), it can be postulated that paucity of nitric 
oxide may affect myocardial blood flow patterns due to adverse changes in microvascular 
vasomotion and coronary vascular resistance. Resultant subclinically impaired coronary flow 
dynamics may explain high development of cardiovascular diseases and poor clinical outlook in 
the OSA population [Vane et al 1998] [Britten et al 2004].  
A variety of imaging tools such as magnetic resonant imaging (MRI), positron emission 
tomography (PET) and single photon emission computed tomography (SPECT) have been used 
for perfusion assessment [Orea-Tejeda et al 2003][Hamasaki et al 2000][Marini et al 2009] 
[Watkins et al 2009][ Herzog et al 2009]. MCE has surfaced as a non invasive, cost effective,
reproducible and bedside technique which has been validated against MRI and SPECT [Moir et al 
2006] [Wei et al 1998] [Di Bello et al 2004]. Yet MCE has not been used to assess myocardial 
perfusion in subjects with moderate to severe OSA.
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In this cross sectional study, I hypothesized that significant perfusion abnormalities exist in 
normotensive moderate-severe OSA patients compared with healthy individuals. In order to test 
this hypothesis, I performed MCE to estimate important myocardial blood flow indices in 
moderate to severe OSA with no confounding cardiovascular risk/disorder and compared them 
with healthy and hypertensive controls. 
3.2.6.3 Methods
The methods have been described in details under section 2 ‘Hypotheses and Methodology’.  
3.2.6.4 Results
45 subjects with moderate to severe OSA were recruited after the diagnosis was established with 
polysomnography. Perfusion analysis was performed in 120 patients (OSA=40, hypertensive=40, 
healthy=40), and the rest were excluded due to suboptimal image quality [Table 3-23].    
On the test day, heart rate in OSA was 73 ±11 beats per minute which was comparable with other 
two groups (p=0.76).  Hypertensive subjects had higher systolic blood pressure compared to 
healthy group (p=0.002). 
At rest, the average segmental blood volume fraction (α) was significantly attenuated in subjects 
with moderate to severe OSA compared to healthy (OSA 21±6 versus healthy 24±4; p=0.005) 
and hypertensives (OSA 21±6 versus hypertensive 24±5; p=0.005). The resting blood flow 
velocity (ß) was significantly higher in healthy subjects compared with patients with OSA 
(healthy 1.7±0.5 versus OSA 1.1±0.5; p<0.0001) and hypertension (healthy 1.7±0.5 versus 
hypertensive 1.3±0.4; p<0.0001). The ‘FR’ (multiplication of α and ß at rest) was significantly 
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attenuated in OSA and hypertensive subjects compared with healthy group (p<0.0001) yet 
comparable between OSA and hypertensive cohorts (p=0.104) [Table 3-24]. 
Post-dipyridamole stress ‘α’ and ‘ß’ were significantly impaired in OSA and hypertensives 
(<0.001 for all comparisons) compared with healthy subjects yet both indices were comparable 
between OSA and hypertensive subjects (p=0.06 and 0.29 respectively). The post stress 
myocardial blood flow, ‘FS’, calculated as a product of post stress α and ß, was also significantly 
impaired in both OSA and hypertensive groups compared with healthy individuals and (p<0.0001 
for both comparisons) [Table 3-24]. 
The MBFR, calculated as a ratio of the ‘FS’ and ‘FR’ was found to be impaired in OSA and 
hypertensive subjects compared to healthy controls (P<0.0001 for both comparisons). The MBFR 
was comparable between the OSA and hypertensive groups (P<0.001) [Table 3-24]. 
On Univariate analysis, no relationship was found between perfusion indices and age, BMI, AHI, 
Blood pressure, glucose and total cholesterol [Table 3-25]
3.2.6.5 Discussion
For the first time, I report sub-clinically yet seriously impaired myocardial perfusion estist in 
otherwise healthy patients with moderate to severe OSA. These findings might clarify the disease 
developing mechanisms and cardiovascular prognosis in OSA population. 
Coronary perfusion is largely regulated by the endothelial nitric oxide secreted from sub-
endocardial arteriolar network [Chilian et al 1986]. In addition to ED, hypoxia, dysregulation of 
β-adrenoreceptor mediated vasodilatation and α-adrenoreceptor mediated vasoconstriction in 
OSA is likely to induce microvascular dysfunction, increase vascular resistance consequently 
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impair myocardial perfusion [Kelm et al 1995][Kirby et al 1995][ Pinto et al 1993]. It has been 
reported that, out of the above, ED is the most important underlying mechanism for development 
of cardiovascular disease, due to its consistent demonstration in OSA population [Kelm et al 
1995] [Al Suwaidi et al 2001][ Celermajer et al 1996][Johnstone et al 1993][Hamasaki et al 
2000][ Casino et al 1993] [Grebe et al 2006][Kato et al 2000]. 
Relationship between blood flow patterns and ED has only been studied at experimental level in 
OSA. Studies seem to suggest that induction of ED leads to significant changes in vascular tone 
at arteriolar level and beyond [Hamilton et al 2008][Hamilton et al 2009]. This would lead to 
uncoupling of the coronary blood flow-myocardial work relationship, which has been reported in 
a canine study [Hamilton et al 2008]. Indeed, there are fundamental physiological differences in 
canine and human models for example, highly variable severity of the OSA and its gradual 
evolution in the humans [Stradling et al 1997]. Hamilton et al experimented that induction of ED 
and OSA in homo sapiens was manifested by marked increase in coronary vascular resistance and 
profound attenuation of the blood flow [Hamilton et al 2009].  It must be noted that the 
myocardial energy demand is tightly coupled with the myocardial blood flow under physiological 
conditions [Kitamura et al 1972][Baller et al 1979]. In post-apnoeic phase of OSA, myocardial 
energy demand (oxygen consumption) increases due to oxygen desaturation, the rise in blood 
flow is vital to maintain adequate myocardial oxygenation [Somers et al 1995][ Ringler et al 
1990]. However, coronary arterial oxygen contents are at a minimum at this point of ventilation 
in the OSA subjects [Chen et al 1999]. This net reduction in myocardial blood flow in the face of 
increased oxygen requirement (due to augmented vascular resistance), could lead to nocturnal 
myocardial ischemia. Indeed initially, these changes in flow could be of brief duration, and in 
patients with milder forms of OSA without concomitant coronary disease may not have clinical 
sequelae; but may well become crucial in those with OSA of at least moderate severity especially 
with coexisting significant coronary stenoses [Peled et al 1999] [Ciaramita et al 2004]. 
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These data are the first to report attenuated perfusion at rest, at stress and MBFR in moderate to 
severe OSA. Since OSA study subjects were normotensive, these perfusion abnormalities can not 
be attributed to commonly occuring hypertension in OSA population. 
I also demonstrated impaired MBFR in otherwise healthy hypertensives compared with healthy 
subjects. These observations are in accordance with the available data. Di Bello et al 
demonstrated attenuated myocardial perfusion in a small group of patients with essential 
hypertension compared with healthy controls [Di Bello et al 2004]. However, due to notable 
prevalence of OSA in hypertensives, we only recruited proven OSA negative hypertensive 
individuals in order to study unconfounded effect of high blood pressure on myocardial perfusion. 
Limitations 
The observational study design is one limitation of this study; however all the measurements and 
recordings were performed and analyzed by the same operator. Furthermore, inter- and intra-
observer variability was measured on 10 subjects and was found to be less than 10%. 
Myocardial perfusion as described above depends largely on the microcirculation. High blood 
pressure in OSA is one of the effects of OSA and is well reported to cause micro circulatory 
dysfunction. I showed slightly high BP in OSA though comparable with healthy subjects. This 
raises the suspicion if the BP contributed to such finding. It’s difficult to answer but uni/multi-
variate analysis did not reveal any such connection. This is a pilot project for MCE in OSA 
subjects and such aspects should be focussed at in future investigations.
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3.2.6.6 Conclusion 
I conclude that healthy subjects with moderate to severe OSA have impaired myocardial 
perfusion, which is likely to be owing to the ED. These observations provide insight into 
mechanisms leading to enhanced risk of cardiovascular disorders and cardiovascular prognosis in 
moderate to severe OSA patients.
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Table 3-23: Clinical Characteristics of Obstructive Sleep Apnoea patients, Hypertensives 
and Healthy Controls 
Variable OSA (SD) Hypertensive 
controls (SD)
Healthy 
controls (SD) 
p
n 40 40 40
Male/Female 32/8 28/12 39/11
0.486
Age (years) 50(10) 49(12) 46(8) 0.083
Aponea 
Hypopnea 
index
33 (21-48) 
*Ψ
4(3-4)Ψ 3(2-4)* <0.0001
Body mass 
index
34(8) 31(5) 32(7) 0.084
Systolic 
Blood 
pressure 
(mmHg)
143(16) 149(21)^ 135(15)^ 0.003
Diastolic 
Blood 
pressure 
(mmHg)
83(12) 85(9) 82(10) 0.514
No. of 
current 
smokers
11 12 15 0.164
Values are given in Mean ± Standard deviation or Median ± Inter-quartile Range. p<0.05 was considered 
Significant.
* Significance between OSA and Healthy subjects; ^ Significance between Hypertensive and Healthy 
subjects; Ψ Significance between OSA and Hypertensive subjects
OSA=Obstructive Sleep Apnoea
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Table 3-24: Comparison of Indices of Myocardial Perfusion amongst Obstructive sleep 
apnoea and controls 
OSA HT Healthy p
n 40 40 40
Segments 4 4 4
FR 26±13* 32±13^ 41±12*^ <0.0001
FS 45±26* 54±25^ 141±39*^ <0.0001
MBFR 1.8±1* 1.7±0.8^ 3.5±1*^ <0.0001
Values are given in Mean ± Standard deviation. p<0.05 was considered Significant.
OSA= Obstructive Sleep Aponea; HT= Hypertension; FR= Myocardial Blood Flow at Rest; FS= 
Myocardial Blood Flow at Stress; MBFR= Myocardial Blood Flow Reserve
* Significance between Obstructive Sleep Aponea and Healthy subjects; ^ Significance between 
Hypertensive and Healthy subjects
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Table 3-25: Univariate analyses of the Pre-CPAP Myocardial perfusion in Obstructive Sleep 
Apnoea
MBFR
r p
Age 0.077 0.632
Height 0.266 0.093
Weight 0.067 0.675
BMI -0.098 0.540
AHI -0.146 0.361
Epworth score 0.241 0.164
Systolic BP -0.063 0.195
Diastolic BP -0.182 0.256
Glucose -0.180 0.309
Total cholesterol -0.257 0.105
r=correlation coefficient; AHI= Apnoea Hypopnoea Index; FMD= Flow mediated Dilatation; BP= Blood 
Pressure; MBFR= Myocardial blood flow reserve; BMI= Body mass index
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3.3 Longitudinal studies 
3.3.1 Impact of Continuous Positive Airway Pressure treatment on flow mediated 
dilatation in moderate to severe Obstructive Sleep Apnoea 
3.3.1.1 Abstract 
Background: Obstructive sleep apnoea (OSA) related endothelial dysfunction has been 
demonstrated using flow mediated dilatation. However the impact continuous positive airway 
pressure (CPAP) on macro-vascular function is not well established in moderate to severe OSA. I 
hypothesized that CPAP improves FMD in moderate to severe OSA.
Methods: 40 with moderate-severe OSA had forearm vascular reactivity studies before and after 
26 weeks of CPAP treatment. Endothelial-dependent vasodilatation (EDV) was assessed by 
measuring brachial artery diameter changes in response to reactive hyperaemia and endothelial-
independent vasodilatation (EIV) was determined after administration of sublingual glyceryl 
trinitrite (GTN).
Results: Pre-treatment, only modest changes in brachial artery diameter were noted. However 
after CPAP, EDV and EIV rose significantly (p<0.0001). 
Conclusion: I conclude that treatment with CPAP improves endothelium dependent- and 
independent vasoreactivity in moderate to severe OSA. As ED is a systemic processm it can be 
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proposed that the CPAP treatment may improve cardiovascular outcome in selected OSA
subjects.
3.3.1.2 Introduction 
It is known that OSA related hypoxia, hypercapnia, sympathetic activation, and intrathoracic 
pressure swings can trigger complex cellular and biochemical processes, which may predispose to 
a pre-atherosclerotic condition, ‘endothelial dysfunction’ (ED) [Dean et al 1993][ Zwillich et al 
1995][ Lavie et al 2003][ Shimokawa et al 1999][Ross et al 1999]. Unsurprisingly, ED has been 
consistently demonstrated in OSA population and is considered responsible for chronic vascular 
diseases such as hypertension, coronary artery disease, heart failure, stroke and arrhythmias [Butt 
et al 2010][Peppard et al 2000]. 
A number of studies have validated FMD as an excellent non-invasive technique to evaluate 
vascular function in OSA before and after CPAP treatment [Celermajer et al 1992][Corretti et al
2002][Tanriverdi et al 2006 (a)]. Notably, treatment with the CPAP improves clinical outlook in 
OSA population. Some studies have reported improved nitric oxide bioavailability in OSA after 
the application of overnight nasal CPAP [Ip et al 2000]. Similarly improved FMD after CPAP in 
OSA has been reported proposing that CPAP may ameliorate ED and reduce the risk of 
development of cardiovascular diseases in OSA population [Lattimore et al 2006]. However these 
available OSA studies had loose exclusion criteria. Also the effects of long term CPAP therapy 
on the FMD in otherwise healthy and normotensive subjects with moderate to severe OSA. 
I hypothesized that prolonged use of CPAP improves vascular responsiveness in normotensive 
moderate to OSA subjects. To test this hypothesis I perfomed FMD on moderate to severe OSA 
subjects before and after 6 months of CPAP therapy. 
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3.3.1.3 Methods
The methods have been described in details under section 2.
3.3.1.4 Results
Table 3-26 represents salient patient characteristics pre- and post-CPAP whilst Table 3-27 shows 
brachial artery reactivity data. This includes absolute and percentage changes in brachial artery 
diameters in response to reactive hyperaemia and sublingual nitrates, before and after CPAP 
therapy. 
FMD was performed on 45 OSA patients at baseline however 40 patients were available after 6 
month of CPAP therapy. The use of CPAP averaged 5.4 hours per night, 5 nights per week per 
patient.   A significant post-CPAP drop was noted in systolic (p<0.0001) and diastolic blood 
pressure (p=0.017) and the Epworth score (p<0.0001) [Table 3-26]. 
Pre- and post-CPAP, mean baseline brachial artery diameter was comparable (p=0.02). Following 
hyperaemia, FMD improved significantly in post-CPAP subjects (p<0.0001) [Table 3-27]. 
Endothelial-independent vasodilatation (EIV), measured following the sublingual administration 
of GTN spray, also increased significantly (p=0.01) [Table 3-27]. 
3.3.1.5 Discussion 
In line with the findinfs of this study, I report that 6 months of CPAP treatment improves macro-
vascular function in the normotensive subjects with moderate to severe OSA.
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One of the postulated mechanisms in the cardiovascular diseases development is that OSA can 
precipitate or accentuate atherogenesis by causing ED, although to date there is no direct 
evidence which supports this hypothesis [Dean et al 1993]. Indeed endothelial injury (paucity of 
NO) could be an important primary event in atherogenesis, followed by intimal thickening and 
formation of atherosclerotic plaques [Ross et al 1999][Shimokawa et al 1999]. CPAP is an 
effective treatment for OSA and enhances endothelial NO release in the macro-circulation [Ip et 
al 2000][Bayram et al 2009] [Lattimore et al 2006]. In addition to NO-dependent pathways, 
CPAP also enhances non-NO pathways, supporting my reported findings of improved EIV 
[Lattimore et al 2006]. Such favourable changes in vascular reactivity have been attributed to the 
amelioration of physiological effects of OSA (such as repetitive hypoxia, surges in systemic 
blood pressure and enhanced sympathetic activity) with the CPAP use. However these CPAP 
studies have notable limitation. For example, Ip et al exclusively studied men and hence the 
results can not be generalised [Ip et al 2000]. Similarly, under-powered cohorts, short follow up, 
inclusion of mild OSA and under-representation of females are notable limitations in others 
[Lattimore et al 2006][ Imadojemu et al 2002]. In particular, the cardiovascular risk factor or 
diseases were not meticulously excluded in previous studies. Hence, independent impact of 
moderate to severe OSA on macro-vascular function remains debatable [Bayram et al 2009]. For 
the first time, the present data have shown that macro-vascular endothelial dysfunction in 
otherwise healthy and normotensive subjects with moderate to severe OSA is reversible with 
compliant long term use of CPAP. These findings are consistent with the available data 
[Lattimore et al 2006][ Imadojemu et al 2002][ Bayram et al 2009][ Ip et al 2000]. 
Hypoxia, altered oxygen dependent biosynthesis of NO from L-arginine and cyclic surges in 
systemic blood pressure are by far the most commonly mechanism of impaired vasoreactivity in 
OSA [Tahawi et al 2001] [Remsburg et al 1999] [Dean et al 1993]. Relief of these physiological 
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derangements with the effective use of CPAP has been proposed as the mechanism leading to 
endothelial recovery after CPAP therapy. 
It must be noted that a close correlation exists between ED in peripheral and coronary circulation 
[Sorensen et al 1995] [Anderson et al 1995]. Based on my findings of CPAP led improved FMD 
in brachial artery, I suggest that appropriate use of CPAP may also ameliorate coronary 
endothelial dysfunction. 
Limitations 
Modestly elevated blood pressure in the study group was one limitation of our study. I monitored 
blood pressure of the OSA subjects in clinics and community and ensured only normotensive 
blood pressure. I feel that this blood pressure level may reflect white coat response in study 
group. Due to unfavourable logistics, I could not perform 24 hour blood pressure which could 
have been useful in demonstrating the mean blood pressure more accurately. One could argue that 
changes in the FMD are secondary to improvement in blood pressure. Therefore, I performed 
univariate/multivariate analysis and found no relationship between changes in the blood pressure 
and the improvement in FMD in OSA subjects. Indeed, absence of the control group is another 
notabel important limitation of this study. I did not perform FMD at the end of the washout period 
which may also raise concerns about carryover effect from treatment.  However, the tests were 
performed and analyzed by single operator to ensure uniformity. The technique was also 
validated with satisfactory inter- and intra-observer variability.  
3.3.1.6 Conclusion 
I propose that effective long term use of CPAP ameliorates OSA induced attenuated brachial 
vasoreactivity. Therefore I suggest that CPAP may provide the opportunity to lower vascular risk 
and may improve cardiovascular outlook and prognosis. 
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Table 3-26: Patient Characteristics
Pre-CPAP Post-CPAP p
n 40 40
Age (Years) 49±10 49±11 0.541
AHI 37 (21-55) Not recorded -
BMI 
(Kg/m2)
35±8 34±8 0.18
Epworth 
score
15 (8-18) 8 (3-22) <0.0001
Systolic BP 
(mmHg)
143±16 133±13 <0.0001
Diastolic BP 
(mmHg)
83±11 79±8 0.017
Values expressed as Mean (Standard Deviation) or Median (Inter quartile range). AHI= Apnoea-Hypopnea 
Index; BMI= Body Mass Index; BP= Blood Pressure; CPAP= Continuous Positive Airway Pressure
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Table 3-27:   Brachial Artery reactivity before and after treatment with continuous positive 
airway pressure therapy
Pre-CPAP Post-CPAP p
Baseline 
Brachial artery 
diameter (mm)
4.5±0.5 4.4±0.6 0.2
Absolute 
change in 
diameter after 
reactive 
hyperaemia 
(mm)
0.3±0.1 0.5±0.2 <0.0001
Change after 
reactive 
hyperaemia 
(%)
7±4 13±6 <0.0001
Absolute 
change in 
diameter after 
GTN (mm)
0.5±0.2 0.7±0.3 <0.0001
Post GTN 
change (%)
11±4 16±7 <0.0001
Values expressed as Mean (Standard Deviation); GTN= Glycerol Trinitrate; CPAP= Continuous Positive 
Airway Pressure
184
3.3.2 Impact of Continuous Positive Airway Pressure Therapy on Micro-Vascular 
Function in Moderate to Severe Obstructive Sleep Apnoea assessed by Laser 
Doppler Flowmetry
3.3.2.1 Abstract 
Background: Obstructive sleep apnoea (OSA) is associated with endothelial dysfunction and 
carries an increased risk of hypertension and cardiovascular diseases due to acceleration of 
atherosclerosis. This study aimed to evaluate the impact of 6 month treatment with continuous 
positive airway pressure (CPAP) on the micro-vascular endothelial function in moderate to severe 
OSA using laser Doppler flowmetry (LDF).
Methods: Micro-vascular reactivity was assessed by LDF in 28 OSA patients at baseline and after 
6 months treatment with CPAP. This technique (LDF) was coupled with iontophoresis which 
allowed the measurement of the response to topically applied acetylcholine (endothelium-
dependent vasodilatation {EDV}) and sodium nitroprusside (endothelium-independent 
vasodilatation {EIV}). 
Results: Both, EDV and EID were impaired in study patients at baseline and improved 
significantly after CPAP therapy (p<0.0001). A significant drop in systolic and diastolic blood 
pressure was also noted. 
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Conclusion: This study shows CPAP led improvement in attenuated micro-vascular endothelial 
function in normotensive moderate to severe OSA subjects. Improvement in endothelial status 
could have important implications on cardiovascular morbidity/mortality in OSA population.
3.3.2.2 Introduction
A meta-analysis of 16 randomized controlled trials demonstrated that regular and efficient use of 
CPAP reduces systolic, diastolic and mean arterial blood pressure in patients with OSA and may 
even help prevent hypertension [Bazzano et al 2007]. Also, the reversal of ED with continuous 
positive airway pressure (CPAP) use has been demonstrated in OSA subjects [Carlson et al 
1996][ Kato et al 2000][ Kraiczi et al 2001]. Several techniques have been used  to study the 
impact of CPAP on systemic vasculature; for example impact of CPAP on macro-vasculature has 
been studied on conduit arteries using flow mediated dilatation and it showed enhanced post-
CPAP vasoreactivity [Imadojemu et al 2002][Ip et al 2000]. However micro-vasculature is a level 
of the systemic circulation which is most relevant in the development of hypertension and 
atherosclerotic process [Taddei et al 1995]. Microcirculatory function can be assessed using laser 
Doppler flowmetry (LDF) coupled with acetylcholine (ACH) and sodium nitroprusside (SNP) 
iontophoresis. Indeed, this non invasive technique has previously been successfully used in a 
number of cardiovascular conditions and is considered highly appropriate for repeated 
microcirculation studies [Debbabi et al 2010][Beer et al 2008][Trzepizur et al 2009]. However no 
previous study has used this to investigate the effects of long term CPAP treatment on 
microvascular dysfunction in otherwise patients with moderate to severe OSA. 
In the present study I tested the hypothesis that 6 months use of CPAP improves microvascular 
endothelial function in patients with newly diagnosed moderate to severe OSA who have no 
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known cardiovascular disease or risk factor. I tested this hypothesis by performing LDF and 
iontophoresis in OSA subjects at baseline and after 6 months of CPAP therapy. 
3.3.2.3 Methods
The methods have been described in details under section 2.
3.3.2.4 Results
Table 3-19 show important patients’ characteristics whilst Table 3-22 shows micro-vascular data 
including peak rise in cutaneous perfusion and percentage changes in response to ACH and SNP, 
before and after CPAP. 
LDF was performed on the right forearm of thirty one patients prior to the initiation of CPAP 
therapy. After 6 months of effective CPAP therapy, 28 patients with reasonable female gender 
representation (25%) were available for follow up. Recorded/Objective data on the use of CPAP 
during follow up averaged 5.1 hours per night 5 nights per week [Table 3-28]. 
A significant reduction is systolic (p<0.0001) and diastolic blood pressure (p=0.017) and the 
Epworth score (p<0.0001) was observed in post-CPAP group [Table 3-28]. 
Pre- and post-CPAP mean baseline perfusion was comparable (p>0.05). After CPAP treatment 
ACH induced endothelial dependent function improved significantly (p<0.001) [Table 3-29]. 
Endothelial-independent perfusion changes, measured following locally administered SNP, also 
increased significantly post-CPAP (p=0.007) [Table 3-29]. 
3.3.2.5 Discussion 
In present study, I demonstrated that microvascular (endothelial) dysfunction in otherwise healthy 
subjects with moderate to severe OSA improves after 6 months of CPAP use. I used LDF as a 
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tool for endothelial assessment which is validated for this purpose but has not been used in 
moderate to severe OSA [Koitka et al 2004][ Rousseau et al 2008]. 
These findings are consistent with the available data suggesting improved vascular function after 
CPAP [Carlson et al 1996][ Kato et al 2000][ Kraiczi et al 2001][ Ip et al 2000][ Lattimore et al 
2006]. Although LDF has rarely been used in OSA subjects yet our data is consistent with the 
available data [Trzepizur et al 2009]. For example, Trzepizur et al reported improved 
microvascular function after 2 month of CPAP therapy in OSA patients compared with healthy 
controls [Trzepizur et al 2009]. EIV remained unchanged according to the authros but this study 
could have been under-powered (n=12) to detect significant difference in endothelial independent 
responses. 
The exact mechanisms of CPAP led improvement of endothelial dependent responses in resistant 
vessels are largely unclear. Chronic sleep deprivation, autonomic dysregulation and perhaps most 
importantly chronic hypoxemia- all of which are widely prevalent in OSA- have been proposed in 
the development of ED in OSA [Amir et al 2004] [Takase et al 2004] [Phillips et al 2000] [Pagani 
et al 2009]. Based on available data, it can be proposed that CPAP therapy enhance endothelial 
dependent responses by amelioration of sleep fragmentation, improved oxygen saturation and 
regulation of autonomic function. 
I also observed significant improvement in SNP-mediated responses after CPAP therapy.  Our 
findings of improved EIV are consistent with recent double blind study where 27 OSA patients 
known to have marked oxygen desaturation were randomized to CPAP for 6 weeks [Cross et al 
2008]. Both, endothelium-dependent and endothelium independent responses were impaired but 
improved markedly after CPAP use [Cross et al 2008]. Larger number of studied did not show 
any CPAP led improvement in SNP mediated responses [Kato et al 2000][Lattimore et al 2006] 
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but the coexisting presence of confounding factors in such investigations should not be ignored. 
Such confounder risk factors such as smoking, hypertension and concurrent use of medications, 
could have significant bearing on the endothelial responses and independent impact of CPAP on 
microvascular function. In contrast, I had stringent enrolment criteria where all OSA patients 
were carefully selected and exclusion of coexisting cardiovascular diseases/risk factors was 
ensured. 
It has been reported that activated inflammatory cytokines in OSA subjects down regulate the 
endothelial receptors, limiting biological effect of the extrinsic nitrates resulting in impaired 
endothelial indepdent vasoreactivity [Bravo et al 2007] [Ferrell et al 2002][ Meier-Ewert et al 
2004] [Iversen et al 1999]. CPAP use inturrupts this inflammary cascade and thus may improve 
EIV. 
Limitations 
Absence of a control group and observational design are main limitations of our study. However, 
the tests were performed and analyzed by single operator to ensure uniformity and was validated 
in ten patients with excellent inter- and intra-observer variability.  Furthermore, our observations 
are limited to moderate to severe OSA and cannot be extrapolated to other categories.
Again, the significant reduction in systolic and diastolic BP was noted after CPAP therapy. It can 
be argued that any improvement in LDF responses are secondary to such improvement in BP, 
however, I did not note any relationship between the reduction of BP and change in 
microvascular reactivity.
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3.3.2.6 Conclusion 
I report that long term CPAP therapy improves micro-vascular reactivity in moderate to severe 
OSA and therefore may have a significant impact on the cardiovascular morbidity and mortality 
in OSA population.
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Table 3-28: Patient Characteristics
Pre-CPAP Post-CPAP p
n 28 28
Age (Years) 51±9 51±10 0.621
AHI 37 (20-54) Not recorded -
BMI 
(Kg/m2)
35±9 35±9 0.773
Epworth 
score
14 (8-18) 4 (0-8) <0.0001
Systolic BP 
(mmHg)
145±17 133±12 <0.0001
Diastolic BP 
(mmHg)
84±13 79±8 0.005
Values expressed as Mean (Standard Deviation) or Median (Inter quartile range). AHI= Apnoea-Hypopnea 
Index; BMI= Body Mass Index; BP= Blood Pressure; CPAP= continuous positive airway pressure therapy; 
BP= blood pressure
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Table 3-29:   Changes in Micro-vascular Blood Flow in response to Acetylcholine and 
Sodium Nitroprusside before and after Continuous Positive Airway Pressure 
Therapy
Pre-CPAP Post-CPAP p
Mean Baseline 
perfusion pre-
ACH (PU)
0.69 (0.57-0.72) 0.61 (0.51-0.71) 0.127
Mean 
maximum 
perfusion post-
ACH (PU)
1.4 (1.1-1.5) 1.3 (1-1.7) 0.811
Mean 
percentage 
increase post-
ACH (%)
103 (55-133) 156 (83-238) 0.001
Mean Baseline 
perfusion pre-
SNP (PU)
0.73 (0.64-0.8) 0.6 (0.53-0.74) 0.08
Mean 
maximum 
perfusion post-
SNP (PU)
1.4 (1.2-1.7) 1.4 (1.2-1.6) 0.569
Mean 
percentage 
change post-
SNP (%)
97 (58-146) 153 (92-223) 0.007
Values in Median (Inter-quartile Range). ACH= Acetylcholine; SNP= sodium nitroprusside, PU= Perfusion 
unit, CPAP= continuous positive airway pressure therapy
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3.3.3 Impact of Continuous Positive Airway Pressure Therapy on Endothelial 
Progenitor Cells and Circulating Endothelial Cells in Moderate to Severe 
Obstructive Sleep Apnea
3.3.3.1 Abstract 
Background: Decreased endothelial progenitor cells (EPCs) and increased circulating endothelial 
cells (CECs) have been described in obstructive sleep apnoea (OSA) and several cardiovascular 
diseases. I investigated the impact of continuous positive airway pressure (CPAP) therapy on 
endothelial repair capacity and apoptosis in otherwise healthy subjects with moderate to severe 
OSA.
Methods:  36 newly diagnosed patients with moderate to severe OSA with no coexisting 
cardiovascular comorbidities were enrolled. Circulating levels of EPCs, a marker of endothelial 
reparation, and CECs, a marker of endothelial apoptosis, were enumerated using flow cytometer
before and after 6 months of nasal CPAP therapy.
Results:  Compared with pre-CPAP, a trend of increasing numbers of EPC was observed post-
CPAP, however it did not reach statistical significance (p=0.677). Additionally, the absolute CEC 
count and EPC/CEC ratio remained unchanged during the follow up (p= 0.61 and 0.238 
respectively).  
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Conclusion: EPC and CEC counts were comparable at baseline and after 6 months of effective 
CPAP treatment in moderate to severe OSA. Treatment with CPAP may not be associated with 
improvement in these markers of endothelial repair capacity and vascular endothelial cell damage 
in OSA patients without concomitant vascular disease.
3.3.3.2 Introduction
The cumulative effect of the perturbed vascular milieu in OSA is believed to result in endothelial 
cell injury or dysfunction/damage, which has been recognized as crucial early event in the 
pathogenesis of cardiovascular disorders [Carlson et al 1996][ Schultz et al 2005]. 
Endothelial progenitor cells (EPCs) represent a circulating pool of bone marrow derived cells to 
replace dysfunctional/damaged endothelium and hence contribute to vascular homeostasis 
[Shantsila et al 2007 (a) (b)]. Reduced levels of circulating EPCs are predictive of worse clinical 
outcome and several cardiovascular risk factors inversely correlate with the number and activity 
of EPCs [Tepper et al 2002][ Chen et al 2004][Schmidt-Lucke et al 2005][ Werner et al 2006]. 
Reduced EPCs count has been demonstrated in OSA subjects [Jelic et al 2009]. 
Several cardiovascular risk factors are closely associated with endothelial apoptosis [Asai et al 
2000][ Tricot et al 2000]. Increased numbers of apoptotic cells (CECs) have been reported in 
OSA and in a variety of vascular conditions such as acute coronary syndrome and heart failure 
[Solovey et al 1997][Quilici et al 2004][ Chong et al 2004]. 
Small studies have reported favourable fluctuations in EPCs and/or CECs levels in OSA subjects, 
after CPAP therapy [Jelic et al 2009][ Jelic et al 2008][ El Solh et al 2007]. However, the effect 
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of long term CPAP therapy on EPCs and CECs count in healthy subjects with moderate to severe 
OSA remains undetermined. 
In this chapter, I tested the hypothesis that these cells strains - acting as markers of ED in 
moderate to severe OSA - may improve after 6 months of CPAP use. I tested this hypothesis by 
performing flow cytometry on the venous blood sample of a carefully selected moderate to severe 
OSA individuals before and after 6 months of CPAP therapy. 
3.3.3.3 Methods
The methods have been described in details under section 2. 
3.3.3.4 Results
Table 3-30 depicts the baseline demographic, anthropomorphic and polysomnographic data 
whilst Table 3-31 shows distribution patterns of CECs and EPCs, pre- and post-CPAP. 
Flow cytometric analysis was performed on the venous blood samples of 40 OSA patients prior to 
initiation of the treatment with CPAP. After 6 months of CPAP therapy, 36 patients (22% female) 
were available for follow up. Recorded/Objective data on the use of CPAP during follow up 
averaged 5.9 hours per night, 5 nights per week. 
A significant post-CPAP reduction is systolic (p<0.0001) and diastolic blood pressure (p=0.017) 
and the Epworth score (p<0.0001) was observed [Table 3-30]. 
As shown in Table 3-31, the number of circulating CD34++ cells, both in absolute count and as 
percentage of peripheral blood mononuclear cells, was not significantly different in OSA patients 
before or after CPAP use (p=0.206 and 0.161 respectively). 
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The absolute numbers of CECs and circulating EPCs in subjects with OSA, pre- and post-CPAP 
are depicted in Table 3-31. There were no statistically significant differences between the groups 
with respect to numbers of CECs (p=0.610), circulating EPCs (p=0.677) and EPC/CEC ratio 
(p=0.238) [Table 3-31]. 
Assessment of correlations between numbers of CECs and circulating EPCs and age, sex, BMI, 
smoking, AHI, Epworth score and blood pressure yielded no statistically significant correlations. 
3.3.3.5 Discussion 
In the present study I observed no differences in EPCs or CECs count in the peripheral blood 
sample of subjects with moderate to severe OSA pre- and post-CPAP.
These findings are in contrast with the previous OSA studies where CPAP led increase in EPCs 
has been demonstrated after short term [Jelic et al 2009] [Jelic et al 2008].  However, smaller 
cohorts, under-representation of female gender, inclusion of subjects with cardiovascular 
disorders and concurrent use of antihypertensives are major limitations of these studies. It must 
be noted that all these factors have substantial and independent impact on the EPCs and CECs 
count and hence I meticulously excluded subjects with any confounding factor. Additionally the 
CPAP follow up was limited to 4 weeks in previous studies compared with present study where 
subjects were followed up after 6 months of adequate CPAP treatment. Finally reduction in CECs 
has also been reported after CPAP in limited available data [El Solh et al 2007] but most of these 
studies were small with gender exclusivity and hence the results can not be extrapolated to the 
whole population. However, I did not notice any significant changes in CECs numbers after 
CPAP therapy. 
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Considering a well reported association between ED and OSA as well as CPAP led improvement 
in ED our findings are somewhat surprising [Kato et al 2000][ Ip et al 2004]. However, there are 
several possible reasons for our findings.  Since the CPAP use results in dramatic and acute 
changes in thoracic pressures and plasma oxygen concentration it can be proposed that such 
physiological effects may not be so obvious and dramatic after prolonged CPAP therapy [Simons 
et al 2011][ Milovanova et al 2009][ Dempsey et al 2007].  Secondly, although our study is 
largest of its kind, due to the relatively rare event rate, our study sample may have been under-
powered to detect a statistically significant difference. This is evident by the trend of increase in 
EPCs after CPAP, which did not reach statistical significance. Additionally, differential 
susceptibility to cardiovascular morbidity in OSA partially depends on factors such as hypoxia, 
sleepiness and obesity; it can be hypothesized that CPAP therapy may interact with these 
physiological factors resulting in different observations [Stanchina et al 2003][ Findley et al 
1983][ White et al 2005][Barbe et al 2001] [Schafer et al 2002]. Although there are serious 
limitations associated with all EPCs/CECs enumeration techniques, the assay of endothelial 
colony-forming units may have been more likely to detect pre- and post-CPAP differences  in the 
cell counts [Shantsila et al 2007 (a)] [Hill et al 2003]. Finally, it can also be derived that CPAP 
led improvement in CEC/EPCs distribution only occurs in OSA patients with coexisting 
cardiovascular diseases.
Limitations
I did not assess the oxygen desaturation, using nadir SaO2. It must be noted that hypoxia is an 
important determinant of endothelial damage in OSA [Dyugovskaya et al 2002] and it can be 
hypothesized that CPAP led changes are more prominent in conjunction with greater degree of 
hypoxia [Stanchina et al 2003][ Findley et al 1983][ White et al 2005].  More importantly, I did 
not assess the functional component of EPCs or CECs and it can be hypothesized that long term 
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CPAP therapy may predominantly alter EPC and/or CEC functional characteristics compared 
with the total circulating cell count. 
Blood pressure is reported to have a strong influence on the EPC and CEC count. In parallel, a 
large body of evidence suggest CPAP led reduction of BP in OSA. Although, I showed BP 
reduction in this study, but no significant quantitative change in EPC and CEC and neither any 
relationship between the change in BP and the change in cellular count.
3.3.3.6 Conclusion 
In conclusion, this study did not reveal any differences in EPCs and CECs, pre- and post-CPAP, 
in subjects with moderate to severe OSA who did not suffer from established cardiovascular 
disease or risk factors. However it is possible that CPAP dominanatly affects the functional 
components (as migratory capacity or EPCs and apoptotic properties of CECs) and that such 
change may be more prominent in subjects with coexisting cardiovascular disorders. 
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Table 3-30: Patient Characteristics
Pre-CPAP Post-CPAP p
n 36 36
Age (Years) 49 (10) 49 (10) 0.821
AHI 37 (21-55) Not recorded
BMI (Kg/m2) 35 (8) 34 (8) 0.180
Epworth 
score
13 (6) 5 (6) <0.0001
Systolic BP 
(mmHg)
143 (16) 133 (13) <0.0001
Diastolic BP 
(mmHg)
83 (11) 79 (8) 0.017
Values expressed as Mean (Standard Deviation) or Median (Inter quartile range). P<0.05 is considered 
statistically significant
CPAP: Continuous Positive Airway Pressure; AHI= Apnoea-Hypopnea Index; BMI= Body Mass Index; 
BP= Blood Pressure.
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Table 3-31: Distribution of Endothelial Progenitor Cells and Circulating Endothelial Cells 
before and after continuous positive airway pressure therapy 
Pre-CPAP Post-CPAP p
N 36 36
%CD34++ 
count
0.0004(0.0003-0.0007) 0.0005(0.0004-0.0006) 0.161
CD34++ count 
(Per ml)
3350(1749-4006) 3166(2346-4789) 0.206
Absolute EPC 
count (Per ml)
75 (38-151) 80 (45-204) 0.677
Absolute CEC 
count (Per ml)
82 (38-144) 83 (59-123) 0.610
EPC/CEC 
Ratio
1 (0.8-1.6) 1 (0.7-1.5) 0.238
EPC: Endothelial Progenitor Cell, CEC: Circulating Endothelial Cell, CPAP: Continuous Positive airway 
Pressure 
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3.3.4 Effect of Continuous Positive Airway Pressure treatment on Pulse Wave 
Analysis and Pulse Wave Velocity in Obstructive Sleep Aponea
3.3.4.1 Abstract 
Background: Obstructive sleep apnea (OSA) is associated with arterial stiffness, hypertension and 
several cardiovascular disorders. The aim of the present study was to determine changes in 
arterial stiffness in healthy subjects with moderate to severe OSA following long term continuous 
positive airway pressure (CPAP) therapy.
Methods: In 26 patients (6 females) with moderate to severe OSA, arterial stiffness was assessed 
by applanation tonometry– derived pulse wave analysis (PWA) and pulse wave velocity (PWV). 
Baseline and Glycerol trinitrate (GTN)/Salbutamol induced changes in aortic augmentation (AA); 
aortic augmentation index (AIx); AIx corrected for heart rate of 75/minute (AIx@75); Sub-
endocardial viability ratio (SEVR)] and PWV measurements were recorded at enrolment and after 
6months of CPAP therapy. 
Results: After CPAP, significant reductions were noted in the PWA indices (AIx@75 – pre-
therapy 19 (IQR 10 - 28) to post therapy 4 (IQR -1.25 – 28); p=0.001). Salbutamol induced 
responses were significantly better post-CPAP compared to pre-CPAP (p<0.01) however only 
modest and statistically insignificant changes was noted in GTN induced responses. PWV 
measurements were also comparable before and after CPAP use and no changes were observed in 
GTN/Salbutamol induced responses. 
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Conclusion: These results suggest that clinically important changes in arterial stiffness may occur 
following long term treatment of moderate to severe OSA with CPAP. 
3.3.4.2 Introduction
Whilst the independent effect of the OSA on cardiovascular health has widely been reported 
[Young et al 2005] [Arzt et al 2005][Peker et al 2006], several studies report a gradual decline in 
the cardiovascular event rate after CPAP use [Marin et al 2005][ Peker et al 2002]. The exact 
explanation for such a reduction is unclear, but antihypertensive effect of CPAP treatment has 
been implicated [Chobanian et al 2003][ Pepperell et al 2002][ Gotsopoulos et al 2004]. 
Nevertheless, the size of anti-hypertensive effect of CPAP is controversial and appears to be 
modulated by several factors such as OSA severity, degree of sleepiness, concomitant use of 
antihypertensive medication, duration and efficacy of treatment and contentiously the arterial 
stiffness [Barnes et al 2004][ Robinson et al 2006][ Börgel et al 2004][ Campos-Rodriguez et al 
2006]. Due to a close correlation with ageing and various cardiovascular risk factors, arterial 
stiffness has also a strong predictive role beyond causing high blood pressure [Vaitkevicius et al 
1993][Dart et al 1991]. Several investigators have probed if cardiovascular risk could be modified 
by reducing arterial stiffness [Oliver et al 2003][ Weber et al 2004]. Indeed short term CPAP
therapy has shown promising reduction in the arterial stifness in OSA population, however effects 
of prolonged use of CPAP in moderate to severe OSA subjects remains largely unclear [Kitahara 
et al 2006][ Phillips et al 2008].
I hypothesized that 6 months of CPAP use reduces arterial stiffness in otherwise healthy subjects 
with moderate to severe OSA. In order to test this hypothesis, I performed applanation tonometry 
on normotensive patients with moderate to severe OSA at the time of diagnosis and repeated 
these measurements after 6months of CPAP treatment.
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3.3.4.3 Methods
The methods have been described in details under section 2. 
3.3.4.4 Results
Table 3-32 depicts the baseline characteristics of OSA subjects whilst Table 3-33 and 3-34 shows 
data on the responsiveness of indices of arterial stiffness to systemically administered GTN and 
Salbutamol, pre- and post-CPAP. 
Pulse wave analysis and pulse wave velocity measurement was completed on 26 patients before 
and after CPAP treatment. Recorded/Objective data on the use of CPAP during follow up 
averaged 5 hours per night 5 nights per week. During follow up a significant post-CPAP drop in 
systolic (p<0.001) diastolic blood pressure (p=0.024) and the Epworth score was observed 
(p<0.01) [Table 3-32]. 
At baseline, compared with pre-CPAP measurements, indices of PWA (AA, AIx, AIx@75 and 
SEVR) were significantly reduced (all p<0.05) however PWV was comparable at before and after 
CPAP therapy [Table 3-33; 3-34]. Following Salbutamol administration, AA, AIx and AIx@75 
were significantly reduced thorough out the 20 minutes of recording (all p<0.05) indicating 
reduction in arterial stiffness after CPAP therapy however PWV and SEVR remained unchanged 
(p>0.05) [Table 3-35]. After GTN administration, AA, AIx and AIx@75 responses were delayed 
compared to Salbutamol induced responses (significant improvement was only noted 20 minutes 
after GTN administration), whilst SEVR and PWV remained unchanged (p>0.05)[Table 3-36]. A 
significant change in baseline values were found between pre- and post-CPAP cohort [Table 3-
37]. 
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Post CPAP indices of arterial stiffness (including AA, AIx and AIx@75) were inversely 
correlated with duration of CPAP usage (r= -0.592, p=0.001; r= -0.592, p=0.001; r= -0.522; 
p=0.006 respectively).
3.3.4.5 Discussion 
This study has three important findings: 1) significant post CPAP improvements in large-conduit 
arterial stiffness in patients with moderate to severe OSA, who were free from any cardiovascular 
comorbidities; 2) enhanced systemic arterial responses to endothelium-dependent (Salbutamol 
induced) and -independent (GTN) vasodilators in post-CPAP arm; 3) post-CPAP blood pressure 
reduction as a likely manifestation of improved arterial elastic properties. 
AIx, AIx@75, SEVR and PWV are some of the direct and indirect indicators of central arterial 
stiffness and could be predictive of cardiovascular events in high-risk population [Wilkinson et al 
2002] [Weber et al 2004] [Williams et al 2009] [Noon et al 2008] [Drager et al 2007 (b)]. These 
indices provide indirect information about left ventricle pressure dynamics, which has a profound 
contribution in the development of left ventricular hypertrophy, heart failure and target end-organ 
damage [Hashimoto et al 2007][Iketani et al 2000][O’Rourke et al 1996].
My observations of improved arterial stiffness (PWA) are consistent with previous CPAP studies 
in OSA subjects [Phillips et al 2008][Drager et al 2007 (b)][Kitahara et al 2006]. I have 
demonstrated that after 6 months of CPAP use arterial elastic propertice change positively as 
manifested by reduction in arterial augmentation.  This study is one of its kinds as previous 
studies were relatively smaller and included OSA subjects with coronary artery disease, 
hypertension and other cardiovascular risk factors which could have confounded the study 
outcome. I ensured adequate female representation whilst some interventional study exclusively 
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enrolled males. Notably, females have a higher incidence of arterial stiffness, hence the findings 
from these investigations can not be extrapolated to the general population [Noon et al 2008]
[Protogerou et al 2007] [Drager et al 2010]. 
I did not detect statistically significant changes in PWV which is in contrast with previous CPAP 
studies and can be explained with a number of reasons [Baguet et al 2009][Drager et al 2010 
(a)][Chung et al 2011][Kitahara et al 2006]. For example I exclusively studied moderate to severe 
OSA population whereas previous investigations also included milder forms of the disease. 
Furthermore, compared to ankle-brachial technique, I used carotid-femoral approach to measure 
PWV and the difference of the techniques could introduce notable difference compared with 
previous findings [Kitahara et al 2006][Nagahama et al 2004]. Previous studies had loose 
exclusion criteria and the OSA subjects with cardiovascular disorders - which are independent 
and notable causes of increased PWV- were not meticulously excluded and could add significant 
bias [Jelic et al 2002][Baguet et al 2009]. Hence, I conclude that, in otherwise healthy middle 
aged population of moderate to severe OSA, CPAP may reduce arterial stiffness but changes in 
PWV are likely to be observed in the subjects with coexisting cardiovascular risk diseases.
I observed for the first time, post-CPAP enhancement in vascular responses to endothelial 
dependent and independent stimuli whilst using applanation tonometry. Macro-vasculature 
contains considerable quantities of vascular smooth muscle, which is directly influenced by the 
nitric oxide and sympathetic tone. CPAP has been demonstrated to accentuate nitric oxide 
production and diminution of sympathetic tone [Ip et al 2004][ Ip et al 2000]. Both of these 
mechanisms contributes to reduce arterial stiffness and enhance vascular responsiveness 
[Waradekar et al 1996][ Narkiewicz et al 1999][ Mills et al 2006]. These hypotheses also partially 
explain my findings of inverse correlation between reduction in arterial stiffness and CPAP 
compliance. 
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In addition, I noted a reduction in peripherally measured systolic and diastolic blood pressure 
which is in accordance with the available data [Phillips et al 2008][ Martínez-García et al 2007][ 
Bazzano et al 2007]. Improvement in arterial atiffness and endothelial status has been implicated 
in the blood pressure lowering effect of CPAP. It is worth mentioning that both reduction in 
blood pressure and arterial stiffness are associated with improved survival in selected cohorts 
[Sawicki et al 1995]. Since this study has shown parallel reduction in arterial stiffness and blood 
pressure, it can be proposed that CPAP may improve cardiovascular prognosis [Nürnberger et al
2002]. 
Limitations 
Ip et al had reported that the improvement in endothelial function is not sustained after stopping 
CPAP for 1 week, despite its previous use for several months [Ip et al 2004]. Therefore, inability 
to perform measurements at the end of the washout period may raise concerns of a carryover 
effect from previous treatment. 
A strong relationship exists between BP and PWA and PWV. In a recent Explore study 
antihypertensive showed significant reduction in PWV and AIx with parallel reduction in the BP, 
suggesting BP reduction as one of the mechanism to reduce arterial stiffness [Boutouyrie et al 
2010]. I demonstrated significant reduction in systolic and diastolic BP after CPAP which is in 
accordance with the available data. Additionally I also demonstrated significant reduction in 
baseline PWA and PWV parameters after CPAP. It can be questioned if such change is secondary 
to anti-hypertensive effect of CPAP. It largely unclear and this study do not answer this to the 
level of satisfaction. I investigated a relationship between the relative reduction in BP and its 
relationship with the relative change in PWA and PWV. I did not find any relationship and hence 
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it’s reasonable to assume that, this change is secondary to CPAP and not purely due to BP 
reduction. It can further be argued that CPAP led reduction in arterial stiffness is mediated by its 
antihypertensive effect. Clearly this needs more investigation to establish a causal relationship 
amongst CPAP, BP and arterial stiffness.
3.3.4.6 Conclusion
In summary, these findings suggest significant reduction in arterial stiffness, improved vascular 
reactivity and and reduction in blood pressure after prolonged CPAP therapy in moderate to 
severe OSA subjects. Considering available data on the relationship between arterial stiffness and 
cardiovascular morbidity/mortality, CPAP use may reduce overall cardiovascular risk in selected 
OSA populations. 
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Table 3-32: Patient Characteristics
Pre-CPAP Post-CPAP p
n 26 26
Age (Years) 49±10 49±10 0.719
AHI 31 (20-46) Not recorded 
BMI (Kg/m2) 31±5 31±5 0.317
Epworth 
score
13±6 7±7 <0.0001
Systolic BP 
(mmHg)
143±17 132±12 <0.0001
Diastolic BP 
(mmHg)
83±13 79±7 0.024
Values expressed as Mean (Standard Deviation) or Median (Inter quartile range). AHI= Apnoea-Hypopnea 
Index; BMI= Body Mass Index; BP= Blood Pressure; CPAP= continuous positive airway pressure
208
Table 3-33:  Indices of Pulse Wave Analysis and Pulse Wave Velocity before and after 
systemic administration of Salbutamol, as Median (Inter-quartile range)
Index Pre-CPAP Post-CPAP p
Baseline 3
AA 14 (10 – 21) 5 (0-19) 0.002
AIx 26 (20-31) 12 (0-32) 0.006
AIx@75 18 (10-29) 7 (-2 – 26 ) 0.007
SEVR 171 (138-196) 152 (140-184) 0.08
PWV 6 (5-7) 5 (5-8) 0.363
After 5 Minutes
AA 22 (15-29) 4 (1-15) 0.004
AIx 25 (12-35) 10 (2-30) 0.01
AIx@75 20 (8-27) 5 (-4 – 25) 0.012
SEVR 168 (147-189) 158 (131-175) 0.023
PWV 6 (5-7) 6 (5-7) 0.763
After 10 Minutes
AA 13 (7-20) 6 (0-15) 0.002
AIx 24 (14-31) 15 (0.5-29) 0.019
AIx@75 17 (7-28) 7 (-1 – 24) 0.011
SEVR 161 (149-183) 163 (135-178) 0.184
PWV 5 (5-7) 6 (5-7) 0.396
After 15 Minutes
AA 14 (7-20) 7 (0.5-16) 0.008
AIx 22 (13-33) 14 (1-25) 0.023
AIx@75 16 (8-29) 5 (-3 – 25) 0.043
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SEVR 168 (155-192) 154 (138-175) 0.023
PWV 6 (5-7) 5 (5-7) 0.841
After 20 Minutes
AA 12 (7-22) 7 (0.5-16) 0.006
AIx 22 (15-33) 14 (1-28) 0.017
AIx@75 15 (7-28) 7 (-4 – 29) 0.042
SEVR 171 (151-184) 152 (133-183) 0.141
PWV 6 (5-7) 6 (5-7) 0.647
HT=Hypertension, CPAP= Continuous Positive Airway Pressure, AA=Aortic Augmentation, 
AIx=Augmentation Index, AIx@75=Augmentation Index at heart rate of 75/minute, SEVR=Sub-
Endocardial Viability Ratio, PWV= Pulse Wave Velocity
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Table 3-34:  Indices of Pulse Wave Analysis and Pulse Wave Velocity before and after 
systemic administration of Glyceryl trinitrate, as Median (Inter-quartile 
range)
Index Pre-CPAP Post-CPAP p
Baseline 4
AA 15 (9 - 22) 5 (-0.5 – 18 ) <0.0001
AIx 26 (17 - 33) 9 (-0.75 – 35) 0.003
AIx@75 19 (10 - 28) 4 (-1.25 – 28) 0.001
SEVR 167 (151 - 187) 150 (133 - 174) 0.021
PWV 6 (5 - 7) 5 (5 - 7) 0.808
After 5 Minutes
AA 3 (-4 – 8) -1 (-6 – 6) 0.271
AIx 5 (-7 – 14) -2 (-10 – 10) 0.420
AIx@75 1 (-9 – 10) -2 (-10 – 9) 0.429
SEVR 163 (145 – 184) 161 (140 – 175) 0.404
PWV 6 (5 - 8) 6 (5 - 7) 0.862
After 10 Minutes
AA 1 (-4 – 9) -4 (-6 – 3) 0.333
AIx 2 (-7 – 13) -7 (-13 – 7) 0.399
AIx@75 -1 (-9 – 8) -8 (-15 – 3) 0.338
SEVR 164 (143-182) 161 (149 – 178) 0.577
PWV 6 (5-8) 6 (5 – 8) 0.661
After 15 Minutes
AA 2 (-4 – 7) -2 (-9 – 3) 0.184
AIx 5 (-6 – 13) -4 (-14 – 7) 0.166
AIx@75 -2 (-12 – 11) -8 (-15 – 6) 0.146
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SEVR 167 (145-185) 166 (145-175) 0.904
PWV 6 (5-7) 6 (5-7) 0.445
After 20 Minutes
AA 4 (-3 – 12) -2 (-6 – 5) 0.038
AIx 7 (-7 – 19) -4 (-12 – 8) 0.05
AIx@75 4 (-11 – 16) -8 (-16 – 8) 0.03
SEVR 165 (145-186) 162 (139-186) 0.339
PWV 6 (5-7) 6 (5-7) 0.071
HT=Hypertension, CPAP= Continuous Positive Airway Pressure, AA=Aortic Augmentation, 
AIx=Augmentation Index, AIx@75=Augmentation Index at heart rate of 75/minute, SEVR=Sub-
Endocardial Viability Ratio, PWV= Pulse Wave Velocity
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Table 3-35: Indices of Pulse Wave Analysis and Pulse Wave Velocity versus time after 
Salbutamol in Post-CPAP Obstructive sleep apnoea patients
Pre-Sal 5 min 10 min 15 min 20 min P
AA 5 (0-19) 4 (1-15) 6 (0-15) 7 (0.5-16) 7 (0.5-16) 0.998
AIX 12 (0-32) 10 (2-30) 15 (0.5-29) 14 (1-25) 14 (1-28) 0.995
AIx@75 7 (-2 – 26 ) 5 (-4 – 25) 7 (-1 – 24) 5 (-3 – 25) 7 (-4 – 29) 0.982
SERV 152 (140-
184)
158 (131-
175)
163 (135-
178)
154 (138-
175)
152 (133-
183)
0.777
PWV 5 (5-8) 6 (5-7) 6 (5-7) 5 (5-7) 6 (5-7) 0.691
Values as Median (Inter-quartile range); p<0.05 is significant
CPAP= Continuous Positive Airway Pressure, AA=Aortic Augmentation, AIx=Augmentation Index, 
AIx@75=Augmentation Index at heart rate of 75/minute, SEVR=Sub-Endocardial Viability Ratio, 
PWV= Pulse Wave Velocity
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Table 3-36: Indices of Pulse Wave Analysis and Pulse Wave Velocity versus time after 
Glycerol trinitrite in Post-CPAP Obstructive sleep apnoea patients
Pre-GTN 5 min 10 min 15 min 20 min P
AA 5 (-0.5 – 18 
)*^ #∞
-1 (-6 – 6)* -4 (-6 – 3)^ -2 (-9 – 3)# -2 (-6 – 5)∞ <0.0001
AIX 9 (-0.75 –
35)*^ #∞
-2 (-10 –
10)*
-7 (-13 – 7)^ -4 (-14 – 7) 
#
-4 (-12 – 8) 
∞
<0.0001
AIx@75 4 (-1.25 –
28)*^ #∞
-2 (-10 – 9)* -8 (-15 – 3)^ -8 (-15 – 6) 
#
-8 (-16 – 8) 
∞
<0.0001
SERV 150 (133 -
174)
161 (140 –
175)
161 (149 –
178)
166 (145-
175)
162 (139-
186)
0.136
PWV 5 (5 - 7) 6 (5 - 7) 6 (5 – 8) 6 (5-7) 6 (5-7) 0.451
Values as Median (Inter-quartile range); p<0.05 is significant
* Significant difference between time 0 and 5 min
^ Significant difference between time 0 and 10 min
# Significant difference between time 0 and 15 min
∞ Significant difference between time 0 and 20 min
CPAP= Continuous Positive Airway Pressure, AA=Aortic Augmentation, AIx=Augmentation Index,
AIx@75=Augmentation Index at heart rate of 75/minute, SEVR=Sub-Endocardial Viability Ratio, 
PWV= Pulse Wave Velocity
214
Table 3-37:  Comparison of the Baseline values in OSA groups at 4 time points; as Median 
(Inter-quartile range)
Pre-CPAP Post-CPAP p
B1 B2 B3 B4
AA 15 (9-21)*^ 14 (9-21)* 
^
5 (0-19)* 5 (-0.5 – 18 ) ^ <0.01
AIx 26 (20-32) *^ 26 (19-33) 
*^
12 (0-32)* 9 (-0.75 – 35) 
^ 
0.002
AIx@75 18 (11-31) *^ 22 (13-31) 
*^
7 (-2 – 26 )* 4 (-1.25 – 28) 
^
0.007
SEVR 162 (138-
194)*^
163 (145-
187)*^
152 (140-
184)*
150 (133 -
174)^
0.02
PWV 6 (5-7) 5.8 (4.8-7) 5 (5-8) 5 (5 - 7) 0.723
B1= Pre-CPAP Pre-Salbutamol Baseline 1; B2= Pre-CPAP Pre-GTN Baseline 2; B3= Post-CPAP Pre-
Salbutamol Baseline 3; B4= Post-CPAP Pre-GTN Baseline 4; Sal= Salbutamol; GTN= Glycerol trinitrite; 
AA=Aortic Augmentation, AIx=Augmentation Index, AIx@75=Augmentation Index at heart rate of 
75/minute, SEVR=Sub-Endocardial Viability Ratio, PWV= Pulse Wave Velocity
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3.3.5 Effect of Continuous Positive Airway Pressure on Left Ventricle Systolic and 
Diastolic in obstructive sleep aponea population 
3.3.5.1 Abstract 
Background: Obstructive sleep apnoea (OSA) has been reported to cause left ventricle (LV) 
systolic/diastolic dysfunction and left atrium (LA) enlargement. I investigated the impact of 
continuous positive airway pressure (CPAP) on LV function and LA volumes in moderate to 
severe OSA subjects, using two-dimensional- (2DE) and real time three-dimensional 
echocardiography (RT3DE).
Methods: 40 newly diagnosed patients with moderate to severe OSA were studied at baseline 
however 37 patients with (apnoea-hypopnoea index- median 36 (inter quartile range 21-51) were 
available after a mean follow up of 6 months. All patients underwent 2DE, tissue Doppler 
imaging and RT3DE before and after CPAP therapy. 
Results:  I demonstrated significant post-CPAP enhancement in LV systolic function, both with 
2DE and RT3DE. Post-CPAP tissue Doppler imaging detected marked improvement in LV filling 
characteristics (E/E’ reduced from 9±4 to 8±2, p=0.02). Additionally, CPAP treatment led to a 
marked reduction in LA volume and LA volume index.  
Conclusion: Long term treatment with CPAP improves LV systolic function and reverses LV 
filling abnormalities and LA structural deformation– partially or completely - in subjects with 
moderate to severe OSA. 
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3.3.5.2 Introduction
A number of observational and therapeutic studies have detected a higher frequency of left 
ventricular (LV) diastolic dysfunction in obstructive sleep apnoea (OSA) patients when compared 
to healthy controls [kim et al 2008][Alchanatis et al 2002][Hedner et al 1990]. The stiffness of 
the LV and resultant reduction in its compliance might cause left atrial (LA) overstretching and 
chamber dilation in order to maintain adequate LV filling. Unsurprisingly LA enlargement have 
been shown in OSA and may be relavant in the high prevalance of atrial fibrillation and stroke in 
OSA population [Kono et al 2007][ Hirschler et al 2006]. LV systolic dysfunction and subsequent 
heart failure has also been reported in OSA, however the data is conflicting [Kim et al
2008][Kraiczi et al 2001] [Alchanatis et al 2002]. 
The data on the effects of continuous positive airway pressure (CPAP) on LV systolic/diastolic 
function in moderate to severe OSA are limited and conflicting. Whilst some report improvement 
in LV systolic/diastolic function (surrogated by conventional markers such as LVEF), other 
showed no post CPAP change [Alchanatis et al 2000] [Bendjelid et al 2005][ Akar et al 2009][
Haruki et al 2010][ Bellone et al 2010][Alchanatis et al 2002]. One reason of such inconsistent 
results is the mere use of 2DE, where wide inter- and intra-observer variability is widely reported. 
Conversely, RT3DE has demonstrated its efficacy in determining LV structural and functional 
propertities [Von Ramm et al 1990][ Shiota et al 1998]. However it has not been used in 
evaluating the effect of CPAP on LV structure and functions in subjects with moderate to severe 
OSA. 
I hypothesized that prolonged CPAP use leads to improvement in LV systolic and diastolic 
function. In order to test this hypothesis I investigated otherwise healthy subjects with moderate 
to severe OSA and comprehensively studied LV structural and functional characteristics using 
2DE as well as RT3DE before and 6 months after CPAP therapy. 
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3.3.5.3 Methods
The methods have been described in details under section 2. 
3.3.5.4 Results
2DE and RT3DE were performed on the 40 patients prior to the initiation of CPAP treatment 
[Table 3-38]. After 6 months of effective CPAP therapy, 37 middle aged patients with were 
available for follow up. Recorded/objective data on the use of CPAP during follow up averaged 
5.7 hours per night 5 nights per week.   On the morning of follow up scans, the average heart rate 
was 72±11 beats per minute which was comparable with the pre-CPAP heart rate (p=0.205). 
During follow up a significant post-CPAP drop in systolic/diastolic blood pressure (p<0.0001 and 
0.03 respectively) and the Epworth score (p<0.01) was observed [Table 3-38]. 
LV Systolic Function
Both, M-mode and modified Simpson’s technqies demonstrated significant improvement LV 
diastolic dimensions and systolic parameters post-CPAP (all p<0.05) [Table 3-39]. RT3DE semi-
automatic planimetry also complemented 2DE findings, where an increased LVEF was noted 
after CPAP therapy (p=0.024) [Table 3-39]. 
LV Diastolic Function
Table 3-40 presents diastolic indices provided by traditional echocardiography and TDI.  
Conventional indices of diastolic function improved after CPAP use with an increase in E 
(p<0.0001), E/A (p<0.0001) and reduction in the peak A velocity (p=0.02) [Table 3-40]. On 
tissue Doppler recordings, OSA patients had prolonged IVRT, greater E/E’ ratio and attenuated 
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septal E’ velocity at baseline, with marked improvement in these indices after CPAP therapy, 
especially reduction in E/E’ ratio (p=0.02). 
LA Volume and LA Volume Index (LAVI)
There was a significant reduction in LA volume and LAVI post-CPAP (p<0.0001 for both) whilst 
using 2DE and RT3DE techniques [Table 3-41].  
3.3.5.5 Discussion 
In this study, I have shown that CPAP therapy enhances LV systolic and diastolic functions in 
otherwise healthy patients with moderate to severe OSA, using 2-DE and RT3DE. The present 
study is the first study to use RT3DE to assess CPAP effect in moderate to severe OSA subjects. 
My findings of CPAP led improvement in LV systolic function, are consistent with available data 
[Bendjelid et al 2005][ Akar et al 2009][ Haruki et al 2010][ Bellone et al 2010][ Alchanatis et al 
2002][ Scharf et al 1996]. For example, Alchanatis et al quantified LVEF in 29 OSA subjects and 
reported an increase in LVEF (p<0.001) after a 6 months treatment with CPAP [Alchanatis et al 
2002]. Also consistent with my results, Haruki et al demonstrated a significant reduction in 
longitudinal, radial, circumferential LV strain after CPAP in OSA subjects [Haruki et al 2010].  
Interestingly, Malone et al reported dose-dependent improvement in LV systolic function in non-
OSA subjects with dilated cardiomyopathy, after 1 month of CPAP treatment [Malone et al 
1991].  It must be noted that compared to all 2DE based methods, RT3DE allows more accurate 
LV volume assessment. This is particularly useful in OSA subjects where real time three 
dimensional imaging can provide better image dataset in a particularly challenging habitus in 
OSA subjects. 
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Improved LV pressure-flow dynamics, reduction in central blood pressure, correction of hypoxia 
and rhythmic intrathoracic pressure swings have been proposed as some of the mechanisms 
whereby CPAP improves LV systolic function [Bendjelid et al 2005][Haruki et al 2010].  
I observed improved LV diastolic profile after CPAP therapy and this is consistent with the 
current data [Konermann et al 1996][Alchanatis et al 2000]. Several studies suggest that OSA 
leads to LV filling abnormalities by causing LV hypertrophy and/or fibrosis, even in the absence 
of hypertension; and that these changes are potentially reversible with CPAP [Alchanatis et al 
2000][ Konermann et al 1996][Malone et al 1991][ Krieger et al 1989][Buda et al 1991]. For 
example Alchanatis et al observed significant reduction after 14 week treatment with CPAP on 
OSA population [Alchanatis et al 2000], whilst Konermann et al detected increased E/A ratio 
(rose by 9.3% compared to baseline; p<0.05) after short term CPAP therapy in patients with 
severe OSA [Konermann et al 1996]. However compared to the present study, most previous 
were smaller and did not investigate tissue Doppler indices which are more sensitive and accurate 
diastolic parameters. 
I demonstrated significant drop in systolic and diastolic blood pressure after CPAP. It is 
noteworthy that reduction in blood pressure and improved systemic vascular resistance has been 
implicated as the underlying mechanisms for CPAP led improvement in diastolic dysfunction 
[Brooks et al 1997].
Abnormal LV relaxation pattern and changes in cardiac visco-elastic characteristics and direct 
exposure of LA to raised LV pressure may augment atrial wall tension resulting in over-stretching 
and ultimately the LA dilatation [Greenberg et al 1979] [Dent et al 2001]. Due to LA geometric 
changes secondary to individual anthropometric differences, I corrected LA volume for body 
surface area and reported as LAVI [Lang et al 2005][Pritchett et al 2003]. I demonstrated post-
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CPAP reduction in LA volume and LAVI in otherwise healthy normotensive patients with 
moderate to severe OSA. These observations are in accordance with limited data [Khan et al 
2008]. 
I demonstrated CPAP related changes in LA remodelling using RT3DE for the first time in 
moderate to severe OSA subjects.  Oliveira et al [Oliveira et al 2009] investigated LA passive 
emptying fraction using RT3DE in OSA but failed to detect structural LA changes. RT3DE is 
particularly useful considering that LA enlargement occurs eccentrically which reduces the 
sensitivity of 2DE methods. It should be borne in mind that, LA remodeling is increasingly 
viewed as a surrogate marker for LV diastolic dysfunction, atrial fibrillation and an independent 
predictor of cardiac failure [Pritchett et al 2005] [Takemoto et al 2005]. Therefore in our study of 
patients without structural/functional heart disease, reduction in LAVI may reflect attenuated risk 
of cardiovascular morbidity. 
Limitations
After CPAP as described in the results, I demonstrated a significant improvement in systolic and 
diastolic parameters with concurrent BP (systolic and diastolic) reduction. It is difficult to say if 
this BP reduction was the underlying factor for such an improvement in LV dynamics, even if my 
analysis does not show a relationship between a change in the BP and the change in such 
parameters.  It is one of the important limitations of this study and is very difficult to answer, 
considering a well known anti-hypertensive effect of CPAP in OSA. Logical reasoning would 
support such correlation but statistical analysis for the present study does not back up such 
hypothesis about BP reduction led change in LV structural and functional parameters. 
Many suggest that the negative LV remodelling is predominantly due to OSA’s ventilatory 
effects ie dramatic and exaggerated changes in pre/after load and autonomic surges causing LVH.  
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Considering that, a relief from such a ventilatory pressure due to OSA through CPAP treatment 
can translate into enhanced LV dynamics. Again, this can not be answered in the present study as 
the AHI was not measured during the follow up due to unfavourable logistics. A study 
investigating the pulmonary pressures during apnoea and hypopnoeas and after CPAP (in OSA) 
and there relationship with change in LV function would probably provide the answer. This study 
can be regarded as a pilot study for future and it focussed more on the general aspects of the 
disease. 
OSA subjects in this study were obese and obesity could alter diastolic characteristics on its own 
merit [Mureddu et al AJC 1996]. However OSA patients had comparable body mass index pre-
and post-CPAP. I did not check the agreement between 2DE and RT3DE outcomes for a given 
index. Observational model is another limitation of this study. However in order to ensure 
uniformity all the measurements and recordings were performed and analyzed by the same 
operator. Furthermore, inter- and intra-observer variability was satisfactory (less than 10%). 
3.3.5.6 Conclusion
Effective treatment with CPAP improves the LV diastolic and systolic function in moderate to 
severe OSA subjects. The beneficial effect on the LA remodelling may have important 
implications as this may reflect diminuted risk of atrial arrhythmias (such as atrial fibrillation) in 
compliant OSA patients. Large and blinded studies would be required to evaluate deeper impact 
of CPAP on LV functional properties in patients with moderate to severe OSA.
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Table 3-38: Patient Characteristics
Pre-CPAP Post-CPAP p
n 37 37
Age (Years) 49±10 49±10 0.451
AHI 36 (21-51) Not recorded
BMI (Kg/m2) 34±7 34±8 0.180
Epworth 
score
13±6 5±6 <0.0001
Systolic BP 
(mmHg)
144±16 133±13 <0.0001
Diastolic BP 
(mmHg)
83±11 80±7 0.025
Values expressed as Mean (Standard Deviation) or Median (Inter quartile range). AHI= Apnoea-Hypopnea 
Index; BMI= Body Mass Index; BP= Blood Pressure, CPAP= continuous Positive Airway Pressure
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Table 3-39: Systolic Indices before and after Continuous Positive Airway Pressure Therapy 
Pre-CPAP Post-CPAP p
n 37 37
M-mode Method
EF (%) 64±7 74±8 <0.0001
LVEDd (cm) 4.9±0.6 5.2±0.6 <0.0001
IVDd (cm) 1.1±0.2 0.99±0.2 <0.0001
PWd (cm) 1.2±0.2 1.1±0.2 0.016
LVEDV (ml) 114±34 136±40 <0.0001
FS (%) 35±5 44±7 <0.0001
Modified Simpson’s Method
EF (%) 65±9 70±7 0.007
RT3DE
EF (%) 66±8 71±9 0.024
LVEDV (ml) 86±25 93±27 0.05
Values are described as Mean (Standard Deviation). P <0.05 was considered statistically significant.
RT3DE= Real Time 3-Dimensional Echocardiography; EF= Ejection Fraction; FS= fractional Shortening; 
IVSd= Interventricular septal dimension in diastole; PWd= Posterior Wall dimension in diastole, LVEDd= 
Left ventricular End-Diastolic dimension; LVEDV= Left Ventricular End-Diastolic Volume, CPAP= 
continuous Positive Airway Pressure
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Table 3-40:   Diastolic Indices before and after Continuous Positive Airway Pressure 
Therapy 
Pre-CPAP Post-CPAP p
n 37 37
E (m/sec) 52±12 64±12 <0.0001
A (m/sec) 53±14 48±12 0.016
E/A 1.0±0.4 1.4±0.4 <0.0001
E’ (sep) 
(m/sec)
6±2 8±2 <0.0001
E/E’(sep) 9±4 8±2 0.02
IVRT (ms) 0.09±0.02 0.07±0.02 <0.0001
Values are described as Mean (Standard Deviation). P <0.05 was considered statistically significant. E=
Mitral early inflow peak velocity, A= Late inflow peak velocity, sep E’= septal E prime, 
IVRT=Isovolumetric relaxation time, CPAP= continuous Positive Airway Pressure
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Table 3-41:   Left atrial Volume Index using Two-Dimensional and Real time 3-Dimensional 
Echocardiography before and after Continuous Positive Airway Pressure 
Therapy
Pre-CPAP Post-CPAP p
n 37 37
Ellipsoid 
Method
26±9 21±6 <0.0001
Area-length 
Method
28±9 23±6 <0.0001
RT3DE 26±8 22±7 <0.0001
Values are described as Mean (Standard Deviation). P <0.05 was considered statistically significant.
CPAP= continuous Positive Airway Pressure, RT3DE= Real time 3-Dimensional Echocardiography
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3.3.6 Impact of Continuous Positive Airway Pressure Therapy on Myocardial 
perfusion in Moderate to Severe Obstructive Sleep Aponea 
3.3.6.1 Abstract 
Background: Obstructive sleep apnea (OSA) has been implicated in the initiation and progression 
of cardiovascular diseases owing to the impairment of myocardial perfusion. I hypothesized that 
myocardial perfusion improves after long term continuous positive airway pressure (CPAP) 
therapy in subjects with moderate to severe OSA. 
Methods: Myocardial blood flow was quantified using myocardial contrast echocardiography in 
36 otherwise healthy subjects with moderate to severe OSA, before and after CPAP treatment. 
Real-time MCE dataset were acquired in three apical views at rest and after dipyridamole stress.
Results: On average patients were middle aged (49 years ±10) and obese (BMI= 34±8 Kg/m2). 
Basal and hyperaemic myocardial perfusion responses improved significantly (p<0.001 for all) 
after 6 months of CPAP therapy.  
Conclusion: Long term CPAP therapy significantly improved myocardial perfusion in otherwise 
healthy subjects with moderate to severe OSA.
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3.3.6.2 Introduction
Untreated OSA is an independent association with cardiovascular disorders and predictive of 
worse cardiovascular outcome [Peker et al 2000][Marin et al 2005] [Young et al 1993][Shahar et 
al 2001]. Subclinically impaired myocardial perfusion has been demonstrated in untreated OSA
using magnetic resonant imaging [Nguyen et al 2010]. Interestingly, a high high prevalence of 
previously undiagnosed OSA in patients admitted with acute myocardial infarction has also been 
reported [Lee et al 2009]. Reassuringly however, CPAP use has shown promising results in 
reversing myocardial perfusion patterns with a suggestion that such enhancement may be 
secondary to improvement in microvascular function located in the sub-endocardial layer 
[Nguyen et al 2010][ Marini et al 2010].  Indeed regular and efficient use of CPAP has shown to 
reverse ED leading to reduction in systemic arterial blood pressure in OSA patients [Bazzano et 
al 2007]. 
However, MCE has not been utilized to detect CPAP led changes in myocardial blood flow 
patterns. It must be noted that MCE has a close agreement with other perfusion assessment 
imaging tools such as MRI and SPECT [Wei et al 1998][Peltier et al 2004][Moir et al 2006] [Di 
Bello et al 2004]. Perhaps most importantly, the available data is limited and no previous study 
has focused on healthy subjects with moderate to severe OSA. 
I hypothesized that the long term CPAP therapy may improve myocardial perfusion - as assessed 
by MCE - in subjects with moderate to severe OSA. In order to test this hypothesis I performed 
MCE on otherwise healthy subjects with moderate to severe OSA before and after 6 months of 
the CPAP use. 
3.3.6.3 Methods
The methods have been described in details under section 2.           
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3.3.6.4 Results
Table 3-42 shows patients’ characteristics at baseline and follow up whilst Table 3-43 show 
indices of myocardial perfusion, pre- and post-CPAP treatment. 
MCE was performed on 40 patients prior to the initiation of the CPAP therapy. During follow up 
duration two patients failed to tolerate CPAP, one developed atrial fibrillation and one withdrew 
from study. Therefore, after 6 months of CPAP therapy, 36 middle aged (49±10 years) patients 
with reasonable female gender representation (20%), were available for follow up. All subjects 
complied with CPAP and use of CPAP averaged 5.4 hours per night 5 nights per week [Table 3-
42]. 
A significant reduction was noticed at follow up in systolic (p<0.0001), diastolic blood pressure 
(p=0.04) and Epworth score (p<0.001) [Table 3-42]. 
At rest Post-CPAP segmental blood volume fraction (α) and the blood flow velocity (ß) were 
significantly greater compared with pre-CPAP {(‘α’ Pre-CPAP 21±6 versus post-CPAP 25±2; 
p=0.001) and (‘ß’ Pre-CPAP 1.2±0.5 versus post-CPAP 1.6 ±0.4; p<0.0001)}. The product of the 
‘α’ and ‘ß’ at rest, regarded as myocardial blood flow at rest (FR), was also statistically greater in 
follow up group (p<0.001) [Table 3-43]. 
The post-stress (induced by Dipyridamole infusion) ‘α’ was 22 ±6 before CPAP treatment which 
rose to 29 ±2 after 6 months of treatment (p<0.001). The post-stress change in ‘ß’ was even more 
pronounced, which increased from 1.9 ±1 to 4.8 ±1 after CPAP (p<0.0001) and therefore 
unsurprisingly the ‘FS’ was also estimated significantly higher after CPAP (p<0.001) [Table 3-
43].
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The MBFR (ratio of the ‘FS’ and ‘FR’) and was greater in post-CPAP group compared to pre-
CPAP indicating significant reversal of the myocardial perfusion after CPAP treatment 
respectively (p<0.0001) [Table 3-43].
3.3.6.5 Discussion 
This is the first study to provide a comprehensive evaluation of subclinical CVD using MCE in 
healthy patients with moderate-severe OSA. OSA Patients had abnormal MBFR, suggesting these 
patients have microvascular disease and endothelial dysfunction. These abnormalities improved 
after 6 months of effective CPAP, providing further evidence that OSA may contribute to the 
development of cardiovascular diseases.
Microvascular disease and endothelial dysfunction are the earliest manifestations of coronary 
heart disease and can be found in patients without obstructive coronary artery disease. Indeed 
subclinical coronary microvascular dysfunction has been previously demonstrated in patients with 
cardiovascular risk factors. For example, coronary flow reserve was reduced by 21% in smokers 
and normalized with vitamin C administration [Kaufmann et al 2000]. Similarly impairment in 
coronary flow reserve has also been shown in asymptomatic subjects with hypercholesterolemia
and angiographically normal coronary arteries with demonstrated reversibility with cholesterol 
lowering strategies [Dayanikli et al 1994] [Gould et al 1994]. Similarly, in the present study, 
patients with OSA with no known coronary or myocardial disease had impaired myocardial 
perfusion which improved after CPAP, suggesting that the presence of microvascular disease is 
due to OSA. To our knowledge, this is the first study to show that patients with OSA have 
microvascular disease measurable by MCE, which improves with therapeutic CPAP.
Several mechanisms have been suggested to explain the relationship between OSA and vascular 
dysfunction [Lanfranchi et al 2001]. Evidence suggests that recurrent apnea-hypopneas in OSA 
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patients are associated with repetitive cycles of hypoxemia and reoxygenation, enhancing 
production of reactive oxygen species. This leads to increased intra cellular oxidative stress and 
breakdown of NO, resulting in vascular dysfunction. The relationship between apnea and vascular 
dysfunction was further supported in a recent study, which showed that regional myocardial 
perfusion defects were present during periods of apnea in patients with OSA without obstructive 
coronary disease but were not present during daytime SPECT [Orea-Tejeda et al 2003]. 
Correction of hypoxia by addressing OSA related ventilatory dysfunction may be underlying 
reason for CPAP led improved perfusion. This is also reported to improve oxidative stress and 
endothelial dysfunction [Lattimore et al 2006] [Imadojemu et al 2002][Ip et al 2000] [Kato et al 
2000]. For example, Mak et al noted normalization of coronary flow reserve shortly after the 
initiation of CPAP therapy in a patient with intermediate epicardial arterial lesion [Mak et al 
2010]. 
Limitations
I have derived that the enhancement in myocardial perfusion in otherwise healthy OSA subjects is 
secondary to reduction in total vascular resistance, resulted from CPAP led improvement in 
endothelial status. However this conclusion is indirect as we did not measure coronary vascular 
resistance directly. I suggest that CPAP effects on the coronary vascular resistance and 
myocardial blood flow should be investigated concomitantly in moderate to severe OSA.
The observational study design is a limitation of this study.  In order to ensure uniformity, all the 
measurements and recordings were performed and analyzed by the same operator. Furthermore, 
we demonstrated satisfactory inter- and intra-observer variability (<10%). Finally, these
observations are limited to healthy middle aged subjects with moderate to severe OSA and cannot 
be extrapolated to patients with milder severity or OSA with co-existing disease. 
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Myocardial perfusion enhanced after CPAP along with the concurrent BP reduction. As the 
myocardial perfusion is directly related to coronary microvasculature which is closely related 
with the endothelial health, I suggest that such change in perfusion is secondary to improved 
endothelial status after CPAP. Improvement in FMD as a surrogate of ED has been described 
elsewhere in this thesis. ED improvement is multifactorial and has been reported with CPAP with 
and without BP reduction. It is very reasonable to question if BP reduction is a dominant 
contributor is such change. I did not note any correlation between BP change and MBFR change 
suggests no such link. Nevertheless I did not demonstrate a direct correlation between marker of 
ED and change in MBFR. This unresolved and unanswered aspect of this study needs to be 
explored in future studies.
3.3.6.6 Conclusion 
In summary, this novel study shows that CPAP led changes in myocardial perfusion in moderate 
to severe OSA in otherwise healthy humans. Our observations need further study or clinical trials 
to determine the prognostic implications of using CPAP in a large population of patients with 
OSA. 
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Table 3-42: Patient Characteristics
Pre-CPAP Post-CPAP p
n 36 36
Age (Years) 49 (10) 49(10) 0.369
AHI 36 (20-50) Not recorded -
BMI (Kg/m2) 34 (8) 34 (8) 0.103
Epworth 
score
13 (5) 6 (7) <0.0001
Systolic BP 
(mmHg)
143±16 133±12 <0.0001
Diastolic BP 
(mmHg)
83±12 79±8 0.04
Values expressed as Mean (Standard Deviation) or Median (Inter quartile range). P<0.05 was considered 
Significant
AHI= Apnoea-Hypopnea Index; BMI= Body Mass Index; BP= Blood Pressure; CPAP= Continuous 
Positive Airway Pressure
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Table 3-43: Indices of Myocardial Perfusion
Pre-CPAP Post-CPAP p
n 36 36
Segments 4 4
FR 26 (13) 41 (12) <0.0001
FS 43 (26) 134 (28) <0.0001
MBFR 1.7 (0.7) 3.5 (1.5) <0.0001
Values expressed as Mean (Standard Deviation). P<0.05 was considered Significant. OSA= Obstructive 
Sleep Aponea; HT= Hypertension; FR= Myocardial Blood Flow at Rest; FS= Myocardial Blood Flow at 
Stress; MBFR= Myocardial Blood Flow Reserve; CPAP= Continuous Positive Airway Pressure
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Section 4 Summary and Conclusion
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4.1 Summary of Findings
In this thesis, I have comprehensively investigated micro- and macro-vascular dysfunction in 
OSA population, with an emphasis on the coronary circulation. I compared moderate to severe 
OSA subjects with hypertensive and healthy controls; however only OSA subjects were followed 
up after 6 months of CPAP teartment. 
In chapter 3.2.1, I have demonstrated that enodhtlial-dependent and -independent FMD is 
impaired in OSA and hypertensive subjects compared with healthy subjects. However, the results 
were comparable between OSA and hypertensives. This clearly demonstrated presence of macro-
vascular dysfunction in OSA and is consistent with the previous studies. After CPAP treatment 
for 6 months, I noted significant improvement in brachial artery reactivity as described in chapter 
3.3.1. 
I studied microvascular perfusion patterns in OSA using laser Doppler flowmetry, in chapter 
3.2.2. I noted impaired ACH and SNP induced responses in OSA as well as in hypertensives 
compared with the healthy controls. Post-CPAP perfusion parameters enhanced significantly in 
OSA cohort and have been described in chapter 3.3.2. 
I did not find a statistically significant difference in parameters of arterial stiffness, amongst the 
groups. In chapter 3.2.3, I demonstrated comparable markers of macro-vascular stiffness such as 
AA, AIx, AIx@75, SEVR and PWV amongst the three groups. Thus, arterial stiffness is more 
pronounced and obviously demonstarable in diseased OSA subjects i.e with coexisting 
cardiovascular diseases. Nevertheless, CPAP therapy led to a dramatic change in these markers 
after 6 months and this has been reported in chapter 3.3.3. 
In chapter 3.2.4, I found no difference in EPC and CEC distribution in OSA compared with 
controls. Also, no significant change was noted after CPAP therapy in either of the cell strains or 
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their ratio as described in 3.3.4. Indeed functional aspects may alter after CPAP (which were not 
explored in the present study) but it can be argued that disturbed distribution patterns may only 
occur in OSA with cardiovascular diseases.
I studied the impact of OSA on cardiac remodeling using convensional 2DE and ‘state-of-the-art’
RT3DE. It must be noted that RT3DE has never been used for this specific purpose before in 
moderate to severe OSA population. I have shown preserved systolic yet impired diastolic 
function in OSA compared with healthy subjects as described in chapter 3.2.5. This is consistent 
with available data. I also demonstrated enlarged LAVI (owing to chronic diastolic dysfunction), 
which may explain high prevalence of atrial fibrillation in OSA population. CPAP was shown to 
have a discernible impact on LV remodeling, as evident by improvement in diastolic impairment 
and reduction in LAVI. These findings may have implications in exploring the AF management 
strategies in moderate to severe OSA subjects as shown in 3.3.5. 
I studied myocardial blood flow patterns using myocardial contrast echocardiography and found 
impaired myocardial perfusion compared with the healthy subjects. MCE has never been 
performed before in OSA cohort. My findings reported in chapter 3.2.6 suggest microvascular 
dysfunction in moderate to severe OSA subjects. I demonstrated marked enhancement in 
myocardial blood flow responses and perfusion indices after 6 months of CPAP treatment, 
chapter 3.3.6. 
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4.2 Suggestions for Future Studies
The studies described in this thesis are novel, owing to its design and techniques used. Moderate 
to severe OSA subjects have never been compared with healthy and ‘disease’ (hypertensive) 
controls simultaneously. I focused on moderate to severe OSA specifically, as it is the primary 
target for CPAP treatment. Similarly my reported studies on FMD, LDF, flow cytometry and 
arterial stiffness are largest of their kind, albeit these have been performed on OSA cohorts 
previously. Most importantly, for the first time I used RT3DE and MCE in moderate to severe 
OSA subjects for LV assessment. 
However these studies have limitations such as exclusion of mild OSA. These limitations should 
be addressed in future studies. Also, most ‘real life’ OSA subjects have complex clinical profile 
where they have conditions such as hypertension and coronary artery disease. It it is possible the 
subjects with such confounding variables may have different perfusion patterns and hence should 
also be studied in comparison with matched controls.
My OSA subjects were non-hypertensive although the average blood pressure was higher than the 
cut-off for the healthy population. The blood pressure readings were taken in the community, 
specialized clinic and during the study and were found to be in the normotensive reange. I feel 
that the average blood pressure could be higher due to an element of white coat hypertension in 
OSA subjects. Indeed the possibility of concealed hypertension can not be ruled out completely, 
as we did not perform a screen 24 hour blood pressure minitoring prior to the study. However, I 
would like to emphasize here that I took utmost care to exclude hypertension in OSA subjects. 
Future studies must ensure to enroll only subjects with desirable average blood pressure on 
ambulatory blood pressure. 
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Some of the observations reported would need further exploration. For example, I report impaired 
endothelial independent responses in OSA compared to healthy subjects. Notably, impaired 
endothelial independent responses have been described in smokers but this has never been 
described before in moderate to severe OSA subjects. Contrary to available data, I did not notice 
any changes in flow cytometric analysis and in the arterial elastic properties. I suggest largers yet 
similar studies to confirm or negate our results.
It is known that OSA subjects have a high incidence of AF compared to healthy subjects. It has 
also been reported that the rate of recurrence is higher in electrically cardioverted or 
electrophysiologically ablated AF subjects with OSA. I reported CPAP led reduction in LA 
volumes, improvement in diastolic impairement and systemic blood pressure, all of which are 
important risk factors for AF. A potential reduction in the cumulative incidence or arrhythmia 
burden (eg. by continuous monitoring) of AF can be derived in CPAP treated subjects. Similarly, 
it can also be hypothesized that the AF related ischaemic stroke rate may also fall in OSA 
subjects. This may have important prognostic and logistic implication. I suggest that occurance 
patterns of AF should be prospectively re-studied in CPAP treated OSA to observe if CPAP led 
cardiac changes translate in a better morbidity. 
MCE has never been previously performed in OSA previously. Hence the present study can be 
used as pilot for future projects. Clearly these data showed subclinically impaired myocardial 
perfusion. However, it should be explored if it determines poorer outcome in untreated OSA 
subjects. Circumstantial evidence supports the presence of cardiovascular disorders in OSA more 
than non-OSA subjects, but do the epidemiological patterns correlate with the impaired 
myocardial perfusion in OSA? I demonstrated a significant improvement in myocardial perfusion 
with CPAP therapy. It would be interesting to examine CPAP induced enhanced cardiac 
perfusion translates into prognostic benefits. 
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4.3 Conclusion
OSA is an important public health condition worldwide. It is strongly associated with 
cardiovascular disorders. Available evidence supports higher incidence of heart failure, CAD, 
hypetrnesion, and stroke in OSA subjects. Investigations of peripheral and coronary vasculature 
proved that systemic endothelial dysfunction exists in OSA subjects. In coronary vasculature, 
endothelial dysfunction manifests as impaired myocardial perfusion which may lead to 
subclinically ischaemic myocardium and ultimately heart failure. OSA also causes cardiac 
remodeling i.e. LVH and LA enlargement, which may have arrhythmic potential such as high 
incidence of AF in OSA. 
Perhaps the most significant observation of this study is that CPAP reverses endothelial 
dysfunction and thus may enhance myocardial perfusion as shown by the MCE. Such positive 
changes in peripheral and myocardial flow patterns may be implicated into an improved clinical 
and prognostic outlook with CPAP. This thesis studies a comprehensive assessment of macro-
and micro-vascular (dys)function in OSA and provide pathophysiological insights into the 
potential benefits of CPAP therapy in OSA.
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Section 5 Appendices 
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5.1 Standard operating Procedures (SOPs)
5.1.1       Flow Mediated Dilatation (FMD)
               Updated by Mehmood Butt, 2008
Introduction
Endothelium-dependent vasodilatation of the brachial artery occurs in response to increased flow. 
This response can be assessed using ultrasound; a forearm cuff is used to occlude the vessel 
downstream. After cuff release, reactive hyperaemia occurs and increased blood flow causes 
nitric oxide (NO) release from the endothelium and consequent endothelium-dependent 
vasodilatation. The endothelium-independent response can be assessed by administration of a 
systemic NO donor such as GTN. Abnormalities in FMD have been found in patients at risk of 
atheroma before evidence of actual atheroma has developed, and it is also a predictor of future 
cardiovascular events, at least in hypertensive patients [Chong et al 2003][Celermajer et al 1992 ]. 
Equipment
You will need:
 Patient (!)
 An available vascular scanner (for around 45 minutes at least)
 Echo jelly (the tubs are refillable)
 ECG monitoring electrodes
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 Apple Mac MO disk or VCR cassette; ideally both
 Timer (can use clock on echo machine if not available)
 Marker pen suitable for skin
 Manual sphygmomanometer (capable of pressures up to 300mmHg)
 GTN spray
1. Preparation
a. you may need to turn all the equipment on: the source projector box is located behind 
the computer desk: switch this on first.
b. Turn on echo machine (switch on the front of the machine about half way down, 
towards the left)
c. Insert an MO disk into the disk reader attached to the Apple Mac laptop (if you want 
to save your images using echopac).
d. Turn on the AppleMac laptop (button at top right of the keyboard); if you are asked 
for a password at any time press space bar then enter
e. open echopac using the icon on the desktop if it isn’t already open (click on ‘finder’ 
at the top and select echopac if echopac is open but hidden, ie running in the 
background).
f. Systems should connect automatically
g. Allow the subject to rest in the room for about 15 minutes before scanning
h. Place the ECG leads on the patient
i. Press ‘patient ID’ on the echo machine console (towards the left) and key in your 
patient’s information. (Or you can do this from echopac)
2. On the echo machine, select the probe 
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a. (To select options using the menus, use the black tracker ball to move the arrow over 
the option, then select by pressing any part of the white area surrounding the tracker 
ball)
b. Press ‘probe’ on left side of echo machine console
c. Select 10MHz; then select arterial limb
d. Use the vascular scanner probe (10MHz), not the echo probe – (the one you want is 
rectangular, about 5cm length, not the smaller echo probe)
3. Label the image (using the ‘text’ button towards the left of the console) as ‘baseline 1’. Scan 
about 2-15cm above elbow (it doesn’t matter much where so long as you get the same segment of 
artery for baseline and measurement scans). Identify the artery with colour doppler if necessary 
(button marked CFM on echo machine) – arterial flow is obviously pulsatile and typically very 
bright on colour flow (it may be blue or red); once identified as arterial, it is easiest to turn colour 
flow off again in order to see the arterial wall clearly. Try to find a section where a long segment 
is clearly visible, ideally with endothelium seen on both superficial and deep walls of the vessel. 
Because you take several measurements (before and after FMD and GTN), it is worth trying to 
note some reference points near the segment being measured; this makes it much easier to be sure 
you are measuring the same segment in subsequent measurements. It’s also worth finding a vessel 
that is easy to identify because the later scans are time dependent and you will be under some 
pressure to find the same vessel quickly. 
4. When you have found a good section of vessel, mark the skin clearly so that you can easily place 
the echo probe in the same position. 
5. Freeze the image (button to the right of the console) when you have a clear segment seen for 
several seconds, and you can then replace the probe in the machine. Scroll backwards and 
forwards (using the tracker ball) to use the R wave of the ECG cycle so that subsequent readings 
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are taken in the same part of the cycle, and so that the image quality is optimal. Press ‘image 
store’ to send the image to echopac (allows someone else to analyse the image without your 
measurements being visible); you may also wish to videotape the image for later analysis (press 
VCR record once to start recording and again to stop recording). 
6. Using ‘caliper’ button, measure 5 readings from leading edge to leading edge of the vessel.  Move 
the cross cursor to the first point, press the white area around the tracker ball once you are happy 
with position, then move to the second area and click again. The machine then displays the 
distance. Select repeat measurement to take 5 readings. Once you have the readings, either note 
them down or send the image with the readings visible to echopac; take the average of the 5 
readings as your measure. Different people use different places to measure: the important thing is 
to be consistent between readings and between patients. In the figure 4-1, both A and B are 
acceptable so long as the same method is performed in all patients.
Figure 4-1
7. Place the cuff on the forearm and inflate to 250-300mmHg (must be at least 50mmHg above 
systolic blood pressure; warn the patient that it will be uncomfortable! Start timing. Keep an eye 
on the pressure in the sphygmomanometer: it may drop a little with time and you will need to 
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keep it above 250mmHg by pumping more air into the cuff. You can now unfreeze the echo 
image; delete the label with the ‘page erase’ button to the left of the console. Then label the 
image ‘FMD’ or similar in preparation for the next image.
8. At 4½minutes, deflate the cuff rapidly. 
9. Repeat the scan 30-90 seconds after cuff deflation. It is worthwhile looking for the artery soon 
(immediately) after cuff deflation so that you can be sure to find the artery within this time, then 
holding the probe steady until your 30-90seconds is reached. Try to identify the same segment as 
you scanned for the first baseline (compare the image you are getting with the image displayed on 
the mac which you sent to echopac), then freeze the image and repeat the measurement as before, 
again using the R wave of the ECG cycle. 
10. Wait 15 minutes to allow the effect of the FMD to wear off. (You can use this time to gather 
other information such as history, drug use, or measuring other things such as carotid IMT; make 
sure you are not doing anything that might upset vasomotor function though (such as blood 
pressure, venesection)
11. Repeat the baseline measurement as before, on the R wave of the ECG cycle. Label as ‘baseline 
2’ and record the image. 
12. Give 2 puffs of sublingual GTN (warn the patient they may get a mild headache / feel dizzy). 
Prepare for the next image by labelling ‘GTN’ or similar
13. Repeat the scan after 4½ minutes, measuring on the R wave of the ECG cycle, and record the 
image to echopac / VCR.
14. Clean jelly off the patient and thank them!
15. The echopac images are stored in the buffer and need to be saved – save to your MO disk using   
the button at the bottom of the screen.
16. Clear up the room: wipe jelly from the probe, make sure the GTN is on the shelf out of reach of 
children etc., tidy up the examination couch, turn off equipment if not going to be used shortly. 
Bear in mind that the equipment is expensive and used by a lot of people...
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Potential problems
This technique takes practise – you should ideally scan about 50 people before recording results 
formally! It is worth trying quite hard to get a good image, and be scrupulous in technique in 
trying to identify the same segment of artery each time. The second scan (FMD / GTN scan as 
opposed to baseline scans) is a bit pressured as there is a time factor involved. As previously 
mentioned, try to find the relevant segment of artery early to give you more time to look. If you 
don’t have time to actually measure the vessel diameter before the next reading is due, you can 
measure it later from echopac (so long as you have sent the image) so don’t worry. It is quite easy 
to forget to send one of the images to echopac – be sure you have recorded one image from each 
scan. The VCR recorder is on / off with each press of the button so make sure you actually stop 
recording after you have captured enough information (otherwise you will be stopping the 
recording next time you try to record something!).
If echopac does not detect the echo machine, turn everything off and start again.
If the Mac crashes, you may need to reset it: the only really reliable way to do this is to 
disconnect the power supply and transiently remove the battery. It’s not very good for the 
computer and all unsaved data will be lost so give the machine time to see if it can recover itself 
before you resort to this. It is vital to label all images as sometimes echopac seems to mix up the 
order it displays the images (so, for example, the baseline may appear either before or after the 
measurement).
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5.1.2       Laser Doppler flowmetry (LDF)
    Updated by Mehmood Butt and Andrew Blann 2008
Health and Safety / COSHH
The only major hazard in this procedure is the risk of damage to the retina due to the laser. 
Therefore avoid eye contact. Some subjects may be allergic to Ach & SNP. Some may respond 
adversely to the electrical current. Obtain consent.
Introduction
The function of large arteries such as the aorta, brachial and femoral can be assessed by their 
dilation response to changes in blood flow (i.e. flow mediated dilatation). This assessment is not 
possible in the study of small arteries and arterioles, often within vascular beds such as the skin. 
However, the recent development of perfusion imaging can assess these small arteries. The 
present SOP is to enable this assessment. Laser Doppler perfusion imaging is based on four 
separate technologies:
 (a) the Doppler shift phenomenon (change of the wavelength of the moving object 
proportionally the speed of the object, i.e., blood cells), 
 (b) the ability of the Laser imaging system to detect this phenomenon, 
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 (c) perfusion of skin with pharmacologically active drugs (acetylcholine [Ach] and sodium 
nitroprusside [SNP]) that will alter small blood vessels close to the surface of the skin, and 
 (d) the electrical delivery of these agents into the skin (ionotophoresis). 
Thus the method allows an evaluation of the perfusion of surface tissues (e.g. skin) in real time 
scale. Changes in skin blood flow can be determined in response to various stimuli. Vasoactive 
substances can be used to alter the flow of blood in the skin vessels if delivered by an appropriate 
means. Iontophoresis is a delivery method that uses the charge of a charged vasoactive substance 
to allow it to be driven through the skin using an electric current. Sodium nitroprusside is a 
vasoactive substance with a negative charge that can be delivered through the skin to the 
microcirculation; once it has passed through the skin it acts as a nitrate donor and therefore acts 
directly on the vessel’s smooth muscle to cause vasodilatation. Thus it is independent of the 
endothelium in its vasodilatory action. Acetylcholine on the other hand is a positively charged 
molecule that can similarly be delivered to the subcutaneous tissues by iontophoresis but it acts 
on the endothelium rather than on the smooth muscle wall, causing endothelial release of nitric 
oxide. Thus acetylcholine acts in an endothelium-dependent way on the vessel wall to produce 
vasodilatation. The vasoactive substances are provided close to the skin in a small perfusion 
chamber that also acts as an electrode. A second electrode is required to complete the circuit, and 
this is attached to a nearby section of skin.
Test solutions
a) 2% acetylcholine chloride (Ach) [Sigma-Aldrich]
b) 1% sodium nitroprusside (SNP) [Sigma-Aldrich] 
Both must be prepared in sterile filtered distilled water (Sigma-Aldrich) and appropriate volumes 
(approximately 1ml aliquots) stored in stored top plastic tubes a fridge at 4°C up to 1 month. 
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These solutions are transferred from the plastic tubes to the iontophoresis chamber with a plastic 
disposable transfer pipette (stores in preparation room and the laboratory). Ensure the reagents are 
allowed reach room. 
Preparing the Laser Doppler Flowmeter (LDPI II, Perimed, Sweden). 
The laser requires a 20 minute warm up period so do this well before the subject is assessed.
1. To switch on the LD, press the green button on Blue Box (Laser Doppler block)
2. Turn on the computer (button front panel).
3. Start LDPIwin 2.6 icon (Laser Doppler software) on the desktop 
4. Check settings of scanning in Measurement dialog if necessary. The settings should be as: 
(1) Repeated Mode; 
(2) Image format: 25 x 25 (width and height);
(3) Start Method: Manual; 
(4) Resolution: High; 
(5) Threshold: 6.2
The equipment should now be ready.
Iontophoresis and Data acquisition
1. For the assessment the patient is laying on the couch comfortably in a constant room 
temperature room for 20 minutes before the start of measurements. All measurements should be 
performed in dim light. The forearm is placed on a supportive cloth/pillow. 
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2. A hairless area of forearm skin in the non-dominant arm is cleaned with a 40% ethanol swab 
and the iontophoresis chamber (Perimed UK) placed over the skin.
3. The reference electrode is placed over the volar aspect of the ipsilateral wrist 15 cm from the 
chamber. 
4. The chamber is then filled with about 0.5 ml Ach (using transfer pipette) with ensuring that no 
air bubbles are visible below the glass cover. The anode (red) is attached to this and the cathode 
(black) to the other (wrist) electrode. 
5. Iontophoresis is not commenced until three complete baseline readings had been taken:
- press New following Start to begin scanning
- press Continue to acquire more scans or End to finish acquisition
- save results obtained.
The computer driving the laser scanner is pre-programmed to scan the area of the iontophoresis 
chamber using high resolution settings (see above). 
6. During baseline readings the iontophoresis power pack is prepared.  Switch on with the left 
hand knob rotating clockwise. Set the unit to deliver 0.1mA over 1 minute (total charge delivered 
6mC) as a continuous current. There is a spare battery in the grey Periiont box.
7. Apply the current and acquire perfusion scans for 6 min following ACh delivery (maximal 
response is usually seen at 2-3 min.). Store the data in an appropriate file on the computer.
8. After the ACh readings are completed, the patient rests if required (5- 20 minutes) then 
proceeds to SNP measurement. 
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9. The chamber is removed and a clean iontophoresis chamber placed approximately 4cm further 
away from the wrist electrode (so that the iontophoresis electrode did not lie within the path of 
the current from the previous recording). 
10. The same procedure is used for SNP (about 0.5 ml) except that the electrode polarity is 
reversed. Acquire perfusion scans for 10 min following SNP delivery (maximal response is 
usually seen at 5-6 min.).
11. Complete the procedure by wiping excess fluids from the subject, disposing of waste material 
etc. Power down the LD and switch it off.
Analysis of results
After the readings had been taken, the images are analysed using the dedicated software package 
provided by the manufacturer. 
1. To select area of interest (i.e. the area of chamber that had vasoactive substance directly in 
contact with the skin) to be analysed use Create Elipse Tool and Pointer Tool.
2. Press right mouse button and select Unlink POI on all images
3. Adjust position of the area of interest on all consequent scans (i.e. for each time point)
4. Save changes
5. Select Export and Images and calculations to Excel to export results to Microsoft Excel; the 
values for each time point are used to determine the peak response (in terms of absolute perfusion 
units, and also % change from baseline), and area under the curve for the perfusion over the 10 
minute experiments.
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6. Save results obtained and print them if necessary.
7. Close software
8. Turn off the computer and switch off Blue Box (Press green button).
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5.1.3       Flow Cytometry
Written by Patrick Goon and Timothy Watson, August 2006
Updated by Mehmood Butt 2008
Introduction
The potential importance for EPC/CECs in the physiological response to endothelial damage has 
led to their investigation in numerous disease settings.  For example EPCs have been shown to 
inversely correlate with cardiovascular (Framingham) risk scores.  Similarly CECs have been 
described to represent endothelial damage. This has led to speculation that the ability to enhance 
their numbers may allow for a novel approach to modulate various disease states.
The definition of these cells has continued to evolve. Currently cited markers include CD34, 
CD146 and Kinase Domain Receptor (KDR).  Importantly, as these cells mature, the cell surface 
markers change.  In addition, other cell lines such as monocytes and tissue resident stem cells 
may cross-differentiate, adding to the complexity of defining this cell population.
This method describes enumeration of KDR+, CD34+, CD45- cells represent EPCs whilst 
CD146+, CD34+ and CD45- cells represent CECs.
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Materials
1) BD “FACS Flow” Running solution [Becton Dickinson Catalogue No. 342003]
Order 6 x 10L containers and keep in stock
2) BD “FACS Rinse” Rinsing Solution [Becton Dickinson Catalogue No.
Order 1L containers only
3) BD “FACS Clean” Cleaning Solution [Becton Dickinson Catalogue No.
Order 1L containers only
4) BD Falcon tubes[Becton Dickinson, Catalogue No. 352054]
Order 10 packs and keep in stock
5) BD Lysing solution [Becton Dickinson Catalogue No. 349202]
6) Distilled water [make >10L at a time using laboratory distilling equipment in HTVBU lab]
7) Phosphate Buffered Saline tablets. [Sigma Catalogue No. P4417]
8) Sodium Azide [Sigma Catalogue No.
9) Bovine Serum Albumin - 100g [Sigma Catalogue No. A-3912]
10) CD45 – FITC conjugated monoclonal antibody - 100 tests [BD Catalogue No. 555482]
11) CD34 – PE Cy5 conjugated monoclonal antibody - 100 tests [BD Catalogue No. 555823]
12) CD146 – PE conjugated monoclonal antibody - 100 tests [Biocytex, France Catalogue No. 130-
080-801]
13) KDR – PE conjugated monoclonal antibody - 100 tests [R&D, UK Catalogue No. 130-080-801]
14) Mouse Serum – 5ml [Sigma Catalogue No. M5905-5mL]
15) Octagam (2.5 g in 50 mls PBS) [Octapharma Ltd]
16) Blue pipette tips [Appleton Woods Catalogue No. HTL160]
17) Yellow pipette tips [Appleton Woods Catalogue No. TG701]
18) 15ml Centrifuge tubes [Sarstedt Catalogue No. 62.554.502]
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Supplier contact details:
Becton Dickinson (UK)
Between Towns Road
Cowley
Oxford ,Oxfordshire
OX4 3LY
Fax: 01865 781578
Appleton Woods Ltd
Lindon House, Heeley Road
Selly Oak, Birmingham B29 6EN
Tel 0121 472 7353, Fax 0121 414 1075.
Freefax orderline 0800 387 462
Sarstedt Ltd.,
68 Boston Road, Beaumont Leys,
Leicester LE4 1AW, United Kingdom
Tel.: +44 1162 359023,
Fax: +44 1162 366099
Octapharma Ltd
6 Elm Court,
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Copse Drive,
Coventry.
CV5 9RG
Telephone: +44 (0) 1676 521000
Fax: +44 (0) 1676 521200
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3. Procedures
3.1 General Preparation
3.1.1 Lysing solution.
Make from 50ml concentrate diluted with 450ml distilled water in ½ litre bottle. Store in fridge.
3.1.2 Wash solution
Make up 1 litre phosphate buffered saline (5 PBS tablets + 1 litre distilled water).  Sterilize in 
autoclave (120C for 2-3hours).  When ready to use add 5g =bovine serum albumin and 0.5g 
Sodium Azide.  Mix thoroughly and store in fridge.
[Caution COSHH Data…]
3.1.3 Mouse Serum 10%
[Dilute 0.5 ml mouse serum in 4.5ml PBS and store in fridge. Remainder can be stored in freezer 
until required.]
3.2 Sample Preparation
3.2.1 Gently vortex the EDTA or citrate blood sample.  Take 100 mL and add to a 15ml centrifuge 
tube.  Add 10ml pre-diluted BD lysing solution.  Put sample on automated mixer for 10 minutes. 
Then centrifuge 700g for 5 minutes
3.2.2 Decant supernatant and add 10mls of PBS/BSA Solution.  Vortex gently to resuspend pellet.  
Then centrifuge once again at 700g for 5 minutes.
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3.2.3 Discard supernatant.  Add 20 uL Octagam (blocks Fc receptor) and 200 uL of 10% mouse serum 
(prevents non-specific binding).  Gently flush in to and out of pipette tip to re-suspend pellet.  
Leave to stand at room temperature for 20 minutes.
3.2.4 Add 10uL each of CD146, KDR, CD34, and CD45 fluorochrome labelled antibodies.  Flush into 
and out of pipette tip to ensure thoroughly mixed and then gently vortex. Stand in the dark at 
room temperature for 20 minutes.
3.2.5 Add 10ml PBS/BSA and centrifuge once again at 700g for 5 minutes.  Discard Supernatant.
3.2.6 Add 200 uL 2% paraformaldehyde solution and flush into and out of pipette tip, followed by 
gentle vortex to ensure thoroughly mixed.  Store sample in dark at 4C until ready to be processed 
(note sample must be processed within three days)
3.2.7 Carefully disconnect the waste container and empty contents down sink with plenty of water.  
Add approximately 20ml concentrated household bleach and reconnect container.
3.2.8 When the indicator light changes from “Not ready” to “Standby”, pressurise the unit (takes about 
20-30 sec) by moving the “Vent Valve” switch to the down position
3.2.9 Any excess air trapped in the sheath filter can, if necessary, be cleared by venting through the 
bleed tube (the dead-ended rubber tube with a cap).
3.2.10 Ensure that a Falcon tube approximately 1/3 full of distilled water is positioned over the needle 
sheath and that the swing arm is positioned under this tube.  Turn the selection dial to the DRAIN 
position.  A squirt of FACS Flow solution will travel along the rubber tubing and bubbles will 
appear in the Falcon tube.  Continue this process for 30 secs.
3.2.11 Now turn the selector dial to the FILL position for another 30 secs.  If further bubbles are seen in 
the Falcon tube, repeat steps 6 and 7.
3.2.12 Finally turn the selector dial to the RUN position and run distilled water for a further 5 minutes.  
This process ensures the machine is clean prior to running samples and helps minimise blockages.
3.2.13 The machine is now ready to run samples.
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3.3 Running Samples.
Note. It is best to learn this from an experienced operator as the intricacies of the Cell Quest 
software are complex.
3.3.1 Click Apple icon in top left of screen and open CellQuest Pro.
3.3.2 Close current document, then open the EPC enumeration document located within the 
Experimental Protocols folder
3.3.3 Click ‘Connect to Cytometer’, located under the ‘Acquisition’ menu.
3.3.4 Under the ‘Cytometer’ menu, click ‘Cytometer Settings’.  Change settings to EPC Settings, also 
located within the Exp Protocols folder.  Make sure to click ‘set’ prior to clicking ‘done’.
3.3.5 Click the ‘Acquisition menu’ once more and click ‘show browser’.  Enter the file name and 
number for data to be stored under and choose an appropriate location to save data to.
3.3.6 Each sample now needs dilution with 600mL PBS/BSA to make a sample volume of 
approximately 1.1ml.  This should be mixed thoroughly and transferred to a BD Falcon tube.  
Open swing arm at bottom right of the cytometer and replace the Falcon tube with the sample to 
be run.  Replace the swing arm under the Falcon tube.
3.3.7 Click Acquire on the browser menu.  The sample will now run for 10mins, 12 seconds.  Cell 
events will be displayed on the screen throughout the process.
3.4 Shut-down procedure
3.4.1 Fill two Falcon tubes (already labelled for use and kept on top of cytometer) half full with FACS 
Rinse and distilled water respectively.
3.4.2 Install FACS Rinse tube (essentially a mixture of detergent and water) over the aspiration sheath.  
Leave the support arm out at 90 degrees for approximately 1 minute.  This cleans the outer 
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portion of the aspiration sheath.  The fluid will be rapidly aspirated, so ensure that the tube 
doesn’t empty completely.
3.4.3 Now replace the side arm under the Falcon tube and aloe to run for approximately 5 minutes.  
This cleans the inner portion of the aspiration sheath and the FACS machine itself.
3.4.4 This step is only to be performed once per week.  Repeat steps 2 & 3 with a Falcon tube 
containing 1/3 FACS Clean solution
3.4.5 Repeat steps 2 and 3 with distilled water.  Once step 3 is complete, Leave the sheath in the BD 
Falcon tube containing distilled water and turn the selection dial to STANDBY and depressurize 
the machine by moving the “Vent Valve” switch to the up position.  The machine will hiss as it 
depressurizes.
3.4.6 Leave the machine on for a further 10 minutes to allow the laser lamp to cool.  Turning the 
machine off prematurely will result in the lamp cracking.
3.4.7 Finally power down the FACScan and Apple Mac.
Note: * If subsequent use of the FACScan is anticipated within the next hour or so, perform 
all the shut-down steps but leave the machine on in STANDBY mode at step 6.
3.5 Monthly maintenance
This maintenance schedule should be performed on a monthly basis to ensure optimal running of 
the FACScan machine.
3.5.1 Perform daily shut-down procedure as above first, to ensure system is relativel clean already.
3.5.2 Depressurize sheath container (FACS Flow container), carefully disconnect and replace container 
with the dedicated sheath container marked FACS Rinse (kept on bench next to machine).  This 
container should be approximately half full with FACS Rinse.
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3.5.3 Disconnect the white tube from the sheath filter and replace this with the white tube from the 
sheath container.  This step bypasses the filter ensuring that FACS Rinse does  not enter this part 
of the machine.
3.5.4 Install a Falcon tube containing FACS Rinse ( about 3ml) and pressurize the system.
3.5.5 Turn selector to DRAIN (30 seconds) and then FILL (30 seconds).  Repeat this step twice.
3.5.6 Turn the selector dial to run and leave for 20 minutes.
3.5.7 Turn selector to Standby and depressurise the machine (vent valve up position).  Repeat steps 4 to 
6, this time with the sheath container for FACS Clean (marked, again should be half full) 
and a Falcon tube also containing FACS Clean.
3.5.8 Turn to standby and depressurise the system once more.
3.5.9 Remove the Falcon tube and replace sheath container with FACSFlow container.  Make sure that 
the probe is thoroughly rinsed with distilled water prior to reinserting!
3.5.10 Reconnect white filter tubes to their original positions and install a Falcon tube of distilled water 
over the aspiration sheath.
3.5.11 Repressurise the system (vent valve down) and turn selector dial to DRAIN (30 secs), then FILL 
(30 secs) twice as before.
3.5.12 Turn selector dial to RUN and leave for 10 minutes.
3.5.13 Finally, de-pressurize machine (vent valve up) and select STANDBY mode.
3.5.14 Allow laser lamp to cool for 10 minutes, then power down machine.
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5.1.4       Pulse wave analysis (PWA) and Pulse wave velocity
Written by Sern Lim 2008
Updated by Mehmood Butt 2010
Introduction
Left ventricular (LV) contraction generates a forward travelling pressure wave. Some of this 
pressure wave will be reflected at sites of impedance mismatch (eg: bifurcations and sites of 
constriction). Increased arterial stiffness results in earlier return of the reflected pressure wave in 
systole rather than diastole. The reflected pressure wave will increase systolic blood pressure, 
termed pressure augmentation and may be expressed as the augmentation index. Increased arterial 
tone, such as that associated with endothelial dysfunction also increases the reflected wave and 
the augmentation index. The analysis of the arterial pressure wave, termed pulse wave analysis 
(PWA) may therefore provide information on the functional properties of the arterial system. The 
administration of salbutamol and GTN also allows assessment of endothelial-dependent and 
independent function as NO-mediated vasodilatation reduces arterial wave reflection. The relative 
change in augmentation index to salbutamol and GTN provides a measure of systemic endothelial 
function. 
Equipment
You will need:
 Patient (!)
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 SphygmoCor with pressure transducer (Millar)
 Laptop computer with SphygmoCor software (for around 45 minutes)
 Power cables and USB connection cables 
 ECG monitoring dots
 Omron BP recorder
 Salbutamol inhalers and GTN spray
Preparation
a. Allow the subject to rest in the room for about 10 minutes before scanning. The test must be done 
in a supine position.
b. While the patient is resting, you should connect the power cables to the SphygmoCor machine (at 
the back) and the laptop computer. The computer should then be connected to the SphygmoCor 
machine (use the USB connection at the back). The ECG cables should be connected to the 
SphygmoCor machine (in front where it says ‘ECG’). 
c. Switch on the SphygmoCor machine first. The lights in front will blink. When the lights stop 
blinking and green light stays on ‘ready’, turn on the computer. This sequence will allow the 
software in the computer to recognise the SphygmoCor. 
d. The SphymoCor icon should be on the computer desktop. Double-click to activate the software. 
A warning will come on the screen, just click ‘allow’.
e. You will see PWA and PWV on the top left of the screen. Click on PWA for pulse wave analysis.
f. Click ‘create new’ on the top right of the screen. You will need to enter the patient details in the 
relevant boxes (eg: date of birth) and click ‘update’.
g. Click on PWA on the top left for pulse wave analysis and then ‘study’ on the top left of the 
screen. Choose radial or carotid by ticking the box. Measure the patient’s brachial blood pressure 
(Omron). Take 3 measurements and use the average of the last two readings. 
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h. Enter BP measurements. Height and weight if you have the data. 
i. Place the ECG leads on the patient and click ‘Capture data’ on the top right of the screen. You are 
now ready to go!
In the drawer of the tonometer machine, you will find the Millar tonometer with a plastic cap to 
protect the high fidelity tip (this cap is important, DO NOT lose it!). The tonometry should be 
connected already. DO NOT disconnect the tonometer. Remove the plastic cap and it is ready for 
use.
Feel for the radial or carotid pulse (depending on which you want to measure) and place the 
tonometer over the pulsation. You will see a pressure trace on screen. The screen will 
automatically adjust the scale to accommodate the pressure trace. You need to make sure the trace 
is consistent for at least 12 seconds. To obtain the measurement, press the spacebar on the laptop. 
The machine will not take the last 2 seconds of recording to give you time to let go and press the 
spacebar.  
The computer screen will then change to the data screen with the ensemble-averaged pressure 
trace (radial or carotid depending on the one you have chosen) shown and the derived central 
arterial pressure trace. First thing to do: check the quality control box on the top left of the screen. 
If this number is red, then the data is of insufficient quality and the measurement will need to be 
repeated. 
The data will be available at the bottom of the screen. At the top right of the screen, click 
‘Export’ to save the data in your folder. You can store the data as a text file or jpeg (the screen 
shot). I would suggest you store both. If you are not doing endothelial function assessment with 
the SphygmoCor, then your study is done!
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If you want to assess endothelial function, you will need to assess endothelium-dependent and 
independent vasodilatation. Endothelium-dependent vasodilation is assessed by giving 2 puffs of 
salbutamol (inhaler). Blood pressure (the other arm) and PWA measurement should be repeated 
at 5, 10 and 15 and 20 minutes to look for maximal decrease in augmentation index. 
This is then followed by 2 puffs of sublingual GTN (warn the patient they may get a mild 
headache / feel dizzy) to assess endothelium-independent vasodilatation [Figure]. Similarly, BP 
and PWA measurement should be repeated at 5, 10, 15 and 20 minutes. 
Make sure you label the files (eg: salbutamol and GTN) when you are storing the data.
Figure 4-2
Potential problems
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1. The high fidelity tonometer is very sensitive to pressure (that is what it is meant to do!). You will 
need practise to achieve a consistent level of pressure in order to obtain reproducible readings. It 
is generally more difficult for carotid artery compared to the radial artery.
2. To avoid any problems with the computer, it should NOT be used for any other reasons (eg: 
surfing the internet). The computer and the tonometer (plus ALL the cables and ECG leads) 
should ALWAYS be kept together.
3. Every operator should create a folder for him/herself and store ALL the data in that folder. This 
should avoid confusion and the relevant data may be easily retrieved.
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5.1.5       Echocardiography
Two-dimensional, Three-Dimensional and Myocardial Contrast Echocardiography 
Written by Mehmood Butt & Girish Dwivedi, 2008
Introduction
Two-dimensional echocardiography (2DE) has been used for many years for gaining structural 
and functional information. However, it has its own limitation especially with regards to 
volumetric analsyis. Lately real time three-dimensional echocardiography (RT3DE) has been 
introduced which have improved the diagnostic yield in subjects with asymmetric cardiac 
geometry.
Myocardial contrast echocardiography (MCE) is destruction-replenishment imaging. The failure 
of echocardiography to give diagnostically useful information in a significant proportion of 
patients has led to the development of specific contrast agents (microbubbles) to enhance 
imaging. The significant acoustic difference created between microbubbles and blood allows for 
their easy detection using specific ultrasound imaging techniques. The current generation of 
ultrasound contrast agents comprises ‘microbubbles’ of a high-molecular-weight gas 
encapsulated in a ‘shell’ of phospholipid or protein. Microbubbles are hemodynamically inert and 
remain entirely within the intravascular space. The development of new ultrasound contrast 
agents and imaging techniques have made possible the assessment of myocardial perfusion, 
permitting simultaneous assessment of global and regional myocardial structure, function and 
perfusion. 
Equipment
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You will need:
 Cooperative subject (Always ensure 24hrs of caffeine free interval prior to the test).
 Echocardiography machine (IE33) free (for around 60-90 minutes at least)
 Echo jelly (the tubs are refillable)
 ECG monitoring electrodes
 Philips computer with excelera software
 Timer (can use clock on echo machine if not available)
 Sphygmomanometer 
 Contrast agent (Sonovue 3-4 vials per patient)
 Dipyridamole (Persantin 0.56mg/kg body weight)
 Aminophylline as an antidote (50-100 mg)
 Resuscitation trolley fully equipped with O2 source (tubing attached)
Method
j. Turn on echo machine (button located on the main body of the machine behind the 
main screen)
k. Turn on the Philips computer with excelera
l. Systems should connect automatically
m. Allow the subject to rest in the room for about 5 minutes before scanning
n. Place the ECG leads on the patient
o. Press ‘patient ID’ on the echo machine console (towards the left) and key in your 
patient’s information.
p. Place an IV cannula and take necessary blood tests (pre MCE flow cytometry EDTA 
sample along with a yellow, and a blue top tube). 
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On the echo machine 
2DE
i. Select the probe (S5)
ii. Set the background gains at a level so that minimal tissue signals are seen
iii. Standard para-sternal long axis, para-sternal short axis, apical 4 chamber, apical 3 chamber, apical 2 
chamber, epigastric and supra-sternal images are visualized and stored. 
RT3DE
a. Select the probe (X3)
b. Select Grey scale 8 and chrome 3 on the contrast option.
c. Standard apical 4 chamber, apical 3 chamber and apical 2 chamber images are visualized and 
stored.
MCE
1. Select the probe (S5)
2. Select the protocol ‘GD’ perfusion
3. Select physio on left screen and press  ‘trigger imaging’ on button
4. Optimise delay to the end of ‘T’ wave in your patient
5. Press contrast option on the right hand screen
6. Select Grey scale 8 and chrome 3 on the contrast option.
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Prepare the infusion pump
a. Prepare 2-3 (3 for obese and less for thin subjects) vials of Sonovue (preparation method in the 
Sonovue box) and withdraw in a syringe provided by Bracco
b. Connect this syringe to the connecting tube provided and place horizontally in the pump.
c. Close the cover of the pump and activate the pump (it will gently rotate for around 90 seconds)
d. Press purge to get rid of the air in the connecting tube
e. Connect the free end of the tube to three way tap attached to IV cannula.
Imaging
a. Set the background gains at a level so that minimal tissue signals are seen
b. Set the focus at the level of mitral valve
c. Start Sonovue (already put in the infusion pump) infusion at the 70-90 ml/hour 
d. It is worth optimizing the machine settings again to obtain best possible myocardial opacification 
with minimal attenuation. 
e. MCE is usually performed in the 3 standard apical (4, 2 and 3 chamber) views. Obtain at least 
two set of images for each view during rest imaging. Infusion of contrast agent can be stopped 
after rest imaging. 
f. Observe the replenishment for at least 15 cardiac cycles following high mechanical index (1) 
microbubble destruction. During this ECH should be triggered, press acquire (on main button 
panel on the echo machine) and then flash (on right hand ECHO display LCD screen) to achieve 
this. 
g. After obtaining rest pictures, checking the blood pressure and auscultating lungs (to rule 
bronchospasm), administer dipyridamole (dose calculated as per body weight) through a three 
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way cannula over 4 mins. It is important to look at the ECG rhythm and measure the BP at least 
twice during the infusion.
h. Restart contrast infusion 90 seconds after finishing the dipyridamole infusion.
i. Repeat the MCE as described during the rest imaging to obtain stress images.
Drug calculation and administration
a. Dipyridamole is available in 2 ML vials (10mg/2ML). For stress following formula is used:
              0.56mg x body weight in kilograms
b. Calculate the dose required and draw in a 10-20 cc syringe using green needle.
c. Draw 10ML normal saline in another 10ML syringe separately as ‘flush’.
d. Take blood pressure reading before injecting dipyridamole.
e. Once images have been taken at rest, dipyridamole is given over a period of 4 minutes in a large 
peripheral cannula. 
f. Flush the cannula with10ML of saline.
g. During the injection continue to monitor the ECG of monitor and take blood pressure (from other 
arm) every 2 minutes or more frequently if necessary.
h. If any alarming symptoms/signs ( such as anaphylaxis, significant drop in blood pressure, 
induction of arrhythmias, any neurological signs, wheeze and/or cough) stop infusion.
i. Management of possible complications is given in another section.
Last but not least
a. Clean jelly off, take the ECG leads off the patient and thank them!
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b. Clear up the room: wipe jelly from the probe; get rid of sharps, tidy up the examination couch, 
and turn off equipment if not going to be used shortly. Bear in mind that the equipment is 
expensive and used by a lot of people...
c. Always check contraindications to the drug use. 
Potential problems 
This technique takes practise – you should ideally be competent in normal 2D echocardiography 
before attempting to perform MCE. It is always helpful to put the cannula in a large vein for 
contrast infusion. Be liberal with the use of aminophylline if you suspect any problems following 
dipyridamole infusion. Try to finish obtaining MCE images before giving dipyridamole. 
However, as the patient safety comes first, if the situation demands, administer IV aminophylline 
(slowly) even if you have to abandon the test. Keep plasma expanders (or normal saline) and IV 
atropine handy, as rarely subjects become hypotensive and bradycardic following dipyridamole 
infusion. 
Aminophylline indication and administration
Should severe chest pain or brochospasm occur, parenteral 75 to 100 mg aminophylline may be 
administered by slow intravenous injection; repeated if necessary. If aminophylline does not 
relieve chest pain symptoms within a few minutes, sublingual nitroglycerin may be administered. 
If chest pain continues despite use of aminophylline and nitroglycerin, the possibility of 
myocardial infarction should be considered.
Management of specific complications
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Anaphylaxis: 
Stop infusion and imaging immediately.
Secure Airway and start 100% Oxygen. 
Get good peripheral line and start IV normal saline. 
Treat with subcutaneous adrenaline, IV hydrocortisone 200mg and 10mg Piriton IV. 
Hypotension:
Stop infusion and imaging immediately.
Secure Airway and start 100% Oxygen. 
Get good peripheral line and start IV normal saline. 
Aminophylline can be given also. 
Bronchospasm:
Stop infusion and imaging immediately.
Secure Airway and start 100% Oxygen. 
Get good peripheral line and start IV normal saline. 
Nebulize with 5mg salbutamol. And give 200mg of IV hydrocortisone. 
Aminophylline can be given also. 
Cardiac arrest or Peri-arrest situation:
To be dealt with according to current resuscitation council guidelines.
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